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INTRODUCTION 
Atherosclerotic cardiovascular disease remains one of the most important causes of 
morbidity and mortality in the industrialized world. Treatment is basically aimed at 
palliation and consists of either pharmacological intervention or revascularization. 
The frrst significant advances in the latter were largely surgical [!]. However, the 
pressing need for treatment with less invasive and potentially less expensive 
techniques, have stimulated the development of non-surgical revascularization 
techniques. Percutaneous transluminal coronary balloon angioplasty, which was first 
performed by Andreas Gruentzig in 1977, is one of the most successful examples and 
provided the stimulus for a rapid technological growth of interventional cardiology 
[2]. It is now widely accepted as a safe and effective treatment of obstructive 
coronary artery disease. However, the risk of abrupt vessel closure during or 
immediately after the intervention and the risk of late luminal renarrowing or 
restenosis continue to compromise its overall safety and efficacy [3,4]. To improve 
the immediate and long-term results of balloon angioplasty, a number of new 
technologies such as intracoronacy stenting, directional or rotational atherectomy and 
laser therapy have been developed and represent the leading edge in the battle against 
atherosclerosis [5-8]. The intracoronary stent has been shown to be effective in the 
treatment of acute or threatened vessel closure due to balloon angioplasty induced 
coronary dissection, alleviating the need for emergency bypass surgery [9]. 
Furthermore, it has been hypothesized that intracoronary stent implantation may 
reduce the incidence of restenosis by optimizing the immediate angiographic results 
which should lead to improved long-term clinical outcome. 
The work presented in the following chapters encompass the clinical and angio-
graphic aspects of intracoronary stent implantation in human coronary arteries. 
The frrst part of this thesis, deals with the technical aspects of intracoronary stenting. 
In particular, since it has been postulated that improved immediate angiographic 
results may reduce the incidence of angiographic restenosis, the changes in lesion 
morphology immediately after stent implantation were studied. Coronary angiograms 
before and after stent implantation were analyzed with the computer-assisted 
Cardiovascular Angiography Analysis System using automated contour detection. In 
the frrst chapter, the principles of this quantitative analysis method are briefly 
reviewed and the potential pittfals in the setting of intracoronary stenting are 
discussed. 
Chapters 2, 3, 4 and 5 detail the immediate changes in stenosis geometry following 
stent implantation and compare these changes between two types of stents and with 
other interventional techniques. 
Obviously, the main task of the medical practictioner is palliation of symptoms and 
eventually improve longevity in addition to palliation. Therefore, the second part of 
this thesis reflects on the clinical aspects of intracoronary stent implantation. 
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The immediate and long-term clinical and angiographic results of Wi1:tor stent 
implantation in native coronary arteries because of restenosis are reviewed in chapter 
6 and 7. The potential role of stent implantation in venous bypass grafts is discussed 
in chapter 8. 
It goes without saying that one of the methods to assess the proper role and merits 
of intracoronary stenting is the conduction of a randomized trial. Some of the aspects 
of the design of such a study are discussed in chapter 9. These data were of use for 
the power calculations for the Benestent Study, of which the results of the pilot phase 
are presented in chapter I 0. This study is an international randomized study 
comparing the safety and efficacy of stent implantation versus balloon angioplasty 
for a de novo lesion in a native coronary artery. 
In the !mal chapter, an attempt has been made to critically review the role of 
intracoronary stent implantation with some reflections on how we may improve the 
results. 
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CHAPTER 1 
CRITICAL APPRAISAL OF QUANTITATIVE 
CORONARY ANGIOGARPHY AND 
ENDOLUMINAL STENT IMPLANTATION 
Peter P de Jaegere, Bradley H Strauss, Marie-Angele Morel, Pim J de Feyter, 
Patrick W Serruys 
Catheterization Laboratory, Department of Cardiology, Thoraxcenter, Erasmus 
University Rotterdam, The Netherlands 
Kluwer Acadentic Publishers (Eds: P.W. Serruys, D. Foley, P.J. de Feyter) 1993, in 
press. 
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INTRODUCTION 
To objectively evaluate the coronary anatomy and its changes following therapeutic 
procedures, a computer assisted analysis procedure was developed in the Thorax-
center by H. Reiber and colleagues [1]. This computer assisted Coronary Angio-
graphy Analysis System or CAAS system has extensively been validated with respect 
to its accuracy and precision on the basis of perspex models filled with contrast 
[2-4]. In addition, the overall short-, medium-, and long-term variations in arterial 
dimensions from repeated coronary angiograms have been determined [2]. This 
method, commonly called Quantitative Coronary Angiography (QCA), has become 
the gold standard in the assessment of the innnediate and long-term results of various 
coronary interventions, both pharmacological and mechanical. In particular, the 
incidence of restenosis or late luminal renarrowing after coronary intervention have 
become an important field of investigation [5]. Initially, it was intended as a system 
to assess the extent of disease within the coronary artery. But with the advent of 
novel therapeutic interventional techniques such as intracoronary stenting, several 
new and unforeseen problems have emerged. In some circumstances, the principles 
had to be adapted to more complicated and complex situations related either to the 
device itseJf or to the effect of the intervention on the angiographlc appearance of 
the treated artery. To appreciate the role and potential pitalls of QCA in the 
assessment of the angiographic results of intracoronary stent implantation, one has 
to understand its basic principles and how the angiographic parameters are defmed. 
This will be discussed in this chapter and additionally the capabilities of the CAAS 
system will be reviewed as well as some of the methodological problems and short-
comings of the system that have become evident from our experience with intracoro-
nary stenting. Although most of our studies are based on the use of automated con-
tour detection, some data on the use of videodensitometry will be discussed as well. 
GENERAL PRINCIPLES OF THE CAAS SYSTEM 
Automated edge detection 
It is beyond the scope of this chapter to review in detail the technical aspects of the 
CAAS system using automated edge detection. However, for the purpose of reader, 
the general aspects are briefly summarized. They are discussed in detail elswhere [6]. 
To analyze a coronary segment in a selected frame of a 35 mm cine~ an 
optically magnified portion of the image encompassing that segment is converted into 
video format by means of a cine-video converter. For the computer-assisted 
definitions of the boundaries of this selected coronary segment, the following steps 
need to be distinguished: 
1) definition of the coronary segment to be analyzed; 
2) edge defmition; 
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Definition of the coronary segment 
The user indicates a number of pathline or centerline points with a sonic pen which 
are subsequently connected by interpolation resulting in the pathline or centerline. 
This line functions as an initial model for subsequent contour detection. The only 
reqnirement of this line, is that it is simated within the arterial boundaries. A 
disavantage of this technique is that the amount of user-interaction may become 
significant, particularly in curved segments or in case of an overlapping side branch, 
in which the distance between subsequent points must be chosen small to make sure 
that the connecting lines will not be drawn outside of the arterial segments. 
Therefore, an update of the pathline or centerline is advocated by computing a new 
line from the contour positions once these have been detected and possibly corrected 
manually. Thereafter the contour detection procedure is repeated. By means of this 
iterative approach the influence of the user defmition of the path line points on the 
detected contour positions can be minimized. Figure 1 illustrates the several steps 
described above. 
Fig. 1. Following the mannual definition of the beginning and end points of the segment to be analyzed, 
the pathline or centerline is detected automatically. Using the automatically detected pathline or centerline, 
the arterial boundaries are detected. The first iteration using minimal cost criteria is followed by a second. 
In the second iteration, the !mal contour are detected with the same edge detection teclmique and using 
the contours of the first iteration as models. 
Edge definition 
For the subsequent computation of the edge pos1Uons, a number of scanlines 
perpendicnlar to the local pathline or centerline are determined. Along these 
scanlines, the brightness profile of the arterial segment is assessed. The contours are 
determined on the basis of the weighted sum of the fiiSt and second derivative 
function applied to the brighness information using the minimal cost criteria. The 
application of the weighted sum of the fiiSt and second derivative function is based 
on the experience that using maximal values of only the first or second derivative 
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functions underestimates or overestimates the true arterial boundary positions, 
respectively [2,6]. 
Contour analysis 
From the contours of the analyzed segment, following smoothing, pincushion 
correction and calibration, a diameter function is determined by computing the 
distances between the left and rigbt edges. The distances between the left and rigbt 
edges in pixels is converted into absolute values by using the catheter as scaling 
device. From these data some relevant parameters are calculated (Figure 2 and 3): 
Direct measurements 
1. minimal luminal diameter (MLD) 
2. maximal diameter 
3. mean diameter 
4. extent of obstruction or lesion length 
5. obstruction area (assuming circular model) 
6. reference area (assuming circular model) 
Interpolated measurements 
1. reference diameter (RD) 
2. symmetry 
3. area plaque 
Derived measurements 
1. percent diameter stenosis (calculated from MLD and RD) 
2. percent area stenosis 
3. curvature 
4. inflow and outflow angle 
5. roughness 
Defmition of angiographic parameters (Figure 2 and 3) 
The direct measurements are derived from the "diameter function" which represents 
the size of the analyzed vessel segment at intervals of approximately 0.1 mm as 
measured by the computed centerline. The diameter values are presented along the 
y-axis and the vessel length is represented along the x-axis. 
The length of the lesion is determined from the diameter function on the basis of 
a curvature analysis and expressed in milimeters. The curvature is computed as the 
average value of all the individual curvature values along the centerline of the 
corouary segment, with the curvature defined as the first derivative of the tangent as 
it moves along the centerline which for a circle is equal to the reciprocal of the 
radius. 
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Fig. 2. The final result of the automated contour 
detection is the diameter function curve from 
which a number of angiographic parameters are 
calculated. The X-axis represents the extent of 
the segment, the Y -axis the value of several 
lesion characteristics such as minimal luminal 
diameter and reference diameter, expressed in 
mm. 
Fig. 3. Graphic display of a diameter function 
curve derived from a schematic coronary vessel. 
The definition of several angiographic variables 
describing the lesion morphology are illustrated. 
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To estimate the original diameter values over the obstructed region, the reference 
diameter is computed. The reference diameter can be selected visually as the nearest 
coronary artery segment that appears normal. However, to standardize this 
measurement and minimize potential errors, the '"interpolated"' reference diameter is 
used in all our studies. This method has the advantage of eliminating the arbitrary 
choice of a reference diameter, which will vary among individual observers, and also 
provides a smoothing effect for the segments adjacent to the stenosis so that extreme 
irregularities in the vessel have little influence on the reference diameter. The 
interpolated reference diameter is taken as the value of the reference diameter 
function at the location of the minimal luminal diameter. The latter is the single 
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smallest diameter value on the diameter function curve. Occasionally, a computer-
defined reference diameter can not be obtained. This occurs in situations where there 
is no reliable proximal or clistal obstruction boundary, such as lesions located at the 
ostia of a vessel or at the origin of side branches or in diffusely cliseased vessels. In 
such circumstances, the analyst may decide to choose a different part of the vessel 
as reference cliameter resulting in a "user-defined" reference diameter. Obviously, 
every user interaction introduces the risk of bias. 
From the miminal luminal diameter and the reference diameter, the percent 
diameter stenosis can easily be calculated. The same holds for the minimal luminal 
cross~sectional area, reference area and percent area stenosis. It is important to note 
that in these calculations a circular cross-section is assumed. An assumption which 
hardly holds in clinical practice [7-9]. The resulting error may be reduced by 
incorporating two orthogonal projections. 
The plaque area is a measure of the atherosclerotic plaque. This area is calculated 
as the sum of pixels between the computer-estimated predisease reference contours 
and the actual detected luminal comtours of the obstructive lesion. Since measure-
ment of plaque area is highly dependent on the length of the stenosis (which is 
subject to considerable variation) and the determination of the reference contours of 
the artery in the presumed prediseased state, the usefulness of this parameter is 
debatable. 
The symmetry value is a measure of the eccentricity of a particular lesion. A 
symmetry measure of 1 denotes a concentric obstruction; the number decreases down 
to 0 with increasing asymmetry or eccentricity of the obstruction. Unfortunately, this 
parameter has not been validated with pathologic studies and thus the pathologist and 
angiographer may not be talking about the same feature. The in- and outflow angle 
are derived from the slope of the diameter function curve at the defmed site of the 
stenotic segment. 
The CAAS system has also attempted to convert information on angiographic 
parameters into functional significance based fluid-dynamic equations (pressure 
gradient, Poisseuille and turbulent resistances) [10-13]. The calculated theoretical 
transstenotic pressure gradient over a particular stenosis describes the hemodynamic 
impact that a particular lesion would have under a range of flow conditions, withln 
the range of "normal" aortic pressures. These calculations do not account for the 
effects of pulsatile flow or of curved and tapered vessels, more than one lesion in a 
vessel, the presence of collater.ils, or perfusion of areas of nonviable myocardium. 
These effects of the entrance and exit angle (along with the absolute lesion diameter, 
percent narrowing, lesion length, blood flow velocity, and inertial and frictional 
effects) are important factors that detennine the physiologic significance of a stenosis 
[14]. The pressure gradient across a stenosis is determined by entrance effects, drag 
effects and exit effects. Although the most important site of energy loss is at the exit 
of a stenosis where the separation of the fluid column occurs, neither the outflow nor 
inflow angle have yet been incorporated into the CAAS software package to calculate 
pressure gradients. 
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Videodensitometry 
Although all our studies describing the changes in stenosis geometry after 
intracoronary stenting have used automated edge detection, there is some experience 
with videodensitometry in the setting of coronary stenting. 
Videodensitometry assesses the relative area stenosis by comparing the density of 
contrast in the diseased or treated segment with the density of contrast in the 
"normal" segment. The advantage of this method is that a single plane densitometric 
profile is sufficient to obtain meaningful data regardless of the lesion morphology. 
For absolute measurements (conversion of the relative area stenosis into absolute area 
stenosis or minimal luminal cross-sectional area), the reference diameter must be 
determined from the edge detection data with the assumption of a circular cross 
section. An example of such an analysis is shown in Figure 4. 
Fig. 4. Single frame angiogram with automated 
contour and videodensitometric analysis of the 
obstruction. Superimposed on the videoimage 
are the diameter function curve (upper curve) 
and the densitometric area function curve (lower 
curve). The minimal luminal diameter and 
minimal luminal cross-sectional area are the 
single lowest values on the diameter and video-
densitometric function curve, respectively. The 
white areas are the measure for the .. athero-
sclerotic~ plaque. 
Although videodensitometry is extremely attractive on a theoretical basis, 
numerous technical problems have limited its use [15]. Videodensitometry is much 
more sensitive than edge detection to densitometric non-linearities, oblique projection 
of an artery, and overlap with other vessels. It is easily appreciated that the advent 
of radiopaque stents has created its own specific problems. 
QCA AND INTRACORONARY STENTING 
Four types of intracoronary stents are currently used in the Thoraxcenter (Table 1). 
Three of these stents, the Wallstent, Palmaz-Schatz stent and the Gianturco-Roubin 
stent are composed of radiolucent stainless steel, whereas the Wiktor stent is 
radiopaque. The radiopacity of the Wiktor stent is explained by its chemical 
composition (tantalum) and its greater wire cross sectional area in comparison with 
the other stents. Tantalum has a higher atoJJJ.ic number than the elements contained 
in the stainless steel stents. Consequently, the larger electronic cloud surrounding the 
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nucleus absorbs more X-ray energy. This in combination with the greater wire cross-
sectional area result in a higher radiopacity (Figure 5). 
Fig. S. The Wiktor stent is entirely composed of tantalum which explains its radiopaque features on 
fluoroscopy. 
Table I. Intracoronary stents used in the Toraxcenter 
Stent 
Wallstent 
Wiktor stent 
Palmaz-Schatz 
Gianturco-Roubin 
Date 
Sept.'86 
Jan. '90 
Sept.'90 
Nov. '92 
QCA and stainless steel stents 
Indication 
venous bypass grafts 
restenosis{bail-out 
Benestent Studyjbail-out 
bail-out 
Although it has been postulated that the ideal stent should be, among other factors, 
radiopaque, poor angiographic visibility does not have to hamper exact stent 
positioning. However, for the analyst, the lack of radiopacity means that the stent 
boundaries may be uncertain which may render the analysis of the innnediate 
changes in stenosis geometry at the stented segment difficult and the precise location 
of late restenosis (within the stent or innnediate!y adjacent) may be in doubt. 
Nevertheless, in most instances one may discern the position of the stent by carefully 
reviewing the angiogram without contrast injection. Furthermore, in all our follow-up 
reports of stenting, we have included restenosis within and innnedlately adjacent to 
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the stented segment to ensure restenosis is not underreported due to this problem 
[16,17]. 
A second problem with angiographic analysis of stented vessels is due to the 
superior results immediately post stenting versus PTCA alone. One could focus on 
the changes in stenosis geometry at the stented segment itself or one could be 
interested in the overall changes in stenosis geometry of the treated coronary artery. 
This implies that, in the first situation, the analyst has to interfere with the automated 
edge detection program in order to let coincide the boundaries of the segment to be 
analyzed with the boundaries of the stent itself. This, we call a "stent analysis". In 
the second situation, there is no need for interaction with the choice of computer 
detected contours. The anatomical landmarks such as vessel branches are used to 
defme the boundaries of the segment to be analyzed and is called "vessel analysis". 
The use of one or the other significantly influences the results of quantitative 
coronary angiography. For instance, in case of complete correction or even 
overdilation of the obstruction segment, a negative value for diameter stenosis may 
be found when using the "vessel analysis" method. This is explained by the fact that 
the minimal luminal diameter ( defmed within the boundaries) is actually larger than 
the reference diameter which is determined according to the diameter of the proximal 
and distal segments (Figure 6). In other circumstances, one may also fmd that the 
minimal luminal diameter is located outside the stent. This results in a so-called 
'"unmasking of a lesion .. (Figure 7). In reporting our angiogarphic studies, we chose 
the pre and post PTCA frames to be analyzed by vessel, and the post stent and 
follow-up f:tlms according to the stent. This ensures that we obtain information 
related to the stent and its immediate adjacent segment rather than describing a more 
severe stenosis somewhere else in the coronary vessel. 
The minimal luminal diameter is now widely accepted as ultimate angiographic 
end point of studies analyzing the immediate and long-term effects of therapeutic 
interventions [18,19]. However, we have learned that the assessment of this 
parameter does not reflect all changes in stenosis geometry of the stented coronary 
artery segment. While there is still some gap between the minimal luminal diameter 
and the reference diameter, the mean diameter of the stented segment closely 
approaches the reference diameter of the treated vessel (Figure 8 A & B). 
QCA and radiopaque stenls 
It goes without saying that the radiopacity of the Wiktor stent facilitates exact stem 
positioning. Furthermore, dislodgement of the stent from the balloon during 
implantation may easily be recognized, promoting its safety. 
It may be argued that the radiopacity of the stent wires interferes with contour 
detection. However, it is our experience that in case of adequate filling of the 
coronary artery with a contrast medium at a concentration of 100%, this is not the 
case. It is, as if automated edge detection ignores the information coming from the 
radiopaque stent wires. This is true for both the analysis innnediately after stent 
implantation as well as for the assessment of neointitual hyperplasia within the stem 
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Fig. 6. Overdilatation of the coronary segment after stent implantation results in a minimal lwninal 
diameter which is greater than the reference diameter and as a result in a negative percent diameter 
stenosis. 
Fig. 7. User·defined extent of the stented segment coinciding with the extent of the stem itself results 
is a ·•stent analysis~. It forces the computer to analyze the changes in stenosis geometry within the stented 
segment. This contrasts with a -vessel analysis- in which no attempt has been made to coincide the extent 
of the analyzed segment with the extent of the stent. Due to the almost perfect improvement of the 
stenosis geometry after stent implantation. a non·significant lesion distal to the stented segment is now 
identified as a residual stenosis outside the stent. 
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Fig. 8. Cumulative distribution curves of the minimal luminal diameter and its changes after stent 
implantation (panel A) and the mean diameter post stenting in relation to the reference diameter of the 
target vessel (panel B). On the X-axis are shown the values of the angiographic variables and on the 
Y-axis the relative number of the population Wlder investigation. It is evident that, in contrast to the mean 
diameter of the stented segment, there is still a gap between the minimal luminal diameter and the 
reference diameter. 
at follow-up (Figure 9 & 10). This is in accordance with phantom studies from our 
laboratory which disclosed that automated edge detection, in contrast to videodensito-
metry, could adequately defme the luminal boundaries of a Wiktor stent-containing 
plexiglass phantom (Figure II) [20]. However, in some cases in which neointimal 
hyperplasia is not clearly defmed on the angiogram and appears as haziness within 
the stent, automated edge detection cannot accurately defme the luminal boundaries 
either. Mannual correction of the contours by the analyst would induce to much bias. 
It is the only situation in which videodensitometry may offer a solution despite the 
inevitable densitometric information coming from the stent itself. Accurate stenosis 
values are obtained by selecting the reference segment ("user-defmed" reference 
diameter) within a non-narrowed segment within the stent itself (Figure 12). Of all 
the follow-up angiograms of the Wiktor stent, videodensitometry had to be used in 
8% of the cases. 
Specific data on videodensitomerty 
In contrast to the situation after PTCA, there is an excellent agreement between the 
minimal luminal cross·sectional area determined by edge detection and videodensito-
metry after stent implantation [21,22]. In 19 patients who underwent balloon 
angioplasty followed by stent implantation, a significant improvement in the 
correlation and variability in the measurement of the minimal luminal cross-sectioual 
area between edge etection and videodensitometry was observerd after stenting [22]. 
This improvement is likely due to smoothing of the vessel contours by the stent and 
remodeling of the stented segment into a more circular configuration. Therefore, we 
believe that both methods are appropriate to assess the inunediate results after 
implantation of stainless steel stents. In a separate in-vitro study in which stainless 
steel and radiopaque stents were placed in known stenoses within plex.iglass 
phantoms, The Wallstent and Palmaz-Schatz stent had minor and clinically 
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Fig. 9. Example of a computer-assisted Coronary Angiography Analysis using automated edge detection 
immediately after Wiktor stent implantation. There was no interference of the radiopaque stent wires with 
the contour detection. 
Fig. 10 (left). A significant luminal renarrowing within the Wiktorstent is appreciated on the angiogram. 
Despite the radiopacity of the stent, automated contour detection resulted in an adequate detection of the 
luminal contours without user interaction. 
Fig. 11 (right). Control (a) and Wiktor stent-containing (b) plexiglass phantoms (3 x 2 mm) filled with 
100% and 50% iopamidol contrast medium, respectively. Graphs show the diameter function (upper curve) 
and the densitometric area function (lower curve). Outside vertical lines on the graph and rightward two 
vertical lines on the phantom are the iesion boundaries. The inner two vertical lines represent the minimal 
points on the diameter and densitometric graphs, respectively. The multiple vertical lines in the left part 
of the graph and the lefward vertical line in the phantom represent the user-defmed reference segment. 
The numbers in the graph represent the maximum and minimum diameters. The boundaries of the Wiktor 
stent are visible in the phantom (arrowheads) and as a step-up in the densitomeuy graph (arrow). 
Reproduced with permission from Strauss et al, Catheterization and Cardiovascular Diagnosis 1991; 
24:259-264. 
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Fig. 12. In case of haziness as expression of restenosis within the Wiktor stent, edge detection cannot 
define the arterial boundaries. In such circumstances, videodensitometry is used. To obtain accurate values 
of the minimal luminal cross-sectional area, the user selects the reference in a non-stenosed segment in 
the Wiktor stent itself. 
insignificant contributions to the densitometric determination of the minimal luminal 
cross-sectional area [20]. Conversely, the radiopacity of the Wiktor stent increased 
the minimal luminal cross-sectional area in these same narrowings by 10-56% 
depending on the concentration of contrast medium and specific stenosis [20]. 
WHY SHOULD WE USE QCA DURING STENT IMPLAN-
TATION? 
Restenosis should be considered as the reparative vessel wall response or perhaps as 
the natural healing process following injury [23,24]. When excessive, this may lead 
to new symptoms and eventually to repeat intervention [25]. One of the objectives 
of stent implantation is to reduce the incidence of restenosis in the hope that it will 
favorably affect the long-term clinical outcome. Stent implantation causes substantial 
injury to the coronary vessel wall and therefore will invariably be associated with 
restenosis. Schwartz et al. demonstrated that the extent of late neointimal hyperplasia 
was directly related to the degree of vessel wall injury following oversized coil stent 
implantation in porcine coronary arteries [26]. In accordance with these data, we 
found that the extent of late luminal renarrowing, increases with the amount of 
luminal gain after stent implantation in human coronary arteries [27]. Resolution of 
clinical or angiographic restenosis may require the creation of the largest possible 
luminal diameter and the control of neointimal hyperplasia. On-line quantitative 
coronary angiography can beneficially be used during stent implantation to minimize 
vessel wall injury and to guide the operator to obtain the most optimal angiographic 
result. Minimizing vessel wall injury is achieved by selecting the appropriate stent 
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immediate changes in stenosis geometry. 
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Relative galn angiography have sho\VD. a positive linear 
Fig.J3. Graphic display of the relation between 
the relative gain (RG - increase in minimal 
Iwninal diameter immediately after stent implan-
tation normalized to the vessel wall) and relative 
loss (RL - decrease in minimal luminal diameter 
at follow-up nonnalized to the vessel wall). A 
positive linear relation was found with a cor-
relation coefficient of 0.38 (p<O.OOl) with a slope 
of 0.61 and an intercept on theY-axis of -0.06. 
correlation between the relative gain and 
relative loss (Figure 13). However, one 
should realize that the greater gains are 
not fully offset by the increased loss in 
ntinimalluminal diameter which is reflect-
ed by the slope of the curve ( < 1). This 
once again confrrms that the superior 
improvement in stenosis geometry after 
stent implantation compensates to some 
degree for late loss. In addition, data from other investigators who used the categor-
ical approach to defme restenosis found that a suboptimal angiographic result after 
stent implantation was associated with an increased risk for restenosis according to 
the 50% diameter stenosis criterion [28,29]. On-line quantitative coronary angio-
graphy is essential to assess the residual stenosis post stent implantation. If necessary, 
an additional balloon angioplasty within the stent can be performed to optimize the 
immediate results (Figure 14). Based on the data of Strauss et al. we perform such 
an additional dilatation when the residual percent diameter stenosis exceeds 20% 
[28]. The size and inflation pressure is determined on the basis of the on-line 
quantitative coronary angiography. 
QCA TO EVALUATE DIFFERENT INTERVENTIONAL TECH-
NIQUES 
There are currently several interventional teclmiques in clinical use. They do not only 
differ in the mechanisms by which they result in luminal enlargement but also in the 
immediate angiographic result or gain and late loss [30]. Because of this difference 
and because the ntinimal luminal diameter at follow-up has been shown to best 
describe the functional status of the patients 6 months after coronary intervention, we 
have proposed the ntinimal luminal diameter at follow-up as the angiographic end 
point in studies comparing different interventional techniques provided that the 
patients included have comparable reference diameter and ntinimalluminal diameter 
prior to the intervention [5,18,19]. 
The angiographic parameters are best used in a continuous approach and displayed 
in cumulative distribution curves reflecting the entire study population under 
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Fig. 14. On-line quantitative coronary angiography disclosed a residual stenosis immediately after stent 
implantation. This infonnation was used to further optimize the dilatation process by performing an 
additional balloon dilatation within the stent. 
evaluation (Figure 8,15) [19]. The advantage of this method is that the absolute 
enlargement of the vessel lumen and the absolute loss of the initial gain in luminal 
size are easily gleaned from the curves and allows the comparison of the innnediate 
and long-term angiographic outcome of different interventional techniques [19]. 
Furthermore, it depicts the process of restenosis independent of any definition. The 
medical practictioner who still would like to use the categorical approach ("present/ 
not present"), can obtain these data from the cumulative distribution curve of the 
percent diameter stenosis at follow-up (Figure 16). 
CONCLUSIONS 
Quantitative coronary angiography has been developed to assess objectively the 
efficacy of modem therapeutic procedures in the catheterization laboratory. The 
advent of new and innovative therapeutic interventions have raised unforeseen 
problems. In most instances, they have effectively been addressed and even solved 
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Fig. 15. The graphic display of the minimal 
luminal diameter post intervention and at follow-
up as a continuous variable in cumulative distrib-
ution curves offeiS the unique advantage that it 
reflects the absolute changes (in this case loss) of 
the initial gain. 'This model is particularly valu-
able in analyzing the value of different interven-
tional techniques and may provide insight into the 
mechanisms of dilatation and restenosis. 
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Fig. 16. Every angiographic variable may be 
displayed as a continuous variable in cumulative 
distribution curves. The minimal luminal diameter 
at follow-up, is depicted in the upper graph. The 
percent diameter stenosis at follow-up is shown 
on the lower graph. The number of patients with 
a diameter stenosis> 50% at follow-up can easily 
be gleaned from this graph. 
thanks to the lmowledge and understanding of the technical limitations of this 
analysis method. This system does not only provide accurate assessment of the 
immediate and long-term changes in stenosis geometry following coronary 
intervention, but can also be used as a tool to understand the mechanisms of luminal 
enlargement and the pathophysiology of restenosis. 
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Feature Topic: Stents in Clinical Practice 
Morphologic Change in Coronary Artery Stenosis With 
the Medtronic Wiktor® Stent: Initial Results From the Core 
Laboratory for Quantitative Angiography 
Patrick Serruys, MD, Peter De Jaegere, MD, Michel Bertrand, MD, Gisbert Kober, MD, 
Jean Francois Marquis, MD, Jan Piessens, MD, Rainer Uebis, MD, Bernard Valeix, MD, and 
Volker Wiegand, MD 
The purpose of this study was to assess the early changes Jn stenosis geometry after 
Implantation of the Medtronic Wlktor'l"' stent in human coronary arteries. Morphologic 
changes were evaluated by quantitative coronary angiography using automated edge 
detection. The hemodynamic significance of the morphologic changes were assessed by 
the calcula1ion of the tttooretlcal pressure drop across the dilated and stented stenosis 
deriveo from the Poiseuile and turbulent resistances assuming a coronary blood flow of 
either 0.5, 1, or 3 ml!sec. Fifty patients were studied before and Immediately after s1ent 
Implantation. The stented coronary artery was the lett anterior descending artery In 26 
patients. the circumflex artery in eight patients. and the rlght coronary ar1ery in 16 pa· 
tlents. Stant Implantation result!XI in an addltlonalincrease In the minimal luminal cross-
sectional area and minimal luminal diameter of the dlla1ed vessel without changing the 
curvature of the stenosis. Furthermore, there was a significant reduction of the •·plaque 
area:· This was associated with a normalization of the calculated resistances to flow and 
presure drop across the stenosis. To a minimal extent. recoil (0.1 ::!:: 0.36 mm) was ob-
served after stent Implantation. 
Key words: coronary stent. quantitative analysis, stenosis geometry 
INTRODUCTION 
Percutaneous Tr:msluminal Coronary Angioplasty 
(PTCA) is now accepted as a safe and effective therapy 
for obstructive coronary artery disease. Gained experi-
ence and improved catheter technology have resulted in 
a high initial success rate [1-3]. These favorable initial 
results arc offset by a restenosis rate of 30% to 40% 
during the first 6 mon after the procedure [4-5]. Stent-
ing of the dilated vessel may offer an alternative ap-
proach for the prevention of rcstenosis [6]. Different 
prostheses have been developed and tested in animal ex-
periments and implanted in humans [7-ll). The 
Wiktor¢~ stent (Medtronic Inc.. Mineapolis. Minn. 
USA) is a new intravascular prosthesis which. in contrast 
to the Wallstent® (Schneider, ZUrich. Switzerland) and 
Palmaz-Schatz® stent (Johnson & Johnson, Warren, 
USA). is not a mesh made of stainless steel. but a ra-
diopaque single loose interdigitating tantalum wire 
which undergoes oxidation after implantation. The re-
sultant oxide (Ta05) is not only very stable. implying 
less changes in surface charge. but also corrosion resis-
© 1991 Wiley-Liss, Inc. 
22 
tant [12]. Potentially. the smaller :unount of endothelial 
smface covered by the stent (less than 10% of the vas-
cular endothelium is covered by a full expanded stent) in 
conjunction with the electrochemical characteristics of 
this stent protect against thrombus form:1tion. As a result 
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of the loose configuration. it has been hypothesized that 
the Wiktof® stcnt accommodates more adequately to the 
natural bending of the coronary artery in contrast to the 
stcnts with a more rigid and stiff mesh architecture such 
as the Palmaz-Schatz® stcnt. The Wiktor® stent. like the 
Palmaz-Schatz® stent. is a balloon expandable endolu-
minal prosthesis and does not exert an active radial force 
on the vascular wall after deployment as occurs with the 
Wallstcnt® (13]. However. the loose configuration of the 
Wikto~ stcnt may have less scaffolding properties com-
pared to the other two intravascular prostheses. 
The purpose of this study was to assess the early mor-
phologic ctumgcs in stenosis geometry. including the oc-
currence of recoil. by quantitative coronary angiography 
and to assess the physiological significance of these 
changes by calculating the pressure drop across the ste-
nosis for a theoretical blood flow of0.5 to 3 mVsec after 
Wiktor® stent implantation in human coronary arteries. 
MATERIALS AND METHODS 
Patients 
Fifty patients (45 male. five female. median age 57 
years-range 30-77) were studied. The patients were 
treated and investigated in the following centers: Depart-
ment of Cardiology. HOpi tal Cardlologiquc Lillc. 
France. Department of Cardiology. Klinikum dcr J. W. 
Goethe Univcrsitiit Frankfurt. Gennany. Department of 
Cardiology. Ottawa. Ontario. Canada. Department of 
Cardiology. University Hospital Gasthuisberg. Leuvcn. 
Belgium. Department of Cardiology. Medical Clinic I 
RWTH Aachen. Germany. Department of Cardiology. 
Georg August Univcrsitiit. GOttingcn. Germany. and the 
Catheterization Laboratory. Thoraxccnter. Rotterdam. 
Netherlands. Written informed consent was obtained 
from every patient. WiktofG> stent (Medtronic Inc .• Min-
neapolis. :Minn .• USA) was implanted because of a frrst 
restcnosis of a native coronary artery in 33 patients. a 
second restcnosis in 12 patients. and a third restenosis in 
five patients. In all patients objective evidence of isch-
emia was documented. The dilated and stcnted coronary 
artery was the left anterior descending artery in 26 pa-
tients (62%). the circumflex ancry in eight patients 
(16%). and the right coronary artery in 16 patients 
(32%). The nominal diameter of the balloon on which 
the stcnt was mounted was 3.0 mm in 23 patients. 3.5 
mrn in 20 patients. and 4.0 mm in seven patients (14%). 
The nominal diameter of the balloon for the total study 
group (mean ::t SD) was 3.35 ± 0.36 mm. 
Description of the Stent 
The endoprosthesis used in this study is a balloon-
expandable stent (Wik"tor®. Medtronic Inc .• Minneapo-
lis. Minn .. USA) constructed of a single tantalum wire 
Fig. 1. a: W!ktorit" stent crimped onto an polyethylene anglo-
plasty balloon before lnflatlon. b: Wiktor:t" stent on fully inflated 
angloplasty balloon. 
(0.125 mm in diameter) which is formed into a sinusoi-
dal wave and wrapped into a helical coil structure. This 
prosthesis is crimped onto the deflated polyethylene bal-
loon of a stand::n"d angioplasty catheter (Fig. la). The 
features of this prosthesis design arc such that by inflat-
ing the balloon the diameter of the stent increases with-
out any alteration in length (14-16 mm. Fig. lb). The 
crimped stcnt profile is approximately 1.5 rnm. The 
maximal diameter of the balloon during inflation deter-
mines the ultimate size of the prosthesis on implantation. 
One inflation at 6-8 atm is sufficient to open the stcnt 
and allows the safe withdrawal of the deflated balloon. 
Stent Implantation 
One day prior to stcnt implantation acetylsalicylic acid 
300 mglday was started. Dextran (100 ccfhr) was admin-
istered 2 hr before the implant and continued throughout 
the procedure. A minimum of 500 cc was infused. A 
total of 20.000 units of heparin was injected intrave-
nously. Full heparinization was maintained until thera-
peutic levels of coumadin therapy were achieved. Con-
ventional balloon angioplasty was performed and 
repeated until the desired angiographic result was ob-
tained. After control coronary angiography for subse-
quent quantitative analysis. the balloonJstent system was 
advanced over a 0.014-in steerable guidewire under flu-
oroscopic control to the treated lesion site. The balloon 
was inflated until the desired expansion of the stent was 
achieved. Subsequently the balloon was deflated and the 
catheter was removed under negative pressure while 
leaving the stent in place. In case of incomplete expan-
sion of the stcnt, a repeat balloon dilatation within the 
stem was performed. After repeat coronary angiography. 
the guiding catheter was removed. The post-procedure 
drug therapy consisted of coumadin for a minimum of 3 
mon and acetylsalicyclic acid (300 mg/day) for 6 mon. 
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Quantitative Coronary Angiography 
The coronary cinc:angiograms were analy-Led by a 
computer-assisted Cardiovascular Angiography Analysis 
System (CAAS). described in deuil elsewhere (14.15]. 
Briefly. this system allows an objective and reproducible 
quantification of a coronary artery stenosis. A 35-mm 
cineframe was selected and digitized with :1 CCD-camera 
at very high resolution (1330 x 1770 pixels) and elec-
tronically a region of interest (512 x 512 pixels) encom-
passing the: arterial segment to be analyzed was selected 
for subsequent analysis by the computer. 
Contours of the arteri:ll segment were detected auto-
matically on the basis of the first and second derivative 
functions of the brightness profile, and corrected for pin-
cushion distortion from the image intensifiers. A calibra-
tion factor was derived from a computer processed seg-
ment of the angio-catheter. From the arterial contour 
data. a diameter function was computed. The minimal 
luminal diameter and a reference diameter. computer-
estimated by the interpolated diameter technique, were 
expressed in millimeters. On the basis of the proximal 
and distal centerline segments and the computed refer-
ence diameter function. the reference contours over the 
obstructed region were reconstructed. The extent of the 
obstruction was determined from the diameter function 
on the basis of curvature analysis and expressed in mil-
limeters. The curvature is computed as the average value 
of all the individual curvature values along the centerline 
of the coronary segment, with the curvature defined as 
the first derivative of the tangent as it moves along the 
centerline which for a circle is equal to the reciprocal of 
the radius. The difference in area between the reference 
and the detected contours over the lesions ("plaque 
area." in mm2) is a measure for the atherosclerotic 
plaque (16). The inflow angle is the average slope of the 
diameter function between the position of the minimal 
obstruction diameter and the position of the proximal 
boundary of the stenotic lesion. The outflow angle is the 
average slope of the diameter function of the minimal 
obstruction diameter and the position of the distal bound-
ary of the stenotic segment. 
The severity of the stenosis can also be expressed as a 
percentage area stenosis: assuming circular cross-
sections at the obstruction and reference position. corre-
sponding luminal areas (mm2) were calculated by com-
paring the minimal area value at the obstruction with the 
reference v:llue obtained following the interpolated di-
ameter technique. An illustration of such a qu.antit::ttive 
analysis of a coronary artery is shown in Figure 2. 
Elastic recoil was calculated as the difference between 
the mean diameter of the balloon when fully infbted and 
the mean diameter of the stented segment immediately 
after stcnt delivery and withdrawal of the balloon. Single 
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identical views during complete expansion of the balloon 
and immediately after stcnt implant::ttion were chosen for 
automated edge detection. 
Hemodynamic Assessment 
To assess the physiological significance of the obstruc-
tion and its changes after angioplasty and stcnting. the 
theoretic pressure drop was calculated using the arterio-
gram and digital computation. according to the formulae 
described in the literature: Pgrad = Q.(Rp + Rt), where 
Pgrad is the theoretic transtenotic pressure decrease (nun 
Hg) over the stenosis. Q is the mean coronary blood flow 
(rnUsec). Rp is the Poiseuillc resistance. and Rt is the 
turbulent resistance [17 .18]. 
These resistances have been deflned as follows: 
Rp = Cl. (length obstruction)/(minimal crc"s-,cctionul =~l'. 
where Cl = 8.1t.{blood vL-cosity) with blood vi...:osity .- 0.03 gtcrn.sec; 
Rt = C2.(1/minirnul cro"·sectionul area- 1/nonnaJ di~tal =~f. 
where C2 = (blood den_,ity)/0.266 with blood dens1ty = 1.0 (1cm'. 
The theoretic tr.tnsstenotic pressure drop was calcu-
lated for theoretic coronary blood flow of 0.5. 1, and 3 
rnUsec. The Poiseuille and turbulent contributions to the 
flow resistance were determined from stenotic geometry 
assessed by quantitative coronary angiography. 
Statistical Analysis 
All values arc expressed as mean with the stand:trd 
deviation of the mean. Comparisons between measure-
ments obtained after PTCA and stcnting were made after 
variance analysis with the Student's r-test for paired ob-
servations. A st::ttistical level <0.05 was considered as 
significant. 
RESULTS 
The morphologic and hemodynamic data (mean ± 
SD) are presented in Tables I. II. and III. 
Stent implantation after balloon angioplasty resulted in 
an additional incrca..">C in minimal luminal cross-sectional 
area and minimal luminal diameter with a concommitant 
decrease in percent::tge area and percentage diameter ste-
nosis compared with the postangioplasty state (Table n. 
Moreover. there was a significant decrease in plaque area 
and inflow and outflow angles while the curvature of the 
lesion was respected (Table m. 
This morphologic improvement was associated with a 
decrease in both the calculated turbulent and Poiscuille 
resistance, as well as the virtual disappearance of the 
theoretical transstcnotic pressure drop for a theoretical 
flow of 0.5. and 3 rnUsec (Table III). 
Fig. 2. 1a-3b. 
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A g. 2. Illustration of a quantitative analysis of a coronary artery. Single plane anglograms of 
the proxlmalleftanterlorc!escendlng before and after balloon angioplastyand immediately after 
stent Implantation with superimposition of the automated contours of the region of interest. 
Below each angiogram Is shown the diameter function of the detected contours of the artery. 
The minimal luminal diameter (vertical line) and the Interpolated diameter function (horizontal 
line) from which the reference diameter Is derived are shOwn. For further explanation, see teXL 
In most patients, the measured diameter of the balloon 
when fully inflated exceeded the measured diameter of 
the stent (Fig. 3). During maximum inflation the mean 
diameter of the balloon for the total study group was 2.98 
± 0.44 and the mean diameter of the stented segment 
immediately following implantation was 2.88 ::!;:: 0.43 
mm (Table IV). This implies arecoilofO.IO ± 0.36mm 
or 3% (P < 0.03). 
26 
DISCUSSION 
Coronary artery stenting has been introduced as an 
adjunct to PTCA in obstructive coronary artery disease 
[6-10.19,32]. The implantation of vascular endopros-
thcses may provide a useful approach to prevent oc-
clusion and restenosis [6]. As for every therapeutic 
procedure, an objective and reproducible technique eval-
uating efficacy is needed. Computer based automated 
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TABLEt. Morphologic Changes Immediately Aftef Balloon Angloplasty and Subsequent 
Stent Implantation 
Pre-PTCA Post-PTCA Po,1-stent P, 
E:-:.tent obstruction (mm) 7.24 ~ 2.48 6.63 ~ 2.63 5.35 ~ 1.86 NS 
Reference diameter (mm) 2.81 ~ 0.47 2.78:!:: 0.48 2.91 ~ 0.43 NS 
/"YlLD (rnm) 1.09:!:: 0.26 1.80 = 0.32 2.45:!:: 0.36 0.00001 
Diameter '1enosi.~ (%) 61.00 = 9.19 34.00 = 10.76 17.00 = 7.18 0.00001 
Reference area (mm~) 6.38 = 2.15 6.26 = 2.18 6.83 ~ 2.07 NS 
MLCA (mm~) 0.99:!:: 0.44 2.63:!:: 0.92 4.8] = 1.42 0.00001 
~ steno,is (<;O) 84.00:!:: 7.58 56.00 = 13.94 31.00:!:: 1!.57 0.00001 
l__P,__jl P~__j 
P, 
0.001 
0.001 
0.00001 
0.00001 
0.[XJ3 
0.00001 
0.00001 
MLCA, minimal luminal cros.-;-~oruil area; MLD. minimal luminal diameter. All pummeters are expressed in 
mean:!:: SO. 
TABLE 11. Morphologic Changes Immediately After Balloon Angloplasty and Subsequent 
Stent Implantation 
Pre-PTCA Post-PTCA Post-stent P, 
Curvature 21.00 = 8.90 21.00 = 8.65 20.00:!:: 9.49 NS 
Plaque area (mm~) 8.53 = 4.33 5.13::3.48 3.33 :!:: 2.29 0.00001 
Inflow angle 23.00:!:: 6.28 15.00 = 5.25 7.00:!:: 15.64 NS 
Outflow angle 23.00:!:: 10.39 19.00 = 19.74 5.00:!:: 15.17 NS 
P,__jl__p,__j 
All par.unet= are exp~ in mean :: SO. 
TABLE IlL Hemodynamic Results Immediately After Balloon Angioplasty and Subsequent 
Stent Implantation 
Pre-PTCA Post-PTCA Post-stent P, 
Rpois 18.00 = 38.44 1.22 :':: 1.72 0.47.:;!; 0.28 0.002 
R""' 11.00 :':: 28.91 0.32 = 0.7:! 0.02 = 0.02 0.01 
Pgnld (0.5 mV=:) 29.00 :':: 67.00 1.52 :': 2.42 0.49 = 0.29 0.004 
Pgrnd (1 rnl!see) 48.00 = 65.57 3.66 = 6.26 1.00 = 0.61 0.00001 
Pgr:.d (3 rnl!"'c) 92.00 :': 126.75 6.45 = 11.53 1.53 :!::0.99 0.00001 
L__P,__jl P~__j 
P, 
NS 
0.()00.> 
0.00001 
0.00001 
P, 
0.003 
0.005 
0.004 
0.004 
0.004 
Rpoi,. Poilic:uilk resistance; Rturb, llltbuknt resistance: Pgrnd, pressure drop. All parameter,; are expressed in mean 
=so. 
edge detection angiographic analysis systems h:lve re-
duced the variability resulting from visual and caliper-
determined contour detection of coronary cincangio-
gr:uns [20-22]. 
The optimal method to quantitatively analyze the im-
mediate angiographic results of coronary stenting in na-
tive coron::rry arteries is still a matter of debate. At 
present. two techniques arc ava.il:lblc: automnted edge 
detection and videodensitometry. The technique of auto-
mated edge detection is limited in eccentric lesions and 
in particular following balloon angioplasty when acute 
tears and dissections distort the anatomy. Videodensito-
metric measurements of cross-sectional area are indepen-
dent of geometric assumptions regarding the shape of the 
stenosis and should. in theory. be more reliable than 
edge detection. especially after the disruptive action of 
balloon angioplasty. which is known to cnuse asymmet-
ric enlargement of the lumen [23.24]. However. a recent 
study has shown that edge detection and videodensitom-
etry are equally acceptable methods of analysis after cor-
onary stenting [25]. This may be explained by the more 
regular and smooth vessel contours after stenting, with 
tncking back of the intimal flaps by the scaffolding prop-
erty of the stent in some cases :md by the remodeling of 
the stented segment into a more circular geometry. 
Moreover, it has been shown that videodensitometry 
overestimates the minimal luminal cross-sectional area. 
particularly in smaller vessels with the Wiktor@l stent 
[26]. This may be due to the radiographic characteristics 
of the stcnt itself. 
X-ray energy dispersion spectrometry studies from our 
laboratory have shown that the structure of the Wiktor® 
stent has only one element, tantalum. which has a higher 
atomic number than the elements contained in the Pal-
maz·Schatz® stent and the Wallstent®. Consequently, 
more X-ray energy is absorbed by the Wiktor® stent 
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Fig. 3. Correlation betwoon the measured diameter of the bal· 
loon when fully Inflated anC: of the s.tent immedlately after 1m-
plantation. 
wire. Furthermore, the Wiktof® stcnt has a greater wire 
cross-sectional area than the other two stents. These 
physical chamctcristics result in a higher rndiopacity in 
comparison with the stainless steel stems. As a result. the 
intraluminal brighmess profile generated by the Wili:or® 
stent makes automated edge detection the appropriate 
technique for quantification of the stented segment. Con-
versely. videodensitometry may be the technique of 
choice for the assessment of restenosis. Intimal hyper-
plasia developing within the stent may not be detected by 
edge detection technique. which is unable to distinguish 
between the radiopaque structure of the wire embedded 
in the vessel wall and the actual boundaries of the lumen 
radiopacified by the contrast medium. For these reasons. 
automated edge detection was used for the immediate 
angiographic assessment in this study. 
The increase in minimal luminal diameter after bal-
loon angioplasty (1.09 ± 0.26 mm to 1.80 ± 0.32 mm). 
is what has been observed in other series [27 .28]. This 
emphasizes that prior to stenting the stenotic lesion has 
been dilated to the extent normally expected. The addi-
tional improvement after the implantation of the 
Wiktof'3 stcnt is comparable to what has been observed 
with either self expanding or balloon expandable stems 
[7.28.29]. The same holds for the minimal luminal 
cross-sectional area. There is a fivefold increase in the 
minimal luminal cross-sectional area after stenting (0.99 
::!: 0.44 mmz to 4.83 ± 1.42 mmz). As previously dem-
onstrated, a normalization of the coronary flow reserve 
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TABLE IV. Nominal Diameter of the Balloon, Measured 
Diameter of Balloon at Maximal Inflation Pressure. anc: of 
Stented Segment by EC:ge Detection 
Nominal Measured Mea.~ured diameter P, 
diameter b:illoon diameter b:illoon ,lenled SCf:!Ilent 
P, 
3.35 :t. 0.36 mm 2.98 :>:: 0.44 rnm 2.88 :>:: 0.43 rnm 0.0001 0.03 
All parameters arc expressed in mean :t. SD. 
may be expected with such an increa.·.;e [30]. As indirect 
confirmation of the above findings. the pressure drop 
across the stenosis remains virtu:llly zero even with a 
theoretical flow of 3 rnllsec and a normalization of the 
calculated resistances. In addition to the increase in the 
minimal luminal cross-sectional area. there is a signifi-
cant change in plaque area. in the inflow and outflow 
angles. :md in the extent of obstruction. while the natural 
curvature of the artery is respected. 
However. the smaller mean diameter of the stented 
segment (2.88 ::!: 0.43 mm) in comparison with the mea-
sured diameter of the fully expanded balloon (2.98 ± 
0.44 mm) suggests some recoil of the stented segment. 
This minimal recoil appears to be a true phenomenon 
since the accuracy and the precision of the CAAS system 
is -30 !J. and 90 !J.. respectively [13-15]. Furthermore, 
the recoil phenomenon has also been observed. although 
to a larger extent. after Wiktof'~ stcnt implant::Ltion in 
Yorkshire pigs [11]. The more pronounced recoil (10%) 
in the animal model compared to the 3% recoil in this 
study may be explained by the foct that in the former 
study the stent was implanted in normal :mirnal coronary 
arteries. These angiographic data indica.te that in contrast 
to b:llloon angioplasty. where recoil amounting to 50% 
has been documented [31], the Wiki:or@l stent appropri-
ately scaffolds the vessel. 
The measured diameter of the inflated balloon at an 
average inflation pressure of 6-8 atm (2.98 ::!: 0.44 mm) 
did not achieve the nominal size of the balloon (3.35 ::!: 
0.36 mm) as specified by the manufacturer. The inflation 
pressure needed to obtain the nominal size of the balloon 
has been tested in air. It may be that a higher inflation 
pressure should be applied to achieve full expansion of 
the balloon to overcome the opposing forces exerted by 
the arterial wall and possibly by the stent itself. 
CONCLUSIONS 
Implantation of the Wiktofli<l stent results in a further 
improvement in stenosis geometry after balloon angio-
plasty. A fivefold increase in the minimal luminal cross-
sectional area with a significant reduction of the inflow 
and outflow angles is observed without changing the 
curvature of the stenosis. This is associated with a nor-
244 Serruys et al. 
malization of the resistances to flow. With the recom-
mended inflation pressure of 6-8 atm. there is no full 
expansion of the b::tlloon on which the stent is mounted. 
Furthermore, some recoil (0.10 ± 0.36 mm) is observed 
after stent implantation. This may be explained by the 
rather loose interdigitating coil structure of this particular 
stent. 
Whether these observations will result in a reduced 
rcstenosis rate in comparison with balloon :mgioplasty 
and to an improved long-term clinical success rate re-
mains to be dctennincd. 
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CHAPTER3 
IMl\1EDIATE CHANGES IN STENOSIS 
GEOMETRY FOLLOWING STENT 
IMPLANTATION: COMPARISON BETWEEN 
A SELF-EXPANDING AND 
A BALLOON-EXPANDABLE STENT 
P.P.T. de Jaegere, B.H. Strauss, W.J. van der Giessen, P.J. de Feyter, 
P.W. Serruys. 
J oflnterven Cardiol1992; 5:71-78. 
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Immediate Changes in Stenosis Geometry Following Stent Implantation: 
Comparison Between a Self-Expanding and a Balloon-Expandable Stent 
PETER P. DE JAEGERE. M.D .. BRADLEY H. STRAUSS. M.D .. 
WILLEM J. VANDER GIESSEN. M.D .. PIM J. DE FEYTER. M.D .. 
and PATRJCK W. SERRUYS. M.D .. PH.D. 
From tht: Catht:tt:ri::ation Laboratory and Laboratory for Quanrirath•t: Angio[!raphic Analysis (Cardiolysis). Thoraxcenrer. 
Rotterdam. The Netherlands 
The immediate changes in stenosis geometry following Walls tent and Wiktor stent implantation in 
native coronary arteries were compared in 92 patients (46 in each group) using automated edge detec-
tion. Patients with comparable baseline stenosis characteristics were selected. Lesions were matched 
for lesion site, reference diameter, and minimal luminal diameter. In both groups, the stented coronary 
artery was the left anterior descending artery in 27 patients (59o/o), the left circumflex artery in four 
patients (9%), and the ri'ght coronary artery in 15 patients (33%). The baseline reference diameter was 
2.86 ::t 0.39 mm and 2.87 ::t 0.42 mm in the Wallstent and Wiktor stent study group. respectively (NS). 
The baseline minimal luminal diameter was identical in both groups (1 .13 ::t 0.24 mm). The nominal 
si::e (mean:!: SD) of the unconstrained Wallstent was 3.5 ::t 0.3 mm and3.3 ± 0.3 mmfor the Wiktor 
stent (P < 0.05). Both types of stems resulted in a similar increase in minimal luminal diameter 
immediately following implantation (Wallstent: 234 ::t 0.38 mm, Wiktor stent: 2.43 ::t 0.27 mm, NS). 
Furthermore. there was a similar decrease in diameter stenosis and increase in minima/luminal cross-
section area following implantation of both stents. These morphological changes were associated with 
a normalization of the hemodynamic parameters in both groups. It is concluded that, although the 
Wallstent and Wiktor stem are different in design and mechanical characteristics, there is a similar 
immediate improvement in stenosis geometry following implantation of both devices. (J lnterven Car-
diol1992: 5:71-78) 
Introduction 
Treating obstructive coronary artery disease 
by means of intravascular catheters is an old 
dream that came true in the late 1970s. 1•2 Percuta-
neous coronary artery balloon angioplasty has 
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31-10-436-2995. 
been plagued by restcnosis since its introduction. 
To circumvent this limiting factor. intracoronary 
stenting has been proposed as an adjunct to bal-
loon angioplasty. 3 Although the exact pathophys-
iological mcchanism(s) responsible for restenosis 
arc largely unknown, intracoronary stcnting may 
result in a lower incidence of restenosis by optim-
izing the balloon dilatation process. Indeed. it has 
been shown that stcnt implantation does not only 
provide scaffolding for the vessel and thereby 
prevents recoil but also results in a larger vessel 
lumen and cross-sectional area compared to bal-
loon angioplasty and thus may compensate for 
late neointimal hYPerplasia.4-7 
Submitted for publication November 5. 1991: accepted for 
publication February 10. 1992. 
At present, several stents are available. each 
with its own specific design and physico-chemical 
characteristics. 6•8 - 10 Distinction can be made be-
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tween self-expanding and balloon-expandable de-
vices. The self-expanding stent, in contrast to the 
balloon-expandable devices. exerts active radial 
force on the vessel wall after dcployment.3 •5 • 11 • 1::: 
This may result in differences in vessel lumen ge-
ometry following stenting. Therefore. the aim of 
this study is to compare the morphological 
changes in stenosis geometry immediately follow-
ing the implantation of a self-expanding stent 
(Wallstent, Medinvent, Lausanne. Switzerland) 
and a balloon-expandable stent (Wiktor stent, 
Medtronic. Inc .. Minneapolis. MN, USA). 
Methods 
Patients. At present. our database contains the 
angiographic data of 257 patients in whom a 
Wallstent (162 patients) or Wiktor stem (95 pa-
tients) were successfully implanted in a native 
coronary artery. Two groups of patients with 
comparable baseline stenosis characteristics 
were selected according to the matching princi-
ple. Only patients in whom a Wallstent or Wiktor 
stent was successfully implanted as elective pro-
cedure in a native coronary artery were eligible. 
Lesions were matched for lesion site, reference 
diameter. and minimal luminal diameter. The cor-
onary artery tree was subdivided into 15 seg-
ments according to the American Heart Associa-
tion guidelines. 13 Since the variability of repeat 
measurement of the reference diameter and mini-
mal luminal diameter from the same cineangio-
gram is 0.10 mm. matching was performed such 
that the difference of this parameter between two 
patients of each group did not exceed 0.20 mm 
(twice the variability or 95% confidence in-
terval). 14 
A total of92 patients (46 in each group) met the 
matching criteria and formed the study popula-
tion. Matching was considered adequate since 
there was an equal number of different stenosis 
locations in both groups (left anterior descending 
coronary artery. 27 patients: left circumflex ar-
tery. 4 patients: and right coronary artery, 15 pa-
tients), the reference diameter was 2.86 = 0.39 
mm and 2.87 ::!: 0.42 mm for the Wallstent group 
and Wiktor stem group. respectively (NS). The 
minimal luminal diameter was identical in both 
groups (1.13 = 0.24). 
Description of the Stents. The Wallstent (Fig. I) 
is a geometrically stable. pliable. and self-ex-
panding prosthesis. woven from a surgical grade 
stainless steel alloy. The stent consists of 16 wire 
ftlaments. each 0.08 mm in diameter. Its clastic 
and pliable properties arc such that its diameter 
can be substantially reduced by moderate elonga-
tion. It can be constrained on a small diameter 
delivery catheter. but spontaneously returns to 
its original (unconstrained) larger diameter when 
the constraining membrane is removed. The 
outer diameter of the stent-catheter system 
mounted on this delivery device is 1.57 mm. using: 
prostheses that expand to a diameter of 6.5 mm. 
The Wiktor stent (Fig. 2) is a radiopaque bal-
loon-expandable stent constructed of a single 
loose interdigitating tantalum wire (0.125 mm in 
diameter) formed into a sinusoidal wave and con-
figured as a helix. The prosthesis is crimped onto 
the deflated polyethylene balloon of a standard 
angioplasty catheter. The crimped stent proflle 
is approximately 1.5 mm. Upon inflation of the 
balloon. the sinusoidal waves expand to that ex-
tent that the stem conforms to the vessel wall. 
The features of the prosthesis arc such that by 
inflating the balloon. the diameter of the stent in-
creases without alteration of its length (14-16 
mm). The maximal diameter of the balloon during 
inflation determines the ultimate size of the pros-
thesis. 
Selection of Stent Size. Selection of the stent 
size was based on the visual assessment of the 
vessel size. The size of the Wallstent was selected 
to obtain an unconstrained diameter of 0.5 mm 
larger than the vessel. For the Wiktor stent. a 
balloon on which the Wiktor stent is mounted 
with a nominal size. which is 0.5 mm larger than 
the vessel. was selected. The size (mean ± SD) 
of the unconstrained Wallstent proved to be 3.5 
::!: 0.3 mm and was 3.3 ::!: 0.3 mm for the Wiktor 
stent (P < 0.05). In case of incomplete expansion 
of either stent. a repeat balloon dilatation within 
the stent was performed. 
Quantitative Coronary Angiography. To assess 
the immediate and long-term changes in stenosis 
geometry, all coronary cineangiograms were ana-
lyzed at the core laboratory in Rotterdam by 
means of the computer-assisted Cardiovascular 
Angiography Analysis System (CAAS). de-
scribed in detail elsewhere. 15 This system allows 
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Figure 1. Self-expanding stent {Wallstent) with membrnoe partially pulled back and expanding stent (top): and stent in position 
illustrating longitudinal flexibility (bottom). 
an objective and reproducible quantification of a 
coronary artery stenosis. Briefly. a 35-mm cine-
frame selected for analysis is digitized with a 
charge coupled device (CCD) camera at high res-
olution (1330 x 1770 pixels) in a matrix size of 
512 x 512 pixels with eight bits of brightness res-
olution. The segment to be analyzed is deter-
mined by selecting a number of centerline points 
that are connected by interpolation. An auto-
mated edge detection program determines the ar-
terial contour by assessing the brightness profile 
along scanlines perpendicular to the centerline. 
Mter correction for pincushion distortion and 
calibration using the guiding catheter as scaling 
device. a diameter function curve can be deter-
mined from the contour analysis by computing 
the distances between the left and right edges. 
From this diameter function curve. several pa-
ra.meters can be computed such as the minimal 
luminal diameter. reference diameter. and diame-
ter stenosis. The variability. precision. and accu-
racy of the system has been reported previ-
ously.14.16 
All angiograms for subsequent analysis were 
performed after intracoronary injection of 2-mg 
isosorbide dinitrate. 
The hemodynamic significance of the obstruc-
tion and its changes after stent implantation were 
evaluated by calculating the theoretic pressure 
drop using the arteriogram and digital computa-
tion. according to the formulae described in the 
literature: Pgrad = Q. (Rp + Rt). where Pgrad 
= the theoretic transstenotic pressure decrease 
(mmHg) over the stenosis. Q =- the mean coro-
nary blood flow (mUsec). Rp = the Poiseuille 
resistance. and Rt = the turbulent resistance. 17 .Is 
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Fij.!W'C 2. Balloon-expandable stent (VIiktor stent) mounted on a conventional polyethylene bu.lloon when de- :md inflated. 
These resistances have been defined as fol-
lows: Rp = Cl. (length obstruction)/(minimal 
cross-sectional area)Z, where Cl = 8.'1T. (blood 
viscosity) with blood viscosity = 0.03 g/cm·sec. 
Rt = C2. (II minimal cross-sectional area - llnor-
mal distal area)2, where C2 = (blood density)/ 
0.266 with blood density = 1.0 g/cm3 • 
The theoretic transstenotic pressure drop was 
calculated for theoretic coronary blood flow of 
0.5. I. and 3 mUsec. The Poiseuille and turbulent 
contributions to the flow resistance were deter-
mined from stenotic geometry assessed by quan-
titative coronary angiography. 
Statistics. Values obtained by quantitative an-
giographic analysis are expressed as means ::!: 
SD. The changes of each angiographic variable 
before and immediately after stent implantation 
were compared by analysis of variance. If signifi-
cant differences were found. two-tailed Student's 
t-tests were applied to paired data. A statistical 
probability of< 0.05 was considered to indicate 
significance. 
Results 
The morphological and hemodynamic changes 
in stenosis geometry are presented in Tables 1 
and 2. There was no difference in any baseline 
angiographic parameter between the two study 
groups. Predilatation with a balloon catheter re-
sulted in a significant increase in minimal luminal 
diameter from 1.13 ± 0.24 mm to 1.86 ± 0.31 
mm and 1.78 ::!: 0.28 mm in the Wallstent group 
and Wik"1or stent group. respectively. There was 
no difference in the minimal luminal diameter 
post-PTCA (percutaneous transluminal coronary 
angioplasty) between the two groups. Stent im-
plantation resulted in a further significant in-
crease in minimal luminal diameter from 1.86 ::!: 
0.31 mm to 2.34 ± 0.38 mm following Wallstent 
implantation and from 1.78 ::!: 0.28 mm to 2.43 
::!: 0.27 mm following Wiktor stent implantation. 
Although the mean change in minimal luminal di-
ameter was 1.21 ± 0.40 mm following Wallstent 
implantation and 1.30::!: 0.30 mm following Wik-
tor stent implantation. there was no statistical dif-
ference in the minimal luminal diameter poststent 
implantation between the two study groups. The 
cumulative distribution of the minimal luminal di-
ameter and its changes is depicted in Figure 3. It 
shows a wider range in minimal luminal diameter 
immediately following Wallstent implantation 
compared to Wiktor stent implantation. Statisti-
cal analysis performed between the two study 
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CUMULATIVE FREQUENCY OF MLD 
80 
80 
40 
20 
(stent) 
o- o WALLSTENT 
""-~cWIKTOR 
OL_--~~---L~--~--~-----L----L---~-----
0 0.5 1 1.5 2 2.5 3 3.5 4 
MLD (mm) 
Fi)!lln' J. Cumulative distribution of the minimallumin:il diameter pre-PTCA. post-PTCA. and immediately foUowing 
stent implantation. 
groups, revealed no difference between any an-
giographic parameter after PTCA and immedi-
ately following stcnt implantation. These mor-
phological changes were associated with a signifi-
cant decrease in the calculated turbulent and 
Poiseuille resistance and a virtual disappearance 
of the pressure drop for a theoretical blood flow 
of 0.5. I. and 3 mUsec (Table 2). 
Discussion 
PTCA. by means of balloon catheters. has 
gained widespread acceptance as a nonsurgical 
method of treating obstructive coronary heart 
disease. Despite its high initial success rate. its 
efficacy is limited by the occurrence of resteno-
sis. 19-~~ Pharmacological efforts to reduce or 
eliminate this proliferative process have largely 
been unsuccessfuL ~~-2~'< This is due partly to the 
lack of knowledge and understanding of the 
pathophysiological mcchanism(s) responsible for 
rcstenosis. Therefore. it is not surprising that 
along with the pharmacological interventions. 
new devices have entered clinical testing to cir-
cumvent restenosis. In this respect. intracoro-
nary stcnting may be a logical approach. It is ob-
vious that implantation of an endovascular pros-
thesis by itself cannot eliminate the triggers for 
the proliferative response of the vessel wall fol-
lowing injury. On the contrary. stcnts could pro-
mote intimal proliferation by stretching medial 
smooth muscle cells. stimulating mural throm-
bus. or attracting inflammatory cells.Z9·30 How-
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Table l. Immediate Morphologieal Changes in Coronary Artery Stenosis Following Wallstent and Wiktor Stent Implantation 
Walls tent 
pre-PTCA post-PTCA post-STENT p, p, 
Ref. Diam. (mm) 2.86 ::t: 0.39 2.95 = 0.49 2.98 = 0.35 NS NS 
MLD(mm) 1.13 = 0.1.4 1.86::0.31 2.34 :: 038 0.00001 0.00001 
DS(%) 60 = 8 36 = 10 22 ::t: 9 0.00001 0.00001 
RA (mm~) 6.52 ::t: 1.78 7.04 = 2.39 7.09 :: 1.68 NS NS 
MLCA(mm~) 1.04 ::t: 0.45 2.81 = 0.89 4.40 = 1.38 0.00001 0.00001 
AS(%) 83 ::': 6 58 ::t: 13 38 ::t: 14 0.00001 0.00001 
____ p, ____ 
___ p, ___ 
Ref. Diam. "" reference diameter; MLD = minimal luminal diameter: DS = diameter stenosb: RA = reference are:.: MCLA "' 
minimal luminal cross sectional area: AS = area stenosis. 
Comparison between the Walbtent and Wiktor Stent study group revealed no statistical difference between any angiographic 
parameter. 
All par.uneters arc expressed in mean = SD. 
ever. by optimizing the luminal geometry and 
minimizing the residual stenosis. a stent may 
compensate for the proliferative process. 
Randomized studies comparing new coronary 
angioplasty techniques arc not available. To com-
pare the angiographic effect of different interven-
tions. patients with identical baseline stenosis 
characteristics have to be selected.~ 1 -n For this 
PUIJ?OSe. the method of matching was used in this 
study. At present. this may be the best surrogate 
for a randomized study. which would be very 
time-consuming. The baseline stenosis character-
istics of the patients herein reported are represen-
tative for the angioplasty population. encoun-
tered in general practice. 6.&.11.::&.33 
Quantitative coronary angiography was used to 
assess the difference in the immediate modifica-
tions in stenosis geometry following Wallstent 
and Wiktor stent implantation. This is not only of 
pure academic importance. but may hold impor-
tant clinical consequences. As stated previously. 
a high initial gain after stent implantation may 
compensate for late ncointimal hyperplasia. A re-
sidual diameter stenosis larger than 20% follow-
ing stenting is an angiographic predictor for rcste-
nosis.34 However. the gain is a double-edged 
sword. Mechanical medial injury is a known 
factor in generating a proliferative vessel 
wall response. Experimental animal and an-
giog:raphic studies indicate a relation between 
Table 2. Immediate Hemodynamic Changes Following Wnllstent ;;md Wiktor Stent Implantation 
Rpois 
Rturb 
Pgrnd (0.5 mUsec) 
Pgrnd (I mUsee) 
Pgrnd (3 mUsec) 
Wallstent 
prc-PTCA post-PTCA post-STENT 
22.55 ::': 61.76 2.34 ± 7.76 1.92 ::': 6.58 
7.98 = 23.72 0.39 ± 0.54 0.04 = 0.10 
30.53 ::': 78.73 2.67 ::t: 7.08 1.95 = 7.47 
56.98 ::0:: 109.73 5.97 ± 14.71 4.05 ::0:: 15.10 
82.51 = 148.09 9.88 ± 22.95 6.14 ::t: 22.88 
---- P, ____ ---- p, ___ _ 
Rpois = Poiseuille resist:lnce: Rturb "' turbulent rcsist::mce: Pgrad "' pressure drop. 
p, p, 
0.02 NS 
0.05 0.0002 
0.02 0.03 
0.002 0.007 
0.002 0.002 
Compurison between the Wallstent ;;md Wlktor Stent study group revealed no statistical difference between ;;my ::mgiogr&phic 
pammctcr. 
All parameters n.re expressed in mean ± SD. 
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Table 1. (continued) 
Wiktor Stent 
pre-PTCA 
2$7 ::!: 0.42 
l.l3 ::!: 0.24 
60 ::!: 7 
6.62 ::!: 1.93 
1.06 ::!: 0.46 
83 ::':: 6 
p, 
post-PTCA 
2.79 ::!: 0.48 
1.78 = 0.28 
35 ::!: 10 
6.29 ::':: 2.16 
2.55 ::':: 0.83 
57::':: 14 
vessel oversizing and neointimal prolifer-
ation. 29-::u 
Both devices resulted in a more than twofold 
increase in minimal luminal diameter and a more 
than fourfold increase in the minimal luminal 
cross-sectional area. Despite the lesser increase 
in minimal luminal diameter post-PTCA in the 
Wiktor group and despite the smaller nominal 
size of the Wiktor stent used in this study. there 
was a larger. although statistically not different. 
increase in minimal luminal diameter following 
Wiktor stent implantation. However. there are 
several unknown factors limiting a comprehen-
sive comparison. First. the number of repeat bal-
loon inflations and balloon size within the Wiktor 
stent is not known. Second. this difference may 
be temporary since the dilatation process of the 
Wallstent continues until an equilibrium is at-
tained between the circumferential elastic resis-
tance of the vessel wall and the dilating force of 
post-STENT 
2.99 ::':: 0.38 
2.43 = 0.27 
18 ::!: 7 
7.11 ::':: 1.88 
4.72 ::!: LOS 
33 ::!: 12 
P, 
0.03 
0.00001 
0.00001 
0.05 
0.00001 
0.00001 
0.00001 
0.00001 
0.00001 
0.0001 
0.00001 
0.00001 
the prosthesis. Moreover. previous and recent 
angiographic studies indicate that both stents di-
late the vessel to the same extent.6·s.n Third. al-
though our experience is that edge detection is 
the appropriate technique for quantification of 
stenosis geometry following Wiktor stent implan-
tation. validation studies with phantom models 
are warranted to verify this. :<5 Furthermore. a se-
lection bias entered in the matching technique 
cannot be excluded. 
Conclusions 
These data indicate that although the Wa!lstent 
and Wiktor stent are different in design and me-
chanical characteristics. there is a similar imme-
diate improvement in stenosis geometry follow-
ing implantation of both devices. 
Table 2. (continued) 
pre-PTCA 
8.71 ::!: 7.98 
4.47 ::!: 4.97 
13.19 ::!: 12.54 
34.90 ::!: 34.46 
66.44 ::!: 66.60 
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P, 
po~t-PTCA 
1.06 = 0.77 
0.26 ::!: 0.36 
1.33 ::!: 1.05 
3.19 ::!: 2.32 
5.59::!: 5.10 
Wiktor Stent 
post-STENT 
0.47 ::!: 0.20 
0.02 ± 0.02 
5.77 ± 35.77 
1.01 ::!: 0.44 
1.53 ::!: 0.74 
Journal of lnterventionnl Cardiology 
p, 
0.00001 
0.00001 
0.00001 
0.00001 
0.00001 
0.00001 
0.00001 
NS 
0.00001 
0.00001 
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Comparative angiographic quantitative analysis 
of the immediate efficacy of coronary 
atherectomy with balloon angioplasty, stenting, 
and rotational ablation 
V. A. W. M. U:mans, B. H. Strauss, B. J. W. M. Rensing, P. de Jaegere, 
P. J. de Feyter, and P. W. Serruys. Rotterdam, The Netherlands 
Directional athere<:tomy has recently been intro-
duced as an alternative to conventional balloon 
dilatation.1 It has been shown to be safe and effective 
when applied in human coronary arteries.2· 3 It was 
initially hypothesized that removal of the atheroscle-
rotic plaque would result in a better immediate result 
with fewer acute complications and a reduced rest-
enosis rate compared with conventional balloon 
angioplasty.4 However, at the present time it is dif-
ficult to compare the respective merits of various 
mechanical interventions, since no randomized 
studies have been attempted. While awaiting these 
trials we used information from our quantitative an-
giography data base to compare patients treated with 
various coronary interventions. Coronary lesions 
from 51 patients who underwent directional atherec-
tomy were analyzed with the computer-based coro-
nary angiography system and matched with similar 
lesions treated by means of balloon angioplasty, in-
tracoronary stenting, and rotational ablation. The 
immediate results from geometric assessment of the 
stenotic lesion by edge detection before and after 
atherectomy are presented and compared with the 
results of conventional balloon angioplasty, intrac-
oronary stenting, and rotational ablation. 
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METHODOLOGY 
Patient group. From September 1989 through Sep-
tember 1990, a total of 51 patients (43 men and 8 
women) underwent an athere<:tomy procedure for 
symptomatic coronary artery disease. Three patients 
underwent two procedures and one patient had three 
procedures. The atherectomy procedure was success-
ful in 54 of the 56 procedures (postprocedural diam~ 
eter of stenosis <50%). The mean age (±SD) was 
58.2 (±10.1) years. At the time of atherectomy 21 
patients were in New York Heart Association func~ 
tional class IV, 11 were in class IDand 19 were in class 
II. Coronary angiography showed one-vessel disease 
in 39 patients, two-vessel disease in eight, and three-
vessel disease in four. The site of obstruction was lo~ 
cated in the left anterior descending coronary artery 
in 31 patients, in the right coronary artery in 13, in 
the circumflex artery in nine, and in the venous by-
pass graft in three. 
Athereetomy procedure. After administration oflo-
cal anesthesia, an llF sheath was inserted into the 
femoral artery. All patients received 250 mg acetyl-
salicylic acid and 10,000 U heparin intravenously. 
Intracoronary injection of isosorbide dinitrate was 
given to minimize any possible spasm. After initial 
angiograms in multiple views were obtained, a special 
llF guiding catheter was placed into the ostium of 
the coronary artery. Under fluoroscopy the guide wire 
was advanced into the distal part of the artery. Then 
the atherectomy device was directed over the guide 
wUe and positioned across the stenosis. The support 
balloon was then inflated up to 0.5 atm, the cutter was 
retracted, and the balloon inflation pressure was in-
creased to 2 to 3 atm. The driving motor was 
activated, and the rotating cutter was slowly ad-
vanced to cut and collect the protruding atheroscle-
Volume 12:2 
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rotic lesion in the collecting chamber located at the 
tip of the catheter. After every pass the balloon was 
deflated and either removed or repositioned. On av-
erage 6.1 ± 2.9 passes in multiple directions were 
performed across a stenosis. Atherectomy was con-
sidered successful when the residual stenosis was less 
than 50% after tissue retrieval After atherectomy 
the arterial and venous sheaths were usually left in 
place for 6 hours. Patients were monitored for 24 
hours, and ECGs and cardiac enzyme levels were ob-
tained twice a day. Nifedipine was given every 2 
hours after the procedure, and patients continued to 
receive aspirin medication for 1 year. 
Quantitative coronary angiography. Quantitative 
analysis of the coronary segments was performed 
with the computer-based Coronary Angiography 
Analysis System, which was previously described in 
detail 5• 6 In essence boundaries of a selected coronary 
artery segment (Fig. 1) are detected automatically 
from optically magnified and video-digitized regions 
of interest (512 X 512 pixels) of a cineframe. The ab-
solute diameter of the stenosis (in m.illi:rneters) is de-
termined with the use of the guiding catheter as a 
scaling device. Calibration of the catheter in absolute 
values (in m.illi:rneters) is achieved by comparing the 
mean diameter of the guiding catheter in pixels with 
the measured si2e in m.illi:rneters. Each individual 
catheter is measured by a micrometer. To correct the 
detected contour of the arterial and catheter seg-
ments for pincushion distortion, a correction vector 
is computed for each pixel based on a computer-pro· 
cessed cineframe with a centimeter grid placed 
against the input screen of the image intensifier. Be-
cause the functional significance of a stenosis is 
related to the expected normal cross-sectional area of 
a vessel at the point of obstruction, we use a computer 
estimation of the original dimension of the artery at 
the site of the obstruction to define the interpolated 
reference area. The percentage diameter and area 
stenosis, as well as the cross-sectional area (in milli-
meters squared), are then calculated. The length of 
the lesion ('m millimeters) is determined from the di-
ameter function on the basis of a curvature analysis. 
By use of the reconstructed borders of the vessel, the 
computer calculates the symmetry coefficient for the 
stenosis. The symmetry index ranges from zero {to-
tally eccentric stenosis) to one {symmetric). The de-
gree of coronary bend is assessed by the curvature 
value at the site of the obstruction. This parameter 
is computed as the average value of all the individual 
curvature values along the center line of the coronary 
segment, with the curvature deiined as the first de-
rivative of the tangent as it moves along the center 
line, which for a circle is equal to the reciprocal of the 
radius. 
Hemodynamic assessment. The hemodynamic re-
sults were determined as described earlier.7•10 Briefly 
the theoretical pressme decrease was calculated by 
means of the arteriogram and digital computation 
according to the formula: Pgrad = Q. (Rp + Q. Rt), 
where Pgrad is the theoretical transstenotic pressure 
decrease (m:rn Hg) over the stenosis, Q is the mean 
coronary flow (ml/sec), Rp is the Poiseuille resis-
tance, and Rt is the turbulence resistance. The the-
oretical transstenotic pressure decrease was calcu-
lated for a theoretical blood flow of 1, 2 and 3 ml/sec. 
The Poiseuille and turbulence contributions to flow 
resistance were determined from stenosis geometry 
assessed by quantitative coronary angiography. 
Matching process. To avoid patient selection bias 
we selected populations with comparable baseline 
stenosis characteristics. The coronary artery tree was 
subdivided into 15 segments according to the Amer-
ican Heart Association guidelines. The lesions were 
individually matched according to the location of the 
stenosis and the reference diameter. Matching was 
considered adequate if the mean difference of the 
reference diameter between the groups was identical 
Three patients who were treated for bypass graft 
stenosis and two patients with an unsuccessful pro-
cedure were excluded from the matching process. 
Thus 51 lesions treated with intracoronary atherec-
tomy were individually matched with "twin"lesions 
treated with balloon angioplasty or self-expandable 
stent. The group treated with the Rotablator {Heart 
Technology Inc., Bellevue, Wash.) was not individu-
ally matched, since only seven patients were in-
cluded. Their results are represented as a group. Cm-
rently the Thoraxcenter angiographic registry con-
tains quantitatively assessed stenosis data for 2300 
patients treated either by angioplasty (n = 1847), in-
tracoronary stenting (n = 406), directional atherec-
tomy (n = 56), or rotational ablation (n = 7). 
Device profiles 
Atherectomy devices. In 50 of 51 patients under-
going atherectomy a6F catheter was used, whereas in 
one patient a 7F atherectomy device was employed. 
The mean diameter of the atherectomy device was 2.1 
mm by quantitative angiographic assessment. 
Balloon angioplasty. The transverse diameter of 
the deflated balloon is an important determinant as 
to whether a stenosis can be crossed. Currently used 
balloons have favorable profile characteristics as ex-
pressed by their small diameter (1.0 mm: ranging 
from 0.8 to 1.1 mm). The balloon sizes were matched 
to the reference diameter with the goal of achieving 
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Fig. 1. A, Detected contours superimposed on original video image for a representative right coronary 
artery stenosis filmed in right anterior oblique projection before direction.al atherectomy. Diameter func-
tion is shown at bottom. White area is measuxe for '"atherosclerotic plaque." Minimum luminal diameter 
(uerticle line) i~ 0.71 mm, corresponding to diameter stenosis of 79% and area stenosis of96%. B, Contour 
analysis of intracoronary utherectomy device without in.fi.o.ted support balloon. This represents fust or 
"prefunctional" stage of intra coronary intervention characterized by intrinsic diameter of device. C, Con-
tow- annlysis of intracoronary filmed atherectomy device with infiated support balloon. Beneath this is 
shown diameter function. Mean diameter is 3.06 mm. This analysis represents second or "operation.al" stage 
in which atherectomy device exhibits its mode of action. D, Single-frame ang:iogram of right coronary ar-
tery filmed in right anterior oblique projection after direction.al atherectomy. Minimum luminal diameter 
increased to 2.27 mm, corresponding to diameter stenosis of 21% and area stenosis of 38%. 
a ratio of 1:1 (inflated balloon diameter:artery diam-
eter). The following balloon diameters were used in 
this study population: 2.0 m.m (n = 1), 2.5 mm 
(n = 12),3.0mm (n = 27),3.4mm(n = 1),3.5(n = 9), 
and 4.0 mm (n = 1). 
Stenting. The self-expanding stent is constrained 
on a small-diameter delivery catheter but assumes its 
unconstrained larger diameter up to 6 mm when the 
constraining membrane is removed. The stent cath-
eter profile mounted on its delivery device is 1.57 
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CASER ! 1.6mm H 0 !1 mm 
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Fig. 2. Schematic representation of concept of functional and theoretical expansion ratio of various in-
tracoronary intervention techniques. First or "prefunctional.'' stage is chnracterized by introduction of de-
vice. In becoming operational some devices ;;et expanded (atherectomy, balloon, stcr1-t), whereas others 
maintain their original dimensions (laser, Rotablator). End result is determined by recoil phenomenon and 
vascular reactivity. Mtor device is removed =imum acute effect :may be purtiruly lost because of elnstic 
recoil vessel. Expansion ratio is subdivided into theoretical expansion ratio. which is determined by oper-
ational device. w.d functional expansion rntio. which takes into account elnstic recoil phenomenon and de-
scribes net result. 
mm.11 In the 51 study patients the unconstrained di-
ameters were 3.0 mm (n = 5), 3.5 mm (n = 29), 4.0 
mm (n = 9), 4.5 mm (n = 1), and 5.0 mm (n = 3); the 
diameter was unknown in four. The stent sizes were 
selected on the basis of the size of the arterial 
segment. taking into account that the stent in its un-
constrained form must have a diameter 0.5 mm larger 
than the reference diameter of the stented vessel.11 
Rotational ablation. With rotational ablation the 
device consists of a rotating abrasive burr of variable 
profile characteristics (from 1.5 to 3.5 mm). In this 
series the largest burr size used was 2.25 mm. Choice 
of burr size was selected according to the reference 
diameter. 
Quantitative assessment of the expansion ratio of the 
various devices. Recently the concept of the expan-
sion ratio has been addressed.12 Briefly the mecha-
nism of all int::acoronary interventions may be di-
vided into three stages. The first or "p::efunctional" 
stage is characterized by the introduction of the de-
vice. The device is not yet operational, and its intrin-
sic dimensions determine to what extent the device 
may be introduced into the coronary tree. During the 
introduction of a bulky device across a s-renotic 
lesion, some degree of dilatation occurs as a direct 
result of a Dotter effect. The second or "operational" 
stage starts when the device becomes operational and 
exhibits its specific mode of action (dilatation, cut-
ting, ablation, vaporization). In becoming opera· 
tiona! the diameter of the device may e.'t!)and 
(atherectomy, balloon, stent) or maintain its original 
dimensions (laser, rotational ablation). During this 
stage the maximum effect of the device is achieved. 
The final result after removal of the device is then 
determined by the reeoil phenomenon and vascular 
reactivity. Consequently the net luminal gain will be 
less than the initial gain when the device is opera-
tional (Fig. 2). 
To distinguish the acute effect of the various 
devices from the vascular reactivity aud recoil phe-
nomenon, we subdivided the e:tpansion ratio into the 
theoretical expansion ratio, which occurs during the 
"operational" stage, and the functional expansion 
ratio, which takes into account the elastic reeoil phe-
nomenon and describes the net result.13 Both the 
theoretical and functional ratios were assessed for all 
interventional devices used in our study. The maxi-
mum achievable diameter of the vessel is calculated 
according to the diame-rer of the operational device 
while it is active. In the case of balloon angioplasty 
and self-expandable stent, this corresponds to the 
diameter of the inflated balloon and to the uncon-
strained diameter of the self-expandable stent. For 
atherectomythis was assessed byintracoronary qwm-
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Table 1. Effect of directional coronary atherectomy on 55 obstructive lesions 
Extent MLD Reference DS MLCA Plaque area 
(~) (mm) (~) (%) (mm2) (mm2) Symmetry index 
Mean :t SD 
Before otherectomy 6.4 :!: 2.5 1.1 :!: 0.4 3.0:!: 0.6 63:!: 11 1.1 :!: 0.$ 8.8:!: 5.6 0.6::!: 0.3 
After othere<:tomy 4.7::!: 2.1 2.5:!: 0.5 3.2 :t 0.4 22:!: 15 5.2 :1: 1.8 2.6 ::!: 2.1 0.7:!: 0.2 
p Vlllue <0.00001 <0.00001 0.03 <0.00001 <0.00001 <0.00001 NS 
Table II. Hemodynamic results immedio.tely after directional coronary atherectomy 
Prc:;su.re r;radi<!nt (mm Hg) 
Poi.seuille rcsi..•tanc:e 
(dynes/sec/cm-5) 
Tu.rbulcnt resistance 
(dynes/scc/cm-5) 
Fww 
(I ml/$CC) 
Fi<>w Fkw 
(2 ml/sec) (3 ml/sec) 
Mean± SD 
Beforo athcre<:tomy 
After athor<Jctomy 
p Vllluo 
39.2::!: 124.8 
0.3 ::!: 0.4 
0.025 
20.6 = 59.7 
0.05 = 0.17 
O.D13 
48.0:!: 154.5 
0.4 :!: 0.1 
0.02$ 
105.5 :!: 380.9 
0.6 :!: 1.0 
<0.01 
197.5:!: 697.0 
1.0 :1: 1.6 
0.042 
SD, Stru>dard deviati<>n. 
titative analysis during inflation of the support hal~ 
loon. The Rotablator does not alter its diameter while 
operational. The postprocedure diameter has been 
measured immediately after withdrawal of the de~ 
vice. For example, when the diameter of an intracor~ 
onary atherectomy device increases from 2.1 mm to 
3.5 mm on inflation of the balloon, the maximum 
achievable vessel diameter becomes 3.5 mm. How-
ever, the final luminal diameter at the end of the 
procedure measures 2.6 mm. Thus the theoretical 
and functional expansion ratios are 1. 7 (3.5/2.1) and 
1.2 (2.6/2.1), respectively. 
Statistical analysis. All values are expressed as mean 
values ± 1 standard deviation. Morphologic and he-
modynamic variables before and after athexectomy 
were compared by the paired Student's t test. Com~ 
parisons of the severity of min.imUlD luminal diame~ 
ter, area of plaque, and diameter of stenosis among 
the groups were performed by means of analysis of 
variance. H significant differences were found, the 
unpaired Student's t test was applied. Differences 
were considered statistically significant at p < 0.05. 
OBSERVATIONS 
Directional athorectomy. Fifty-six lesions in 51 pa~ 
tients were studied, and a mean of 1.4 angiographic 
projections per lesion were analyzed. The morpho-
logic and hemodynamic data are presented in Tables 
I and II, respectively. The mean values for the min-
im.UlD luminal diameter before and after atherectomy 
were 1.1 ± 0.4 mm and 2.5 ± 0.4 mm, respectively. 
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This morphologic improvement was associated with 
a significant decrease in the calculated Poiseuille and 
turbulent resistance, as well as a theoretical trans-
stenotic gradient decrease for a theoretical flow of 1 
ml/""". 
Atherectomy ver$us angloplasty and stentlng. 
Matching according to lesion distribution and refer-
ence diameter was considered adequate since the 
reference diameter was equal in all groups (3.0 ± 0.6 
mm), whereas the mean difference for this parameter 
between the groups was 0.0 ± 0.1 mm. No preproce· 
dural differences were found among patients under-
going atherectomy, balloon angioplasty, and stenting 
with regard to minimum luminal diameter (1.2 ± 0.4 
mm vs 1.2 ± 0.3 mm vs 1.2 ± 0.5 m.m), diameter 
stenosis(63 ± 10% vs62 ± 10% vs60 ± 12%),area 
plaque (8.8 ± 5.8 mm2 vs 8.2 ± 4.5 mm2 vs 8.4 ± 4.5 
mm2),andsym.metryvalue(0.5 ± 0.3vs0.6 ± 0.3vs 
0.5 ± 0.2). Curvature value was less in the atherec-
tomy group compared with the angioplasty group 
(15.9 ± 7.0 vs 22.2 ± 13.1). Table ID represents the 
changes in minimum luminal diameter, diameter of 
stenosis, and area plaque induced by presently avail-
able intra coronary interventional devices as assessed 
by quantitative angiography in our institution. A 
signi1icantly larger gain in llllDen diameter was 
achieved by directional atherectomy and stenting 
compared with balloon angioplasty (1.4 mm and 1.3 
mm vs 0.7 mm; p < 0.00001). Rotational ablation re~ 
suited in the smallest luminal increment (1.2 ± 0.4 
mm to 1.6 ± 0.1 mm). 
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Table 111. Comparative quantitative analysis of the immediate results of utherect.omy, angioplasty, and stenting 
Athcrectomy PTCA Stenting 
Before After &:!ore After &!ore After 
MLD(mm) 1.2 :1: 0.4 2..6:t:0.4 1.2 :1: 0.3 1.9 :1: 0.4" 1.2 :1: 0.5 2..5 :1: OAt 
AP (nun') 8.8 :!: 5.8 2..6 :1: 2.1 &2 :1:4.5 5.3 :1: 4.0" 8.4 :1: 4.5 3.5:1: 2..4t 
DS(%) 63 :1: 10 20:!: 11 62:!: 10 36:1:11" 60:!: 12 20 ± 9t 
PTCA, Percutll.n('(>\1!1 ttanrJuminal coro"""Y nngioplo•tr. Ml.O, minimalluminol dinnlcter; AJ>, nren plaque; OS. dinnlcter stenoslr;. 
• p < O.OOOOlathcroctomy vcnms PTCA Md ~tentiov; ""''""' PTCA. 
tP Value n<>t significant for nthc:cctomy """"'.If; otentin~. 
Table IV. Quantitative assessment of the theoretical and functional expansion ratio of intracoronary devices 
Expansion rotio 
Device 
profile (mm) 
Maximum diameter Postintervcntio=l 
Intervention achieved (mm) • diameter (mm) • Theoretical Functional 
Balloon l.lllgioplaaty 
Self-(Jxpandable atents 
Directional atherectomy 
Rotational ablation 
1.0 (0.8-1.1) 
1.6 
2.1 (2.0-2.4) 
2.0 (1.5-2..3} 
"Asse>""d by quantitative <:OtO"""Y nnal~ 
tDne<>.,trolncd ~tnnt diatncter. 
2.8:!: 0.5 
3.3 :!: 0.3t 
3.3:!: 0.5 
1.9:1:0.4 
Quantitative analysis of tho theoretical and functional 
expansion ratio. Quantitative analysis of the intracor-
onary atherectomy device shows a mean diameter of 
2.1 mm, which increases to 3.3 mm after inflation of 
the support balloon. Compared with the other de-
vices atherectomy has a larger catheter delivery sys-
tem, which limits the theoretical and effective ex-
pansion ratio (1.6 and 1.2, respectively). Balloon 
angioplasty and stenting give superior expansion 
ratios, since they are introduced on smaller delivery 
systems. Rotational ablation had the lowest expan. 
sion ratio, since the Rotablator does not change in 
size while in operation (Table IV). 
COMMENTS 
Over the past 5 years there has been a rapid 
increase in the development of new interventional 
devices aimed at supplementing conventional bal-
loon dilatation. This progress in technology has 
resulted in the introduction of directional coronary 
atherectorny, intracoronary stenting, rotational cor-
onary ablation, and laser-assisted angioplasty. Clin-
ical studies have demonstrated the feaSJ."bility and 
safety of these interventions; however, the relative 
efficacy of each technique remains to be assessed. 
Edge detection versus vldeodensltometry. The im-
mediate efficacy of the various coronary interven-
tions should be assessed by reproducible quantitative 
angiographic measurementsY Visual estimation of 
the severity of stenosis alone results in unacceptable 
1.9 ± 0.4 ~9 1.9 
2.5:!: 0.4 2.5 1.6 
2.6 :!: 0.4 1.6 1.2 
1.6 :1: 0.2 1.0 0.8 
variation in the assessment of changes in coronary 
artery lesions. To obtain values that are objective and 
reproducible, a computer-assisted technique that 
uses automated edge detection or videodensitometry 
should be applied.15 Whether edge-detection tech-
niques are inferior to videodensitometry remains an 
unresolved issue. Results of a previous study'> dem-
onstrated that the edge-detection method correlates 
well with densitometric analysis of the severity of 
stenosis before angioplasty. However, after angio-
plasty discrepancies between these types of measure-
ments may be observed when a single-plane view is 
used.16 Recently we have shown that a linear rela-
tionship exists between edge detection and video-
densitometry both before and after atherectomy, al-
though the strength of this relationship deteriorates 
slightly after atherectomy.17 Therefore we felt justi-
fied in assessing the immediate efficacy of coronary 
atherectomy by edge-detection analysis. 
Atherectomy versus angloplasty and stentlng. With 
the increasing number of interventional modalities, 
current indications and patient selection become 
difficult. This study demonstrates the important 
finding that atherectomy and stenting result in a 
larger increase in minimum luminal diameter when 
compared with results ofballoonangioplasty (1.4 and 
1.3 mm vs 0.7 mm,p < 0.00001). In addition, no dif-
ferences in the postinterventional an.giographic re-
sults were observed between groups undergoing 
atherectomy and stenting. Results of this study con-
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firm the findings of Muller etaL18; however, with our 
more refined matching te<:hnique individual atherec-
tomy lesions were directly compared with anglo-
graphically similar lesions treated by angioplasty or 
stenting. Although a randomized trial is the optimum 
method for comparing the short- and long-term 
results of new interventional techniques, matching 
based on quantitative analysis might become an ac-
ceptable alternative while patients are awaiting these 
trials. With the use of this matching program we se-
lected populations with comparable baseline stenosis 
parameters. The lesions were adequately matched, 
since no differences were found in reference diame-
ter, minimal luminal diameter, area plaque, and 
symmetry index among the three groups. Whether 
the superior immediate results after atherectomy 
and stenting will be associated with a reduction in 
restenosis remains to be assessed in random trials. 
lntracoronary devices. The expansion ratio is an 
important concept that relates the final effect of the 
intracoronazy device on the arterial diameter to the 
size of the catheter required to deliver this effect.12 
The maximum effect of the device may be partially 
lost because of the elastic recoil of the vessel The ex-
pansion ratio has been subdivided into two compo-
nents, theoretical and functional, to separate these 
infl.uences.13 Balloon angioplasty and stenting give 
extremely favorable theoretical and functional ex-
pansion ratios (2.9 and 1.9 vs 2.5 and 1.6, respective-
ly), since they may be delivered on low.profile cath-
eters. The directional atherectomy device is more 
limited by the size of the housing and collecting 
chamber. The dimensions of the rotational atherec-
tomy device do not change during the operation and 
therefore this procedure exhibits the lowest theoret-
ical expansion ratio. 
Although balloon angioplasty has the most favor-
able expansion ratio, the final result is profoundly 
influenced by the elastic recoil of the vessel 19.2° 
Stenting and atherectomy appear to be more effec-
tive in resisting elastic recoil, although the meclla-
nisms are likely different. Stenting effectively pre-
vents this recoil phenomenon presumably because of 
its scaffolding function and its intrinsic dilating 
effect_lO,l3 By physically removing tissue atherec-
toroy appears to diminish the potential elastic recoil 
effect. However, the actual diameter of the atherec-
toxny device limits its suitability in smaller coronary 
arteries. 
Limitations. There are several limitations of this 
study. First, it is an uncontrolled retrospective ob-
servational study limited to a subset of patients who 
underwent successful coronary intervention. Al-
though matching for angiographic variables is a 
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promising technique to assess the efficacy of intra-
coronazy interventions, patient- and procedure-
related variables should also be included in the anal-
ysis. Second, this study is based on early experiences 
with atherectomy and stenting. Future design 
changes and improved operator experience may fur-
ther improve the immediate and long·term results. 
Finally, the efficacy of all intracorona.ry interventions 
will be limited by the problem of restenosis, which 
necessitates careful and complete angiographic fol-
low-up. Thus controlled clinical trials are imperative 
in the future to determine the immediate angie-
graphic results and the long-term efficacy of these 
interventions and whether any benefit can be shown 
in particular patient subgroups. 
Conclusions. Quantitative angiographic assessment 
of the immediate results after directional atherec-
tomy shows significant improvement in the goomet."Y 
and hemodynamics of stenosis. While patients axe 
awaiting randomized trials, matching on the basis of 
quantitative analysis might become an acceptable 
alternative for objective and comparative assessment 
of various interventional techniques. In matched 
populations directional atherectomy and stenting 
appear to be more effective intracoronazy interven-
tional devices than balloon angioplasty based on the 
immediate result; however, atherectomy is limited in 
smaller coronary vessels by its larger size. Tbeoreti· 
cally stenting has the most favorable characteristics 
as a dilating device, although its clinical use is limited 
by its more complicated patient management. 
SUMMARY 
Interventional cardiology has branched in two di-
rections: devices that primarily dilate coronary 
stenoses and those that debulk coronary tissue. 
Presently the optimum coronary intervention has not 
been found. While patients are awaiting randomized 
trials, a comparison based on matched quantitative 
coronary analysis may be useful to evaluate results of 
new interventional te<:hniques. Therefore we com-
pared 51 patients undergoing atherectomy with in· 
dividually matched patients who were undergoing 
balloon angioplasty and stenting. The lesions were 
matched according to location of stenosis and refer-
ence diameter. Atherectomy and stenting resulted in 
larger gains in minimal luminal diameter compared 
with conventional balloon angioplasty. The minimal 
luminaldiameterwasincreasedfrom 1.2 ± 0.4mm to 
2.6 ± 0.4 mm in the atherectomy group and from 
1.2 ± 0.3 mm to 1.9 ± 0.4 mm in the angioplasty 
group (p < 0.00001). Atherectomy and stenting re-
sulted in similar gains in :minimum luminal diameter 
(1.4 mm vs 1.3 mm, p = NS). In addition, atherec-
VOiu..,..1Z2 
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tomy and stenting appear to be more effective in re-
sisting elastic recoil because of tissue removal and 
an intrinsic dilating effect, respectively. In matched 
populations directional atherectomy and stentin.g 
appear to be more effective intracorona.>y inter-
ventional devices than balloon angioplasty based on 
the immediate results. However, atherectomy is 
limited in smaller coronary vessels because of its 
larger size. 
We thank Eline Montnuban vo.n Swijndrw:t. 1\.furie Angele 
Mord. and the Cnrd.ioJy,;U; Coro Laboratory for the qUJllltitntive 
an~ographic anal)'l;i» and Murjolein Wapenillll' for her secretarial 
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INTRODUCTION 
The exact mechanisms by which balloon angioplasty leads to luminal enlargement 
and clinical improvement remain unclear [1]. Several mechanimshave been proposed 
but principally rely on histopathological examination of experimentally induced 
atherosclerosis ill animals or postmortem examination of human coronary arteries and 
therefore preclude any fmn conclusions [2-7]. In vivo serial analysis of the vascular 
wall during balloon angioplasty with intravascnlar ultrasound has shown that in 
addition to plastic changes such as plaque fracture and compression, elastic changes 
occur which contribute to luminal enlargement [1,8,9,10]. As a response to these 
elastic changes, recoil may occur and constitute a mechanical reason for loss of gain 
achieved during balloon angioplasty [11]. It has been reported that elastic recoil 
accmmts for an average 32% to 47% loss of the maximal achievable vessel diameter 
or vessel cross-sectional area [12-16]. To improve the immediate and long-term 
results of balloon angioplasty, intra coronary stent implantation has been advocated 
[17]. At present, the stent is the ouly catheter techoology which scaffolds the vessel 
and therefore may prevent recoil. A number of stents are currently available [17 -21]. 
They differ in geometry, wire thickness and physico-chemical characteristics. It has 
been hypothesized that the Wiktor stent, which is constructed of a single loose 
interdigitating tantalum wire, may have less scaffolding properties compared to the 
other stents with a more rigid and stiff mesh architecture. Therefore, the purpose of 
this study was to detertnine elastic recoil immediately after Wiktor stent implantation 
in native coronary arteries and to assess whether there is compression or .. late recoil" 
of the stent itself at follow-up. 
METHODS 
Patients 
The study population consisted of 77 consecutive patients (88% male, age 58± 9 
years) in whom a single Wiktor stent (Figure 1) was successfully implanted and in 
whom repeat angiography was performed at (mean ± sd) 5.7 ± 1.3 montha. In all 
patients, a stent was implanted because of recurrence of angina with objective 
evidence of ischemie due to restenosis of a lesion in a native coronary artery. A f:rrst 
restenosis was documented in 44 patients (57%), a second in 27 patients (35%) and 
a third in 6 patients (8%). The target vessel was the left anterior descending artery 
in 42 patients (54%), the circumflex artery in 9 patients (12%) and the right coronary 
artery in 26 patients (34%). The nominal size of the stent used was (mean ± SD) 
3.40 ± 0.37 mm (3.0 mm device in 30 patients (39%), 3.5 nun device in 33 patients 
(43%) and a 4.0 nun device in 14 patients (19%)). The baseline angiographic 
characteristics of the study population are shown in Table 1. Written informed 
consent was required for every patient. The study protocol was approved by the 
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Fig. 1. The Wiktor stent is a radiopaque balloon expandable device, constructed of a single loose 
interdigitating tantalum wire (0.125 mm in diameter), formed into a sinusoidal wave and wrapped into a 
helical coil structure. Thestent is crimped onto the deflated polyethylene balloon of a standard angioplasty 
catheter. The features are such that by inflating the balloon the diameter of the stent increases without any 
alteration in length (14 - 16 mm). The crimped stent profile is approximately 15 rnm. 
Table I. Baseline angiographic data of the 77 study patients. 
Reference diameter (nun) 
Minimal luminal diameter (mm) 
Diameter stenosis (%) 
Reference area (mm2) 
Minimal luminal cross-sectional area (mm2) 
Area stenosis (%) 
Lesion length (nun) 
Plaque area (mrn2) 
Symmetry 
All parameters are expressed as mean ± SD. 
2.88 ± 055 
1.14 ± 037 
60 ± 10 
6.68 ± 236 
1.13 ± 0.85 
82 ± 11 
12.6 ± 233 
13.8 ± 5.00 
050 ± 030 
ethics committee of the individual hospitals. The procedure of stent implantation and 
anticoagulation protocol have been described in depth elsewhere [22]. 
Assessment of recoil 
All coronary angiograms were analyzed by the computer assisted Cardiovascular 
Angiography Analysis System (CAAS) using automated edge detection as previously 
described [23]. Single identical views before and after stent implantation and during 
complete expansion of the balloon on which the stent was mounted were chosen for 
quantitative analysis. The same X-ray setting in tenns of kilovoltage and milli-
amperes were used during the cine recordings. Vessel segments were analyzed in the 
least foreshortened projection that is, peipendicular to the incoming X-ray beam. To 
maximally dilate the vessel and to control vasomotion, the same amount of 
intracoronary nitrates - either nitroglycerin, 0.1 to 0.3 mg, or isosorbide dinitrate, 1 
to 3 mg - was administered before and after stent implantation [24]. 
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Definition of recoil 
Elastic recoil inunediately after stent implantation was defmed by the difference 
between the mean diameter of the fully expanded balloon on which the stent was 
mounted and the mean diameter of the stented segment inunediately after stent 
deployment (Figure 2). The time interval between balloon inflation and post stent 
cine recordings was usually less than 1 min. Advantage was taken of the unique 
radiopaque properties of the Wiktor stent to analyze whether there was compression 
or "late recoil" of the stent itself at follow-up. The mean diameter of the stent itself 
was measured without opacification of the vessel. Compression was calculated by 
comparing the mean stent diameter inunediately after implantation and at follow-up 
(Figure 3). 
A number of clinical (gender and age), angiographic (target vessel, vessel size, 
minimal luminal diameter before and after intervention, percent diameter stenosis, 
lesion length, plaque area, symmetry, curvature) and procedural variables (stent/artery 
ratio defmed as the ratio of the mean diameter of the fully expanded balloon on 
which the stent was mounted and the interpolated reference diameter) were selected 
to study their relation with acute and chronic recoil. 
Furthermore, the relation between acute recoil and late restenosis was analyzed. 
For this pmpose recoil was not only defmed by the definition descn"bed above, but 
also as the difference between the mean diameter of the fmal balloon diameter and 
the minimal luminal diameter post stenting. This was done because restenosis is 
clasically described by the loss in minimal luminal diameter (difference between the 
minimal luminal diameter post intervention and the minimal luminal diameter at 
follow-up). In addition, the incidence of restenosis was defmed according to the 
categorical approach using the 0.72 mm and the 50% diameter stenosis criteria [19]. 
Statistical Analysis 
Data are presented as mean± standard deviation. The 95% confidence intervals were 
calculated with the statistical package CIA [25]. When using an univariate analysis, 
continuous variables were divided in three subgroups. Subgroups from categorical or 
discrete variables, or obtained from continuous variables were compared by means 
of the estimated differences and their 95% confidence interval 
To obtain independent predictors of recoil, variables were entered in a multiple 
linear regression analysis in which recoil was the dependent variable. Multiple linear 
regression analysis was performed to assess the relationship between the variables 
that were statistically significant at an 0.05 level in the univariate analysis 
(independent variables X1) and recoil (dependent variable Y): Y = ~0 + ~ 1X1, were 
~O is the intercept and ~ 1 the regression coefficient. The standard criteria of the F 
statistic being or not being significant at a 0.10 level were used for inclusion and 
elimination in the model, respectively. Continuous variables were entered as such in 
the multivariate analysis, except for variables with two of three tertiles showing 
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Fig. 2 Quantitative analysis with the computer-assisted Cardiovascular Angiography Analysis System 
using automated edge detection of the fully expanded balloon on whlch a Wiktor stent is mo\Ulted (left 
panel) and of the stented segment immediately after stent deplo)Tilent (right panel). Superimposed on the 
videoimage is the diameter function curve. The mean diameter of the fully expanded balloon and of the 
stented segment amounts to 3.40 and 2.97 mm, respectively. Tins corresponds to an acute recoil of 0.43 
nun or 12.6%, in this case. 
Fig. 3. Advantage was taken of the radiopaque properties of the stent for automated detection of its 
boWldaries with the same system and methods illustrated in Figure 2 in order to define late compression 
or -late recoil- of the stent itself. In this case, the mean diameter of the stent immediately after 
implantation and at follow-up was 3.02 mm (left panel) and 3.10 mm (right panel), respectively. This 
suggests some increase in the diameter of the stent itself or negative -late recoil- of 0.08 rnm or 2.6%. 
approximately the same amount of recoil. These were entered as discrete variables 
[26]. Statistical analysis was carried out with a commercial statistical package (SAS 
- release 6.03). 
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RESULTS 
Acute recoil 
The mean diameter of the fully expanded balloon and stented segment was 
3.05 ± 0.37 mm and 2.80 ± 0.44 mm, respectively (Table 2). Therefore acute recoil 
amounted to 0.25 ± 0.32 mm or 8.2%. 
Table 2 Acute recoil following Wiktor stent implantation in native coronary arteries. 
Mean diameter fully 
expanded balloon 
3.05 ± 037 nun 
Mean diameter stented 
segment 
2.80 ± 0.44 mm 0.25 ± 032 rnm 
All variables are expressed as mean ± SD; !:.. difference; CI - confidence interval. 
95% Cl 
(0.18; 0.33 rnm) 
Univariate analysis identified sex, reference diameter, lesion length and stent/artery 
ratio as potential predictors of acute recoil (Table 3). After multivariate analysis, only 
sex and stentfartery ratio prevailed as the two independent predictors of acute recoil 
(Figure 4). 
Table3. Relation between clinical and angiographic variables and acute recoil. Results of the univariate 
analysis. 
n Acute recoil (:mm) 
" 
95% CI 
Sex 
Male 68 029 ± 0.32 
Female 9 -0.01 ± 021 0.30 (0.08; 051) 
Reference diameter (mm)* 
< 25 23 0.36 ± 0.30 
25- 3.0 26 025 ± 028 0.11 (-Q.05; 028) 
~ 3.0 26 0.15 ± 035 021 (0.03; 0.40) 
Lesion length (mm)* 
< 115 25 0.35 ± 022 
115-13.5 25 0.19 ± 0.23 0.16 (0.04;029) 
;:: 13.5 25 021 ± 0.45 0.14 ( -o.05; 0.34) 
Stent/artecy ratio* 
< 1.00 23 O.o? ± 0.27 
1.00-1.13 25 0.24 ± 0.21 -0.17 ( -Q.3!;0.03) 
~ 1.13 27 0.43 ± 036 -0.36 (-Q.51;-Q.12) 
All parameters are expressed as mean ± SD; 1::.. difference 
* of 2 patients the reference diameter, lesion length and stent/artery ratio was not known. 
"Late recoil" 
Late compression of the stent itself was not observed. On the contrary. the overall 
difference of the mean diameter of the stent itself inunediately after implantation and 
at follow-up was -0.15 ± 0.33 mm, suggesting an overall increase in diameter of 
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1.5 
·. 
0.5 .. . . 
. .. 
• :_. ~':. •• X• 
x -1 ><:x •• 0~--~--------~~~T..---------------
X 
X 
-0.5 L._ _________ __,c..:.;_ ________ _ 
0.4 0.6 0.8 1.2 1.4 1.6 
Stent/artery ratio (mm) 
Fig. 4. Graphic display of the linear regression analysis studying the relation between acute recoil (Y-
axis) and stent/artery ratio (X-a:xis). Stent oversizing is associated with significant more recoil. Dots 
denotes data of male patients, crosses denotes data of female patients. 
5.0% (Table 4). Lesion length and mean diameter of the stent immediately after 
implantation were identified as predictors of late (negative) recoil in the univariate 
analysis. They were both retained as independent predictors in the multivariate 
analysis. 
Table 4. -Late recoil- following Wiktor stent implantation in native coronary arteries. 
Mean stent diameter immediately 
after implantation 
2.99 ± 0.41 mm 
Mean stent diameter 
at follow-up 
3.13 ± 0.37 nun 
"- 95% Cl 
-0.15 ± 0.33 mm -D.23; -0.D7 
All variables are expressed as mean ± SD; A difference; a - confidence interval. 
Relation between acute recoil and late restenosis 
The incidence of restenosis was 43% and 27% according to the 0.72 mm and 50% 
diameter stenosis criteria, respectively (Table 5). Irrespective of the defmition of 
acute recoil described above, there was no difference in the degree of recoil between 
patients with restenosis and those without angiographic restenosis (Table 5). When 
defming recoil as the difference between the mean fmal balloon dian1eter and the 
minima! lumina! diameter post stenting, there was a trend towards a greater degree 
of recoil in patients without restenosis compared to those with restenosis according 
to the 0.72 mm criterion (0.70 ± 0.30 mm versus 0.58 ± 0.27 mm, respectively). 
Moreover, linear regression analysis disclosed a weak but negative correlation 
between acute recoil and loss in minimal luminal diameter (r = 0.25, slope: -0.55, 
p = 0.04). This trend towards an inverse relationship indicates that patients with more 
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Table 5. Relation between acute recoil (mm) and late restenosis 
Restenosis criterion 
0.72mm 50% Diameter Stenosis 
Yes No !>. Yes No !>. 
n- 33 n- 44 n- 21 n- 54 
Acute recoil 1 026 ± 0.26 0.25 ± 0.29 -0.02 ± 0.30 0.28 ± 0.42 024 ± 028 0.04 ± 0.32 
95% a 0.13; 039 0.!6; 034 -0.14; 0.16 0.09; 0.47 0.16; 0.31 -0.12; 02! 
Acute recoil 2 058 ± 0.27 0.70 ± 0.30 -0.12 ± 0.29 0.63 ± 0.28 0.64 ± 0.31 -0.01 ± 0.30 
95%0 0.48; 0.67 0.61 ; 0.79 -0.25 ; O.QI 0.51 ; 0.76 0.56; 0.73 -0.16; 0.14 
All values are expressed as mean± SD. Acute recoi11 - difference between mean final balloon diameter 
and mean diameter stented segment. Acute recoil2 - difference between mean f'mal balloon diameter and 
minimal luminal diameter post stent implantation. a - confidence interval. 
acute recoil tended to have a smaller loss in mininlalluminal diameter. There was 
no relation between acute recoil and mininlalluminal diameter at follow-up (r = 0.0, 
slope: -0.004, p = 0.99). 
DISCUSSION 
Although the precise mechanisms by which balloon angioplasty lead to luminal 
enlargement are still incompletely understood, there is now substantial evidence that 
in addition to plastic changes (e.g. plaque fracture, plaque compression, dissection), 
elastic changes (arterial wall stretching) occur which contribute to the dilatation 
process [1,8,9,1!]. As a response to these elastic changes, elastic recoil after balloon 
angioplasty has been reported to be responsible for 32% to 47% loss of the 
theoretically achievable result which in tum may affect the long-term angiographic 
outcome [12-16]. Since it has been hypothesized that the Wiktor stent may offer less 
scaffolding properties in comparison with other stents, the behaviour of the vessel 
wall after Wiktor stem implantation and of the stent itself at follow-up were studied 
using quantitative coronary angiography. 
In comparison with historical data on balloon angioplasty, only a limited amount 
of recoil (0.25 mm or 8.2%) was found [12-16]. This is in accordance with the 
degree of recoil observed after Wiktor stent implantation in non-atherogenic porcine 
coronary arteries [27]. These data, furthermore, compare favorably with those of 
other investigators assessing recoil after stent implantation in hwnan coronary arteries 
[28-30]. In these studies recoil is reported to vary between 3.5 and 17.7% following 
Palmaz-Schatz stem implantation and between 20 and 22% following Gianturco-
Roubin and Wiktor stent implantation [28-30]. The difference in recoil after Wiktor 
stem implantation between the study reported by Popma et al (22%) and this study 
(8.2%) is most likely related to the difference in defntitions used [29]. In the former, 
recoil was defined as the difference between the mean fmal balloon diameter and the 
mininlal luminal diameter post stem implantation, while in this study recoil was 
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defmed as the difference in the mean fmal balloon diameter and the mean diameter 
of the stented segment. This defmition was chosen because we were interested in the 
behaviour of the vessel wall of the entire stented segment. Studies using either 
quantitative coronary angiography or a combination of a balloon catheter which 
houses a ultrasound transducer clearly demonstrated that balloon expansion is not 
uniform [11,16]. This has recently been observed in balloons on which a stent was 
mounted resulting in asymmetric stent expansion [31]. This suggets that one part of 
the dilated or stented segment may yield more easily to the mechanical force of the 
balloon than the other. Therefore, one segment may experience more stretch than the 
other and consequently more recoil [11,16,31]. It is noteworthy that, if recoil is 
defmed according to the defmitions proposed by other investigators, it amounts to 
0.65 ± 0.30 mm or 21% which is strikingly similar to the degree of recoil after 
Wiktor stent implantation reported by Popma et al. [29]. 
In accordance with data on balloon angioplasty, stent oversizing was found to be 
the strongest independent predictor of acute recoil after Wiktor stent implantation 
[12,13,15]. Such a relation was also found by Leon et al. in patients who received 
a Palmaz..Schatz stent, but is at variance with the data of Haude et al [28,30]. The 
discrepancy between the herein reported results and those of Leon et al., on one 
hand, and the results of Haude et alon the other, is unclear. It may be related to 
differences in matching the stent size to the vessel size. In this study, most patients 
(52%) received a stent which was larger than the target vessel. The mean stentfartery 
ratio was 1.08 ± 0.15 (median 1.0, range 0.5 - 1.5). Haude et al. reported a mean 
stentfartery ratio of 0.96 [30]. 
In this study, female gender was found to predict acute recoil and contrasts with 
data on balloon angioplasty [12]. One should realize that this conclusion, although 
statistically significant, was based on data of ouly nine female patients. Its biological 
significance is unclear. It is unlikely that the response of the coronary artery to 
mechanical energy is different between males and females. 
Another interesting observation is that there was no late compression of the Wiktor 
stent itself at follow-up. On the contrary, overall there was an negative "late recoil". 
Although the principle of balloon-expandable stent implantation is based on the 
plastic deformation of the stent beyond its elastic properties, it can be speculated that 
chronic damage to the vessel wall, as observed after Wiktor stent implantation in 
porcine coronary arteries, may offset opposing forces of the vessel wall pennitting 
further stent expansion [32]. Whether this damage is due to movement of the rigid 
implant within the vessel wall or due to local weakening of the media underneath the 
stent wires reflecting reparative processess remains to be elucidated. 
The absence of late recoil in addition to the evidence that acute recoil does not 
contribute to late luminal renarrowing or restenosis (Table 5) indicate that late loss 
in minintallurninal diameter is due to tissue ingrowth into the lumen of the stented 
segment. 1bis is in accordance with pathologic observations disclosing that the 
predominant cause of restenosis following balloon angioplasty or stent implantation 
is extensive neointimal thickening due to smooth muscle cell proliferation at the 
dilated or stented site [27,32,33-37]. 
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Contrast angiography to assess recoil 
Elastic recoil implies an active component of the vessel wall which, for obvious 
reasons, cannot be directly studied with contrast angiography. This teclu:rique, which 
was used in almost all other studies on recoil after balloon angioplasty and 
intracoronaty stenting, at best describes the luminal changes but does not provide any 
insight into the underlying pathological mechanisms [12-16,26-28]. 1n addition to 
recoil, other mechanisms such as vasoconstriction, platelet deposition, nonocclusive 
mutal thrombus fonnation and subintimal hemorrhage have been proposed to cause 
early luminal narrowing [12]. Although attractive from a theoretical point of view, 
they are unlikely to explain these changes. Vasomotion was controlled by intra coron-
ary injection of nitrates before each cine nm which effectively reverses vasoconstric-
tion [24]. Given the intrinsic thrombogenicity of the intracoronaty stent, platelet 
deposition and mutal thrombus formation cannot be ruled out. It is nevertheless 
unlikely to be the cause of the reduced luminal diameter talting into accmmt the time 
interval between stent implantation and control angiography. The same holds for 
intramutal hemorrhage. Stents have been shown to effectively prevent vessel collapse 
in such circumstances [38]. 
Obviously, the ideal method to study the nature of vessel wall behaviour during 
coronaty intervention is the use of intravascular ultrasound and preferably the use of 
a combination of a balloon-ultrasound imaging catheter described by Isner et al. [11]. 
This method offers the unique opportunity to continuously assess vessel wall changes 
before, after and above all during balloon inflation. The preliminary results of Gorge 
et al who used conventional intravascular ultrasound teclu:riques suggests that recoil 
indeed exists after stent implantation [39]. 
Automated edge detection to quantify recoil 
To quantify recoil, one has to rely on cardiac imaging tedmiques with lmown 
precision, accurracy, inter- and intraobserver variablity. The computer-assisted 
Cardiovascular Angiography Analysis System used in this study has been extensively 
validated in both the clinical as well as in the experimental setting following balloon 
angioplasty and stent implantation [ 40-43]. Despite the radiopacity of the Wiktor 
stent, it is our experience that in case of adequate filling of the balloon or coronary 
artery with contrast medium at a concentration of 100%, the radiopaque stent wires 
do not interfere with the automated contour detection [19,22,43]. This is explained 
by the high iodine content in the coronary artery in such circumstances which 
absorps most of the incoming X -rays. Tills is, furthermore, in accordance with 
phantom studies from our laboratory which disclosed that automated contour 
detection, in contrast to videodensitometry, adequately identified luminal contours of 
a Wiktor stent -containing plexiglass phantom [ 43]. With respect to intravascular 
ultrasmmd, one should aclmowlegde that notwithstanding its value and importance, 
the delineation of the arterial boundaries is subjective and therefore may not always 
be precise. 
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CONCLUSIONS 
The Wiktor stent effectively scaffolds the instrumented vessel. Although statistically 
significant, only a minimal amount of acute recoil was noted which did not 
contribute to late 11lll1inal renarrowing or restenosis. In addition, no late compression 
of the stent itself was observed. Therefore, tissue ingrowth into the lumen of the 
stented segment is the main cause of late luminal renarrowing after stent implan-
tation. 
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CHAPTER 6 
WIKTOR STENT IMPLANTATION IN PATIENTS 
WITH RESTENOSIS FOLLOWING 
BALLOON ANGIOPLASTY OF 
A NATIVE CORONARY ARTERY 
P.P.T. de Jaegere, P.W. Serruys, M. Bertrand, V. Wiegand, G. Kober, 
J F. Marquis, B. Valeix, R. Uebis, J. Piessens. 
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Wiktor Stent Implantation in Patients with 
Restenosis Following Balloon Angioplasty of a 
Native Coronary Artery 
Peter P. de Jaegere, MD, Patrick W. Serruys, MD. Michel Bertrand, MD, 
Volker Wiegand, MD, Gisbert Kober, MD, Jean Francois Marquis, MD, 
Bernard Valeix, MD, Rainer Uebis, MD, and Jan Piessens, MD 
lntracoronary stenting has been introduced as an 
adjunct to balloon angiopl.asty aimed at overcom~ 
ing its limitations, namely acute vessel closure and 
late restenosis. This study reports the first experi· 
ence with the Wiktorno stent implanted in the first 
50 consecutive patients. All patients had resteno--
sis of a native coronary artery lesion after prior 
balloon angioplasty. The target coronary artery 
was the left anterior descending artery in 26 pa-
tients, the circumflex artery in 7 patients and the 
right coronary artery in 17 patients. The implan-
tation success rate was 98% (49 of 50 patients). 
There were no pnx:edural deaths. Atute or sub· 
acute thrombotic stent occlusion oeeurTed in S pa-
tients (10o/o). All 5 patients sustained a nonfatal 
acute myocardial infarction. Four of these patients 
underwent recanaliZation by means of .balloon an· 
gioplasty; the remaining patient was referred for 
bypass surgery. A major bleeding complication oc-
curred in 11 patients {22% ): groin bleeding neces-
sitating blood transfusion in 6, gastrointestinal 
bleeding in 3 and hematuria in 2. Repeat angiog· 
raphy was performed at a mean of 5.6 ± 1.1 
months in all but 1 patient undergoing impUmta· 
tion. Restenosis, defined by a reduction of ;:::0.72 
mm in the minimal luminal diameter or a change in 
diameter stenosis from < to ;:::SO%, occurred in 
20 (45%) and 13 (29o/o) patients, respectively. In 
this first experience, the easiness and high tec:hni· 
cal success rate of Wiktor stent implantation are 
overshadowed by a high incidence of subacute 
stent occlusion and bleeding complications. Al-
though direet comparison with balloon angioplasty 
regarding the incidence of subsequent restenosis 
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rate is not possible, the experience reported in 
this study compares favorably with data reported 
in other published reports. 
(Am J Cardiol 1992;69:598-602) 
P ercutaneous transluminal coronary balloon an-gioplasty (PTCA) has established its role as a nonsurgical revascularization procedure in select-
ed patients with obstructive coronary artery disease. 
Gained operator experience and improved catheter 
technology has resulted in a high immediate success 
rate and a low incidence of complications.1 These favor-
able initial results are compromised by the unpredict-
able problem of late restenosis. occurring in 20 to 40% 
of the patients after successful PTCA.Z-~ Furthermore.. 
there is some evidence that the recurrence of subsequent 
restenosis after repeat PTCA increases with the number 
of repeat interventions.6- 9 Intracoronary stents are one 
of the new technologies that (along with pharmacologic 
interventions. atherectomy and laser techniques) have 
entered clinical testing to address this problem.JO Re-
cently. the first experience with the self-expandable 
Wallstent® and the balloon expandable Palrn.az-Schatz® 
stent have been reported. 11 •12 The stent used in this 
study is the Medtronic Wiktor™ stent which. in contrast 
to the Wallstent and the Palmaz-Schatz stent. is not a 
mesh-made stainless steel device but a coil-like prosthe-
sis made of a single loose interdigitating tantalum wire 
formed into a sinusoidal wave and configured as a helix. 
This loose configuration may offer less scaffolding prop-
erties compared with the other 2 stents. Therefore. the 
purpose of this study was to assess the immediate and 
lonS""tcrm clinical and angiographic results following 
Wiktor stcnt implantation in the first 50 consecutive pa-
tients with restenosis following balloon angioplasty of a 
native coronary artery lesion. 
METHODS 
Patients: The study group consisted of the frrst 50 
consecutive patients in whom a single Wiktor stent im-
plantation was attempted (Table 1). All patients had re-
currence of angina with objective evidence of ischemia 
due to restenosis of a native coronary artery lesion fol-
lowing PTCA. A first rcstcnosis was documented in 33 
patients. a second rcstcnosis in 13 patients and a third in 
4 patients. The dilated and stcnted coronary artery was 
the left anterior descending artery in 26 patients (52%). 
MARCH l, 1992 
the circumflex artery in 7 patients (14%) and the right 
coronary artery in 17 patients (34%). A written in-
formed consent was required for every patient. The 
study protocol was approved by the ethics committee of 
the individual hospitals. The stents used in this study 
are shown in Figures I and 2. They are described in 
detail elsewhere as well as the drug protocol associated 
with stent implantation. 11 ·13 The angiograms were ana-
lyzed using automated edge-detection as previously de-
scribed.14·15 
End points: Primary clinical end points were death, 
myocardial infarction, bypass surgery or repeat inter-
vention and bleeding complications. All deaths were 
considered cardiac, unless an unequivocal noncardiae 
cause could be established. The primary angiograpbic 
end point was the change in minimal luminal diameter 
at the dilated and stented segment at 6 months relative 
to the baseline. If a revascularization procedure involv-
ing the stented segment had been performed before 6 
months repeat angiography. the last angiogram before 
this intervention was used to obtain follow-up values. 
irrespective of the timing of repeat PTCA (hours. days 
or weeks). The secondary angiographic end point was 
the incidence of restenosis defmed according to the fol-
lowing criteria: Erst. a continuous approach was used in 
which restenosis was defmed by a reduction of ~0.72 
mm in the minimal luminal diameter at follow-up. This 
change in minimal luminal diameter has been found to 
be a reliable indicator of angiograpbic progression of 
vessel narrowing. This value takes into account the limi-
tations of coronary anglographic measurements and 
represents twice the long-term variability of repeat mea-
surements of a coronary artery obstruction with the 
Cardiovascular Angiographic Analysis System. IS Sec-
ond. a categorical approach was used in which an in-
crease in diameter stenosis of <50% immediately after 
stent implantation to =:50% at follow-up was used as a 
cutoff point to defme rcstenosis. This criterion was se-
lected since common clinical practice bas continued to 
express lesion severity as a percentage of stenosis. 
Statistics: Values obtallled by quantitative angio-
graplric analysis are expressed as mean ± SD. The 
means for each angiograpbic variable before PTCA, af-
ter PTCA. immediately after stcnt implantation and at 
follow-up were compared by analysis of variance. If sig-
nificant differences were found. 2-ta.iled t tests were ap-
plied to paired data. A statistical probability of <0.05 
was considered significant. In the patient with the miss-
FIGURE 1. Mecftronic Wiktor stent mounted on a conventional 
pol)ethyletie balloon whoa deflated {top panel) and inflated 
{b<Jttom panel). 
TABLE I Clinical Characteristics 
No. oi potl<:>nts 50 
A~o (mean :t SO, yrs) 55:: 9 
Moo 
" Functional cla~s· 
I 10 
II 5 
"' 
14 
"' 
20 
S~tcm1c llypertonslon 
' Chole5.!<trOI > 200 mg% 
' Ct~arette smokers u
OtJbatCS mcllltust 6 
"Ae<:or<!lng to eooadlan C.rdlovo"""'"' Society 
tAl:norHn,ultn-dePondent. 
ing follow-up angiogram and no clinical evidence of re-
stenosis.. imputation of the minimal luminal diameter at 
follow-up was performed: the minimal luminal diameter 
at follow-up of this patient was calculated by subtract-
ing the mean change of the minimal luminal diameter 
of the entire study population from the value of the 
minimal luminal diameter immediately after stent im-
plantation of this particular patient. 
RESULTS 
Clinical results: The implantation success rate was 
98% (49 of 50 attempted implants). In 1 patient. the 
stent could not be delivered at the target site due to the 
inability to cross a tortuous proximal right coronary ar-
tery. There were no procedural related deaths. How-
ever. subacute thrombotic stent occlusion occurred in 5 
patients (10%) while still in the hospital. The occur-
rence to this thrombotic event with respect to the im-
plantation was as follows: day 0"" I patient. day 1 = 1 
DIAMETER BALLOON (mm) 
4.5 f ,--------:--. 
12.98 : 0.441 ° 
4 
3.5 
2.5 
oo 
0 
00 
cil>o 
@· 
0::000 
0 00 0 
or:Sc::Jo o 
0 0 00 
0 
0 
ooo 
0 
0 
0 
0 
0 
0 0 
1 2.88 • 0.43 1 
2.5 3 3.5 4 4.5 
DIAMETER STENT (mm) 
FJGURE 2. Dtfferenee between the mean diameter of the bal-
loon when fuDy inflated and sterrted segment immediately af. 
ter implantation. 
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TABL£ II Changes in Minimal Luminal Diameter After Wiktor Stcnt Implantation 
6ctor~ 
""' 1.09 ± 0.26 
After 
PTCA 
l.SO ± 0.32 
AtterStcnt 
lmpiJntatlon 
2.45 ± 0.35 
At Follow-Up 
All Pts. 
(n ~ 491 
1.59 ± 0.79 
Pts. Without 
Sub<lcute 
Occlusion 
(n ~ 44) 
1.78 ± 0.60 M<nJmJIIumlnQI diJmctor 
(mm) 
Ol~meter~ten0$t~ (%) 61±9 34±11 18±7 45±25 
--p < 0.00001-- -- p < 0.001-- -- p < 0.00001--
p < 0.00001 
39 ± 18 
All p.oorom<1e,., "''""P""'ot'd 0> mcoo • SD. 
PTCA- pe~utunoou' tron>lumlnotcotort<>rya"glopla'~· 
patient. day 4 "" 1 patient. and day 5 = 2 patients. Four 
patients underwent recanalization by means of conven· 
tiona! balloon angioplasty. In 1 of these patients adjunc-
tive thrombolytic therapy was used. In the remaining 
patient. repeat PTCA was not attempted because retro-
spective analysis of the implantation angiogram re· 
vealed incomplete stent expansion. This patient was re· 
ferred for emergency bypass surgery. AilS patients sus--
tained a nonfatal acute myocardial infarction (mean ± 
SD, creatine phosphokinase 1.797 ± 1.849 U/liter). A 
major bleeding complication occurred in II patients 
(22%): 6 patients sustained. a groin hematoma nccessi· 
tating blood transfusion. 3 patients had a gastrointesti· 
nal bleeding (2 duodenal ulcers.. 1 intestinal polyps) and 
2 patients had hematuria. One patient had an infected 
pharyngeal hematoma caused by acenocoumarol thera· 
py at 3 months after implant. 
During follow-up. I patient died 3 months after stent 
implantation following prostate surgery. This patient 
had a history of bypass surgery. mitral valve replace-
ment and multiple PTCA's. Because of severe disabling 
heart failure., he was screened for heart transplantation. 
During this period. a prostate adenoma was found and 
surgically removed. The second day after surgery. he 
died because of heart failure. Although necropsy was 
not perfonned. death was not considered stcnt-related 
because there was no clinical evidence of restenosis. No 
patient sustained an acute myocardial infarction. Three 
patients (6%) underwent bypass surgery (2 patients 3.5 
% 
20 
months and 1 patient 6 months after the stent implanta-
tion). There was a significant improvement in function· 
a1 class at 6-month follow-up. Before stent implantation. 
1 0 patients were in class I. 6 in class II. 14 in class III 
and 20 in class IV. according to the Canadian Cardio-
vascular Society. At follow·up. 34 patients were in class 
I, 9 in class Il. 4 in class III and 3 in class IV. 
Angiographie results: Wiktor stent implantation re--
sulted in a further significant increase in minimallumi· 
nal diameter. from 1.80 ± 0.32 mm immediately fol· 
lowing balloon angioplasty to 2.45 ± 0.35 mm immedi· 
atcly after stent implantation. This was a::wciated with 
a reduction in diameter stenosis from 34 ± 11 to 18 ± 
7% (Table II). There was no change in the reference 
diameter before and after PTCA (2.81 ± 0.48 and 2.80 
± 0.48 rnm. respectively. p =not significant). However. 
there was a significant increase after stent implantation 
(2.98 ± 0.42 mm.. p <0.00001). which was conllillled at 
follow·up (2.91 ± 0.55 mm). In most patients the mea-
sured diameter of the balloon when fully inflated was 
higher than the measured diameter of the stent (Figure 
2). During maximal inflation the mean diameter of the 
balloon for the total study group was 2.98 ± 0.44 mm. 
The mean diameter of the stented segment immediately 
after implantation was 2.88 ± 0.43 mm. This implies a 
recoil of 0.10 ± 0.36 mm (p <0.03). 
Repeat angiography was performed in all patients 
with successful stent implantation (49 patients). except 
in 1, who died 3 months after stent implantation follow-
flGURE 3. Cumu1atiYe distribution of the 
minimal luminal diameter {Ml.D) of the en-
tire study population and its c;hanps im-
mediately after balkMM1 angioplasty, 5tent 
implantation and at follow~. PTCA "' 
percutaneous tramlumlnal coronary ang;~ 
oL-~c_~~~~~--~~~--L_ 
0 ~ u 2 u • u 
MLD (mm) --
PRE PTCA 
POST $TENT 
-:- POST PTCA 
FOLLOW-UP 
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ing prostate surgery. There was no clinical evidence of 
restenosis in this patient. The mean time interval be~ 
tween stent implantation and control study was 5.6 ± 
l.l months. Overall. the minimal luminal diameter was 
found to have decreased from 2.45 ± 0.35 to 1.59 ± 
0.79 mm (p <0.00001). The percentage of stenosis had 
increased from 18 ± 7 to 45 ± 25% (p <0.0001. Table 
IT). When only patients without clinical evidence of sub-
acute vessel closure during hospital stay (44 patients) 
were included. the minimal luminal diameter and per~ 
centage of stenosis were 1.78 ± 0.60 mm and 39 ± 
18%, respectively (Table II). Figure 3 displays the cu~ 
mulative distribution of the minimal luminal diameter 
and its changes (immediately after balloon angioplasty 
and stent implantation and at follow~up). The addition~ 
al increase in minimal luminal diameter immediately 
after stcnt implantation is lost at follow~up. 
The incidence of restenosis depended on the defmi~ 
tion used. When a change of ~0.72 nun in minimal 
luminal diameter was used as the criterion. restenosis 
was observed withln the stent in 19 patients (43%) and 
in the segment immediately distal to the stcnt in 1 (2%) 
of the 44 patients without clinical evidence of subacute 
stent occlusion during hospital stay. Of these 44 pa~ 
tients. the percentage of stenosis at follow~up had in~ 
creased to ~50% withln the stent in 12 (27%) and in the 
segment distal to the stent in 1 (2%). Therefore, the 
total restenosis rate was 45% according to the 0.72 nun 
criterion and 29% according to the 50% diameter steno~ 
sis criterion (Figure 4). 
DISCUSSION 
Clinical results: Intracoronary stents are currently 
being tested in clinical practice to reduce the incidence 
of acute vessel occlusion and restenosis following bal~ 
loon angioplasty. Several stents are available. each with 
its own specific design. composition and physicochemi~ 
cal behavior once implanted. Implanting foreign body 
material implies an increased risk for acute thrombosis. 
Therefore, a stringent anticoagulation protocol is man-
datory. Despite the protocol previously described. a 
thrombotic subacute stent occlusion occurred in 5 pa-
tients (10%). Three of these patients did not receive 
dextran and 1 patient was not properly treated with 
acenocoumarol. Of the 44 patients without clinical cvi~ 
dence of subacute stent occlusion during hospital stay. 
only 6 (14%) did not receive dextran. Unfortunately, 
since central assessment of anticoagulation was not per-
formed. the exact role of the failure of anticoagulation 
with respect to subacute thrombotic stent occlusion can-
not be elucidated. Although it is tempting to speculate 
that suboptimal anticoagulation may be the main cause 
of stent occlusion. other pathophysiologic mechanisms 
also may be involved. Before stent implantation, balloon 
angioplasty is performed to facilitate stent delivery. The 
disruptive action of the balloon may cause intimal dis-
section. which in turn may be the primary cause of an 
ensuing thrombotic event. Furthermore, patients' relat-
ed factors such as acute ischemic syndromes. procedure-
related factors such as technical difficult stent implanta-
tion and angiographic related factors such as small 
vessel size and total occlusion may predispose to throm-
botic stent occlusion. In this study group. no difference 
in vessel size was seen in patients with and without sub-
acute stent occlusion (reference diameter 2.8 ± 0.4 and 
2.8 ± 0.5 mm. respectively (p = not significant). The 
reported subacute stent occlusion rate compares very fa-
vorably with the initial Wallstent experience (20% in 
105 patients). but is similar to the subacute occlusion 
rate following the extended Wallstent experience (12% 
in an additional160 patients).11 •16 However, it contrasts 
sharply with the incidence of 0.6% following Palmaz~ 
Schatz stent implantation. 12 True comparison is not 
possible because the studies differ in methods for pa~ 
tient selection. indication for stcnt implantation and 
type of vessel stented. Furthermore. the very low inci-
dence of 0.6% reported by Schatz.. has not been con. 
finned by a recent study. using the same dcvice.17 In 
this latter study, an incidence of 16% is repOrted. Proba-
bly, the incidence of subacute stent occlusion may be 
reduced by a more detailed coagulation monitoring. In~ 
deed. recent work indicates that measurement of pro-
thrombin fragment 1 + 2 and its changes after stent 
implantation may be predictive for subacute thrombotic 
stent occlusion. 1M 
Another matter of concern is the risk of bleeding. 
inherently associated with aggressive anticoagulation. 
The incidence of bleeding is negligible after PTCA but 
is substantial when a combination of intravenous and 
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FIGURE 4. Change$ In tbe minimal luminal diameter (MLD) at 
follow-up (F !U) after 1Nikt« stent implantation in native coro-
nary arteries. The diameter of eaeh segment immediately after 
stent implantation is plotted against tbe diameter at follow-up. 
The Ones on each side of tbe line of identity (d1agonal) repre-
sent twice the variability (95% confidence interval) of dupll-
eate measurements (a change- of 2:0.72 mm). Of the 49 pa-
tients,. S {10%) sustained a subacute stent oc:dusion (OCCL) 
(X-axis).ln the remaining 44 patients. restenosis was • 
served in 20 patients {45%} aoconfing to tbe 0.72 mm criteri~ 
on and in 13 patients (29%) ac:cording to tbe SO% diameter 
$tenosis (DS) criterion-
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oral anticoagulant drugs are administered.12 The most 
serious bleedlng complication is intracranial hemor-
rhage.. which occurred in 1 of 174 patients following 
Pahnaz-Schatz stent implantation and in 3 of 265 pa-
tients following Wallstent implantation.12.16 Another as-
pect to be considered regarding anticoagulation is the 
longer period of hospitalization, which in turn increases 
the overall costs of the procedure. 19 In this study, the 
hospital stay was (mean ± SO) 11.8 ± 7.4 days for the 
entire study population. 
Angiographie results: The smaller mean diameter of 
the stented segment (2.88 ± 0.43 rom) compared with 
the measured diameter of the fully expanded balloon 
(2.98 ± 0.44 rom) suggests some recoil of the stented 
segment. This minimal recoil appears to be a true phe-
nomenon since the accuracy and the precision of the 
quantitative coronary angiography system used in this 
study is -30 and 90 p., respectively.15 Furthermore, re-
coil has also been observed, although to a larger extent. 
after Wiktor stent implantation in Yorkshire pigs.20 The 
more pronounced recoil ( 1 0%) observed in the animal 
model compared with recoil observed in this study (3%) 
may be explained by the fact that in the former animal 
study the stent was implanted in normal coronary arter-
ies. All these angiographic data indicate that in contrast 
to balloon angioplasty. where recoil amounting to 50% 
has been documented. the Wik:tor stent appropriately 
scaffolds the vesseJ.21 
Restenosis and recurrence of restenosis remains the 
major limitation of (repeat) PTCA. Whether intracoro-
nary stents can address this issue appropriately is still 
unknown. There are some encouraging data from pre-
liminary reports.22.23 However, frrm conclusions cannot 
be drawn. since these data stem from nonrandomized 
studies in which single and multiple stent implantations 
have been performed in both native coronary arteries 
and venous bypass grafts have been performed in pa-
tients with either acute ischemic syndromes or stable 
angina for a variety of indications (primary stent im-
plantation, restenosis, bail out). Patients undergoing re-
peat PTCA appear to be at a higher risk for recurrence 
of restenosis after repeat intervention. The angiographic 
documented restcnosis rate increases from 34% after a 
second dilatation to 40% after a fourth dilatation.6.9 
This is probably an underestimation of the actual inci-
dence owing to incomplete angiographic follow-up. Re-
peat angiography is mandatory in all patients, even in 
patients free of angina at follow-up since approximately 
25% of the patients with restenosis are asymptomatic.24 
Taking into account the limitations of these nonran-
domized observational studies, as is done in this study. 
the incidence of 29% restenosis using the 50% diameter 
stenosis criterion compares favorably with data from 
those former studies. Indeed. randomized studies are 
needed to deftne the exact role of intracoronary stenting 
in the prevention of (recurrent) restenosis. 
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CHAPTER 7 
ANGIOGRAPHIC PREDICTORS OF RECURRENCE 
OF RESTENOSIS FOLLOWING 
WIKTOR STENT IMPLANTATION 
IN NATIVE CORONARY ARTERIES 
P.P.T. de Jaegere, P.W. Serruys, M. Bertrand, V. Wiegand, J.F. Marquis, 
M. Vrolicx, J. Piessens, B. Valeix, G. Kober, H. Bonnier, W. Rutsch, R. Uebis. 
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INTRODUCTION 
Percutaneous transluminal coronary balloon angioplasty is now widely accepted as 
a safe and effective treatment in selected patients with obstructive coronary artery 
disease [1]. However, acute vessel closure and late restenosis are inherent to balloon 
angioplasty and continue to compromise its efficacy [2,3]. Although the exact 
pathophysiologic mechanism(s) and factors responsible for restenosis are largely· 
unlmown, some clinical and angiographic variables have been identified as potential 
risk factors [4]. There is, furthermore, some evidence that repeat angioplasty of a 
previously dilated lesion in a native coronary artery is associated with a higher 
incidence of restenosis [5-9]. The Wiktor stent has been used to treat such patients. 
The incidence of recurrence of restenosis following Wiktor stent implantation in the 
fust 50 consecutive patients has recently been published [10]. The subject of this 
paper is to try to identify angiographic predictors of recurrence of restenosis 
following Wiktor stent implantation. This may not only have important clinical 
consequences but may also broaden our understanding of the pathophysiology of 
restenosis. 
METHODS 
Patients 
Between Jannary 1990 and May 1992, Wiktor stent implantation was attempted in 
193 patients because of recurrence of angina due to restenosis of a native coronary 
artery lesion following prior balloon angioplasty. The study popnlation herein 
reported consists of the 91 out of the 109 consecutive patients with successful stent 
implantation without clinical evidence of thrombotic stent occlusion during hospital 
stay and in whom the scheduled follow-up angiography was completed at (mean ± 
109 CONSECUTIVE PATIENTS 
..... ~=13 (SUB)ACUTE OCCLUSIONS 
(6 CABG/ 8 re-PTCA/ thromboLysis) 
F~=1 DEATH (HEART FAILURE) AT 3 months 
F~=3 REFUSALS 
..... ~= 1 MISSING 
91 CONSECUTIVE PATIENTS 
WITH ANGIOGRAPHIC FOLLOW-UP • 
* 5.7:: 1.9 months 
Fig. 1. Flow diagram showing angiographlc follow-up in the first I 09 consecutive patients. In hospital 
acute or subacute occlusion occurred in 13 patients (12%). Of the remaining 96 patients who were 
discharged without clinical evidence of (sub)acute occlusion, 91 underwent repeat angiography at (mean 
± sd) 5.7 ± 1.9 months after stent implantation. 
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sd) 5. 7 ± 1.9 months (Figure 1 ). 
Eighty-one patients were male (89%), the age (mean ± sd) was 58± 11 years. A 
frrst restenosis was documented in 50 patients (55%), a second in 32 patients (35%), 
a third in 8 patients (9%) and a fourth in one other patient (1% ). In all patients, a 
single Wiktor stent was implanted except in one, in whom a single stent was implant-
ed in both the left anterior descending and the right coronary artery. The target vessel 
was the left anterior descending artery in 48 patients (52%), the right coronary artery 
in 31 patients (34%), the left circmnflex in 12 patients (13%). In another patient 
(1% ), a single Wiktor stent was implanted in the left main stem. The size of the stent 
used (mean ± sd) was 3.4 ± 0.4 mm; 3.0 mm device in 38 patients (41 %), 3.5 mm 
device in 40 patients (44%) and a 4.0 mm device in 14 patients (15%). The stent is 
described in detail elsewhere as well as the associated drug protocol [11]. 
Angiographic variables and definition of restenosis 
Based on the quantitative angiographic data, multiple variables were identified and 
recorded for each lesion. These variables were of a priori clinical interest on the basis 
of previously published reports on balloon angioplasty and intracoronary stenting and 
of a more fundamental scientific interest based on experimental studies on stent 
implantation in animals [4,12-16]. The following continuous variables were selected: 
obstruction diameter before and immediately after stent implantation, baseline 
reference diameter and diameter stenosis, length of target lesion, plaque area and the 
relative gain defmed by the increase in minimal luminal diameter immediately 
following stent implantation normalized to the vessel size. In addition to these 
continuous variables, one discrete variable (Left anterior descending artery) was 
selected. All coronary angiograms were analyzed with the computer assisted 
Cardiovascular Angiography Analysis System. Its principles and definitions of 
angiograpltic variables have been described in a previous study on Wiktor stent 
implantation [11]. Since the primary objective of this study was to identify angie-
graphic variables predicting restenosis, the process of restenosis was dichotomized 
and defined according to the 0.72 mm and 50% diameter stenosis criteria [17]. 
Statistics 
A relative risk analysis was performed for the aforementioned angiographic variables. 
To avoid an arbitrarY subdivision of data in the continuous variables, the median 
value was chosen as cut off point. The selection of this value as cut off point has the 
advantage of being consistent for all values and thus avoids any bias in the selection 
of subgroups that might be undertaken to emphasize a particular point. All values are 
expressed as means ± SD. The risk for restenosis for each parameter according to the 
0.72 nun and 50% diameter stenosis criteria was detennined by using an univariate 
analysis and is expressed as odds ratio with corresponding 95% confidence interval. 
An odds ratio of 1.0 for a particular variable implies that the presence of that 
variable poses no additional risk for restenosis, an odds ratio greater than 1.0 or less 
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than 1.0 implies additional or reduction in risk. Furthermore, since experimental 
animal data indicate that there is a relation between the severity of vessel wall injmy 
and the extent of subsequent neointimal thickening, the relation between relative gain 
(as index of vessel wall injmy) and relative loss (as index of neointimal thickening) 
was studied using a regression analysis. The relative gain is defmed above. The 
relative loss is the difference between the minimal luminal diameter immediately 
after stent implantation and at follow-up normalized to the vessel size. 
RESULTS 
Incidence of restenosis 
The changes in stenosis geometry are summarized in Table L The incidence of 
restenosis was 44% (40[91 patients) according to the 0.72 mm criterion and 30% 
(27/91 patients) according to the 50% diameter stenosis criterion. When the stent is 
used as a unit, the incidence ofrestenosis was 45% (41 out of the 92 stents) and 29% 
(27 out of the 92 stents), respectively (Figure 2). 
4 
MLD F/U {mm) 
3 
2 
+: CHRON OCCL: 4(4%) 
IIIII ~ SO'Ja: 27(29%) 
. 
~ 0.72mm 
•N-41 (45!f.) 
MLD POST -$TENT(mm) 
0.72 mm LONG TERitiiARIABIUTY 
Fig. 2 Changes in the minimal luminal diameter at follow-up following Wiktor stent implantation. The 
diameter of each segment immediately after stent implantation is plotted against the diameter at follow-up. 
The lines on each side of the line of identity (diagonal) represent twice the variability (95% confidence 
interval) of duplicate measurements (a change ;:: 0.72 mm). A significant decrease in minimal luminal 
diameter according to the 0.72 nun criterion was foWld in 41 out of the 92 stents implanted (45%). The 
incidence of restenosis according to the 50% diameter stenosis criterion was 29% (27 out of the 92 stents). 
Of these, 4 stents were completely occluded at follow-up, as shovm on the X-axis. 
Angiograplric predictors 
The relative risk and 95% confidence intervals for each variable using either of the 
two criteria are shown in Table 2. The only statistically significant predictor of 
76 
Table 1. Findings at quantitative angiography following wiktor stem implantation (n - 91 patients). 
Before PTCA After PTCA After Stent At follow-up 
Implantation 
Reference diameter (mm) 2.85 ± 0.49 2.80 ± 0.48 3.02 ± 0.42 2.98 ± 0.47 
Minimal luminal diameter (mm) 1.13 ± 0.36 1.77 ± 0.36 2.45 ± 0.34 1.73 ± 0.67 
Diameter stenosis (%) 60 ±10 35 ±II 19 ± 7 42 ± 21 
All parameters are expressed as mean± SD. PTCA -percutaneous transluminal coronary angioplasty. 
All changes were higly significant (p < 0.00001), except for the reference diameter; only the difference 
in reference diameter after stent implantation and after PTCA was statistically significant (p < 0.001). 
Table 2. Angiographic predictors of restenosis following Wiktor stent implantation. 
Angiographic variable 
Relative gain (mrn) 
MUt.imal Luminal Diameter post (rrun) 
Minimal Luminal Diameter pre (mm) 
Lesion length (nun) 
Reference Diameter pre (mm) 
Plaque area (mm2) 
Diameter stenosis pre (%) 
Left anterior descending artery 
~ 0.48 
~ 2.38 
~ 1.08 
~ 6.48 
:::; 2.77 
~ 7.47 
~ 61 
Restenosis criteria 
0.72 mm criterion 
2.7 (1.1 - 6.4) 
1.8 (0.8 - 42) 
1.6 (0.7 - 3.7) 
1.4 (0.6 - 32) 
1.3 (0.6 - 2.9) 
1.3 (0.6 - 2.9) 
1.0 (0.4 - 2.3) 
0.7 (0.3 - 1.7) 
50% diameter 
stenosis criterion 
1.1 (0.4 - 2.7) 
0.5 (02 - 1.4) 
2.7 (1.0 - 7 2) 
1.8 (0.7 - 4.6) 
1.4 (0.5 - 3.4) 
1.1 (0.4 - 2.7) 
1.3 (0.5 - 32) 
1.1 (0.5 - 2.8) 
recurrence of restenosis according to the 0.72 rom criterion was the relative gain 
when it exceeded 0.48 (odds ratio 2.7, 95% confidence interval 1.1 - 6.4). Related 
to the relative gain is the obstruction diameter before and after stent implantation. 
Although their odds ratio exceeds 1.0, their corresponding 95% confidence interval 
precludes any fmn conclusion. The same holds for lesion length, reference diameter 
and plaque area. The left anterior descending artery was not identified as a risk factor 
for recurrence of restenosis. When using the 50% diameter stenosis criterion, no 
angiographic predictor of restenosis was evident. 
The number of balloon angioplasty performed before stent implantation did not 
influence the risk for subsequent restenosis after stenting. The odds for restenosis in 
case of stent implantation for a second, third or fourth restenosis compared with stent 
implantation for a frrst restenosis was 0.8 (95% confidence interval 0.4 - 1.8) 
according to the 0.72 mm criterion and was 1.5 (95% confidence 0.6 - 3.7) 
according to the 50% diameter stenosis criterion. 
Regression analysis 
The relation between relative gain, as index of vessel wall injury, and relative loss, 
as index of late nee-intimal hyperplasia as vessel wall response to injury, is shown 
in Figure 3. A Pearson product-moment correlation coefficient of 038 was found 
(p < 0.001, slope 0.61, intercept -0.06). 
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Fig. 3. Graphic display of the relation between the relative gain (RG - increase in minimal luminal 
diameter inunediately after stent implantation nonnalized to the vessel wall) and relative loss (RL -
decrease in minimal lwninal diameter at follow-up nonnalized to the vessel wall). A positive linear 
relation was found with a correlation coefficient of 0.38 (p < 0.001) with a slope of 0.61 and an intercept 
on the Y -axis of -0.06. 
DISCUSSION 
The primary objective of this study was not the determination of the incidence of 
recurrent restenosis following Wil1:or stent implantation in patients with restenosis 
after previous balloon angioplasty. However, it is noteworthy that the incidence of 
post -stent restenosis reported here in the 91 patients is identical to the incidence of 
recurrent restenosis in the frrst 50 consecutive patients [10]. Detailed analysis of a 
subgroup of 7 4 patients revealed that there was no late compression of the stent 
itself. Therefore, late loss or restenosis was due to ingrowth of tissue into the lumen 
of the stented segment [18]. 
The lack of randomized studies precludes any conclusion as to whether stent 
implantation in this subset of patients will reduce the incidence of subsequent 
restenosis. Moreover, the exact incidence of recurrent restenosis after repeat balloon 
angioplasty is not lmown. There is some evidence that it increases with the number 
of repeat angioplasty. A second restenosis has been reported to occur in 25 and 34%, 
but amounts to 39 and 40% following a third or fonrth angioplasty, respectively 
[5-9]. These data should be interpreted with caution consideting the difference 
between the study populations, the difference in defmition of restenosis and in the 
time and completeness of follow-up angiography. In the present study in which stents 
were implanted because of restenosis, the risk for recurrent restenosis after stenting 
did not differ between patients with a frrst restenosis and patients with a second, third 
or fourth restenosis. Two other studies failed to show a statistically siginificant differ-
ence in the restenosis rate for primary or de novo lesions compared with lesions who 
had undergone previous balloon angioplasty [12,13]. However, subgroup analysis of 
those patients in whom a single Palmaz-Schatz stent was implanted showed a 
restenosis rate of 13% compared with 36% for patients with previous restenosis [13]. 
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The pathogenesis of restenosis remains incompletely understood. Histologic data have 
shown that any injury to the vessel wall, whatever its nature, will invariably be 
associated with neointimal hyperplasia as a non-specific tissue response leading to 
restenosis when excessive [14,19-23]. lt is both of scientific and utmost clinical 
importance to !mow and understand its pathogenesis but also to !mow the factors 
controlling the extent of the vessel wall response following injury. Experimental 
animal studies, postmortem pathologic observations in humans and angiographic 
studies have shown that the extent of neointhnal hyperplasia is proportional to the 
degree of injury applied to the vessel wall (Figure 4) [14-16,24]. This is in accord 
with earlier work in the porcine model, describing a relation between the degree of 
injury and early platelet deposition [25,26]. ln the present study, the relative gain was 
used as angiographic correlate of vessel wall injury. This parameter was found to be 
the only statistically signillcant predictor of recurrence of restenosis when using the 
0.72 mm criterion. The drawback of the latter is, frrst, that the process of restenosis 
is dichotomized (present/not present) and secondly, that although statistically 
justifiable, cutoff points are used for the angiographic variables under investigatioiL 
However, the continuous approach underscores these Imdings by indicating a positive 
linear relation between the relative gain and relative loss. These observations were 
still valid when using absolute measurements. However, the correlation between the 
absolute gain and absolute loss was somewhat weaker (r ~ 0.21, p ~ 0.05). This is 
explained by the fact that the use of absolute values does not relate these changes to 
--,-·-r-;;--~ 
_"',_,_-or-
N•7 N•~ 
Nobuy<>~hl et ~~­
J.Am.Coii.Cordlol, "!1 
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--···- ! r; 
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Fig. 4. Experimental animal data, postmortem pathologic observations inhunansand angiographicstudies 
independently from each other indicate a proportional relationship between the degree of vessel wall injury 
and the extent of late neointimal thickening. Left panel: coil stent implantation in domistic pigs results in 
a more extensive smooth muscle cell proliferation in case of rupture of the internal elastic lamina and 
consequent medial injury (reproduced with permission from Schwarz et al. Circulation 1990;82: 
2190-2200), middle panel: pathologic observations in human indicate that deep arterial injury is associated 
with more extensive intimal proliferation (reproduced with permission from Nobuyoshi et al. JAm Coil 
Cardiol1991;17:433-439), right panel: an angiographic study assessing the immediate and long-term 
changes in stenosis geometry following balloon angioplasty, shows that restenosis defmed as~ 0.72 mm 
decrease in minimal luminal diameter (MLD, bold line), was foWld to be signifanctly correlated with both 
a larger increase in MLD and larger absolute dimension after balloon angioplasty (reproduced with 
permission from Bean et al, JAm Coil Cardiol1992;19:258-266). 
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the vessel size. Although we found no difference in absolute loss between small and 
large vessels, an identical loss in minimal luminal diameter represents a larger 
relative loss in a small vessel than in a large vessel and vice versa. This confmns 
other studies using a categorical approach to defme restenosis after stenting, that 
small vessels are not per se more prone to restenosis than large vessels [12,13,27]. 
This concept, describing a proportional relationhip between vessel wall injury and 
neointimal thickening, has been reported in other studies using quantitative coronary 
angiography. Bean eta!. found that restenosis (0.72 mm criterion) was signillcantly 
correlated with beth a greater improvement in obstruction diameter and a larger 
absolute dimension after balloon angioplasty [16]. FUttherrnore, in a recent study the 
absolute change in minimal hnninal diameter was reported to be the greatest single 
determinant of late luminal narrowing after balloon angiop!asty [28]. 1n another 
report, it was found that interventions achieving a .. bigger., lumen provoke a 
concomitantly larger relative loss, so that the ultimate end point of various treatment 
modalities is similar [29]. 
All these findings carry potential far-reaching clinical implications. Clearly, the 
greater the improvement in minimal luminal diameter achieved by intervention, the 
greater the magnitude of subsequent luminal narrowing will be. Unfortunately, what 
can not be drawn from the data is how much damage the clinician may inflict on the 
vessel wall. On one hand, a suboptimal angiographic result is associated with a 
higher risk of subacute occlusion due to rheologic factors and platelet deposition and 
a higher need for repeat balloon angioplasty but, on the other hand, improvement of 
the initial result may be at the price of more extensive late neo-intirnal thickening 
[14-16,30,31]. This indistinctness can be circumvented by proper matching the 
balloon size or device with the vessel wall using on line quantitative coronary 
angiography. This is underscored by the data displayed in Figure 5 indicating that the 
more the stent is oversized, the greater the loss in minimal luminal diameter will be. 
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Fig. 5. Graphic display of the relation between the stentfartery ratio (X·axis) and relative loss (Y·axis). 
A positive linear relation was found with a correlation coefficient of 0.35 (p < 0.002) with a slope of 0.60 
and an intercept of -0.40. 
So far, there are two other angiographic studies which have attempted to identify 
risk factors for restenosis or recurrence of restenosis and found. as in the present 
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study, that the vessel size, severity of stenosis expressed as diameter stenosis and 
length of the lesion not to be associated with an increased risk for restenosis [12,13]. 
As mentioned above, the indication (primary or secondary stenting) was not 
associated with an increased risk for restenosis [12,13]. In accordance with these two 
studies on stenting and one other study on balloon angioplasty, the target vessel was 
not associated with an increased risk for (recmrent) restenosis [12,13,32]. 
Study limitations: The study limitations are essentialy two fold. First, the precision 
of relative gain as an angiographic index of vessel wall injnry and relative loss as an 
index of neointimal hyperplasia has not been studied. The coronary angiogram is a 
two dimensionallwnenograrn descnbing the changes in stenosis geometry but not the 
nature and/or extent of the pathology explaining these angiographic changes. 
Therefore, the measurement of the minimal lwninal diameter, and consequently the 
relative gain and loss, are subject to potential imprecision. Secondly, the effect of 
other clinical, procedural and lesion-related characteristics on the development of late 
neointimal hyperplasia, has not been considered. It is conceivable that, if they play 
a role in the pathogenesis of neointimal thickening, they were uneqnally distnbuted 
over the study population. 
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INTRODUCTION 
The management of recurrent ischemia in patients who have had previous saphenous 
venous bypass surgery poses a serious, difficult problem. Recurrent ischemia occurs 
not only due to attrition of the saphenous vein grafts but also to progression of 
coronary artery disease in the native coronary arteries. The attrition rate during the 
frrst year after surgery is 15 to 20%; between 1 to 6 years after surgery it is 1 to 2% 
per year and between 6 to 10 years after surgery the rate is 4% per year [1-8]. By 
five years, about 45% of the grafts are occluded [3, 7]. Progression of native coronary 
artery disease occurs in approximately 5% of the patients per year after operation 
[8-11]. Symptoms recur or progress in about 5% of patients per year and it has been 
estimated that 10% to 15% of the patients will require repeat surgery within I 0 years 
after initial surgery [11-15]. However, currently improved surgically techniques in 
combination with administration of aspirin and risk factor modification have 
improved early graft attrition rate and may improve longterm attrition [16]. Despite 
improved surgical resnlts it may be expected that the number of patients with 
recurrence of ischemia will increase, because the pool of operated patients continues 
to accumnlate. 
Reoperation is technically more difficnlt to perform and is associated with a rather 
high mortality (3% to 6.5%) and high peri-<:>perative myocardial infarction rate (3.4% 
to 11.5%) and the likelihood on complete relief of symptoms is less compared to a 
frrst operation [11-16]. Tiris has stimnlated the search for an alternative treatment. 
Gruentzig reported already in 1979 that vein graft angioplasty was successful in 
5 of 7 attempts [17]. However, three out of five demonstrated restenosis during 
follow-up and Gruentzig suggested that the "different kind of disease" in the bypass 
graft may have explained the high recurrence rate in graft stenosis. Since then many 
studies concerning angioplasty of lesions in saphenous vein grafts have been 
reported. 
In this article we review the literature and we will discuss the indications, the 
initial and late resnlts of angioplasty of saphenous venous bypasses and we will 
briefly discuss the role of new techniques including stents, directional and 
extractional atherectomy, and laser angioplasty. 
Patho-anatomy of saphenous venous grafts 
The pathophysiological mechanisms underlying graft failure can, arbitrarily, be 
distinguished into those occurring early, within 1 year, and late after surgery. In each 
period one assumes a specific predominant pathogenetic mechanism. although one 
must bear in mind that the different pathological processes may occur in a continuous 
fashion and overlap in time [18,19]. 
Graft occlusion early after surgery is usually associated with acute thrombosis 
[18,19]. Tiris is possibly attributable to harvesting and handling of the vein, or to 
failure of surgical techniques at anastomosis sites [20]. 
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Fig. 1. Histological cross-section of a two year old saphenous vein graft showing a severe lum.in.al. 
narrowing due to concentric intimal thickening (arrows) consisting of fibre-collagenous tissue. 
(Elastic van Giesson stain x 25 magnification). 
Fig. 2. Saphenous vein (v) -coronary artery (a) anastomosis, 9 months after bypass surgery, showing 
intimal thickening (I) and occlusive thrombus 
(Elastic van Giesson stain x 25 magnification). 
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Fibro-intimal hyperplasia is the dominant feature 1 to 12 months following surgery 
[20-22]. The cells of fibro-intimal hyperplasia resemble smooth muscle cells and 
some cells may have a "foamy" cytoplasmic appearance [21]. Focally stenotic lesions 
produced by this process appear particularly amenable to dilatation. 
In the late period after surgery fibro-intimal hyperplasia at rrrst remains the 
dominant feature but gradually atherosclerotic lesions become more frequent (Figure 
1 and 2) [19]. The fibro-intimallesion gradually dintinishes its cellularity and the 
smooth muscle cells are replaced by fibrous tissue and the matrix is increased. With 
time there appears to be an increase in the number of "foam cells" within the intima. 
The development of atherosclerosis in the aortocoronary vein grafts is an important 
factor in late graft stenosis and occlusion [23-32]. The atherosclerotic process 
proceeds to a fully developed complex atherosclerotic plaque (Figure 3) and rupture 
of the plaque leads to a superimposed thrombotic occlusion [23,24]. The plaques are 
often large, fragile and ulcerated and the graft may show aneurysmal dilatation 
[25,26]. 
There is still some controversy as to whether venous graft atherosclerosis differs 
from coronary atherosclerosis. Some investigators suggest [28,29] that vein graft 
lesions contain more foam cells, and that they exhibit an inflammatory reaction with 
foreign body giant cells. This process undenuines the thickened intima so that the 
fibrous cap is weakened (Figure 4) [28]. One study demonstrated lack of a fibrous 
cap [29]. This thinning and weakening of the fibrous cap may explain the greater 
propensity of venous plaque rupture and thrombosis. The propensity of thrombus 
fonnation in vein grafts is enlarged because the lack of side branches. the large 
diameter of vessels and consequently low flow velocities may contribute to platelet 
aggregation and thrombus formation. These factors may explain the frequent 
occurrence of thrombotic complications or embolization of material during balloon 
angioplasty. 
However, other investigators [18,19,26,30-32] favour the opinion that athero-
sclerosis vein graft disease is not different from arterial atherosclerosis. 
Immediate results of angioplasty for saphenous venous bypass grafts. 
Ford et al. [33] reported a small series of 7 patients of whom 6 patients were dilated 
successfully. Since then, many centers have reported their initial result of angiop!asty 
of saphenous vein grafts. Only the upgraded latest reports per center are presented 
(Table 1). 
The initial success rate varies from 75 to 94% with a combined overall success 
rate of 88%. The major complication rate is low with a procedural related death rate 
of less than 1%, a myocardial infarction rate of approximately 4% and a need for 
urgent surgery of less than 2%. Remarkable is the low tendency to abrupt occlusion 
and the relative high success rate, probably due to the absence of sidebranches and 
tortuosity. The risk of embolization of friable, thrombotic material into the native 
circulation is less than 3%. Emboli usually occur during attempts in older grafts, with 
long diseased segments containing friable, thrombotic lesions. The initial success rate 
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Fig. 3. Six year old vein graft showing severe luminal narrowing by a ~classical~ atherosclerotic plaque; 
fatty debris is covered by a fibrous cap (Fe) (lwnen; arrow). 
(Elastic van Giesson stain x 25 magnification). 
Fig. 4. Four year old saphenous bypass graft showing a concentric fibrous intimal thickening and an 
eccentric atherosclerotic plaque with fatty debris seperated from the lwnen (2) by a very thin fibrous cap 
(arrows). (Elastic van Giesson stain x 25 magnification). 
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Table 1. Initial results of angioplasty of saphenous vein grafts 
Authors (year) No. Oinical Procedural complications 
of pts Succ= 
% (piS) Death Ml Embolization Acute CABG 
(%) (%) (%) (%) 
Douglas [34] 1983 62 94 (58) 0 2 0 2 
El Gamal [35] 1984 44 93 (41) 0 5 0 0 
Block [36] !984 40 78 (31) 0 0 0 25 
Corbelli [37] !985 35 89 (31) 0 0 0 3.0 
Reeder [38] !986 19 84 (16) 5 5 0 0 
Douglas [39] !986 235 92 (216) 0 7* 3 1.3 
Cote [40] !987 82 85 (70) 0 2 1 
Ernst [41] 1987 33 97 (32) 0 3 n.r. 0 
Dorros [42] 1988 53 83 (44) 2 2 6 2 
Reed [43] 1989 54 90 (47) 0 0 0 2 
Cooper [44] 1989 24 75 (18) 4 0 n.r. 0 
Platko [45] !989 10! 90 (90) 2 6 3 2 
Webb [46] !990 140 85 (II9) 0 4 n.r. 
Meester [47] 1991 84 82 (69) 8 n.r. 25 
Plokker [48] !991 454 90 (408) 0.7 2.8 n.r. 1.3 
Reeves [49} !991 57 83 (47) 2 9 7 2 
Total !571 88 (1337) <1% <4% <3% <2% 
* 15 of 16 patients had non-q-wave infarction; n.r.: not reported. W ~ myocardial infarction; CABG = 
coronary artery bypass grafting. 
Table 2 Initial success rate of dilatation of saphenous vein grafts at different sites. 
Site of venous graft dilation 
Author Year 
Proximal Body Distal 
% Oesions) % (lesions) % (lesions) 
Douglas [34] 1983 80 (5) 96 (23) 94 (34) 
Dorros [50] 1984 84 (12) 88 (8) 69 (!3) 
Corbelli [37] 1985 88 (26) !00 (7) 93 (14) 
Pinkerton [51] 1988 94 (36) 90 (29) 94 (35) 
Cooper [44] 1989 56 (9) 67 (3) 92 (12) 
Platko [45] 1989 89 (53) 100 (24) 93 (30) 
Webb [46] 1990 80 (47) 86 (39) 89 (56) 
Meester [ 4 7] 1991 86 (28) 97 (33) 81 (32) 
Total 86 (216) 93 (162) 90 (226) 
depends on the site of dilatation (Table 2). The overall combined initial results of 
dilatation of the proximal site is 87%, of the body 94% and of the distal site 90%. 
These rates appear to be similar, except for a slight lower success rate for dilatation 
at the proximal site. The high success rate and low complication rate reflects the 
careful selection of patients and probably difficult potentially risky lesions including 
long diffuse lesions, or ulcerated, thtombotic, friable lesions have been excluded from 
these series. 
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Restenosis after successful dilatation of saphenous vein grafts 
The restenosis rate (defmed as >50% luminal diameter in the majority of the 
reported studies) after an initial successful angioplasty depends highly on the site of 
the dilation within the graft (fable 3). Ostial, or very proximal lesions of the graft 
tend to have a very high restenosis rate on average 58%; the restenosis rate of the 
body of the graft is 52% and the restenosis rate in the distal, anastomotic part of the 
graft is 28%. The overall combined restenosis rate is 42%. The restenosis figures 
probably overestimate the true incidence of restenosis because not all asymptomatic 
patients are restudied. The angiographic completeness of follow-up varied from 56% 
to 100% in the reported studies (fable 3). 
Table 3. Restenosis after successful angioplasty of saphenous venous grafts 
Author Year No. of Definition Completeness Angiographic restenosis by site Oesions) 
Pts Restenosis Angiographic 
F.U. (%) Prox. Body Distal All sites(%) 
Douglas [34] 1983 41 n.r. n.r. 1/2 9/17 4/22 14/41 (34) 
El Gamal [35] 1984 16 >50% 61 1/2 5/12 2/3 7/17 (41) 
Block [36] 1984 22 >50% 71 n;r. n.r. n.r. 12/22 (55) 
Dm·ros [50] 1984 26 n.r. nr. 8/10 2/7 2/9 12/26 (46) 
Reeder [38] 1986 16 > 30% 100 2/3 3/5 3/8 8/16 (50) 
Douglas [39] 1986 130 n.r. ni. 11/14 40/65 10/51 61/130 (47) 
Cote [40] 1987 26 >50% 70 3/9 5/21 2/13 10/43 (23) 
Dorros [42] 1988 25 n.r. 57 3/5 3/7 4/13 10/25 (40) 
Pinkerton [51] 1988 23 n.r. 92 1/3 3/5 6/15 10/23 (44) 
P!atko [45] 1989 49 >50% 56 21/42 9/20 10/24 40/86 (47) 
Meester [47] 1991 59 >50% n.r. n.r. n.r. n.r. 13/59 (22) 
Reeves [49] 1991 45 >50% 93 7/11 20/32 5/14 32/57 (56) 
Total 478 58/!01 99/191 48/172 229/545 
(58%) (52%) (28%) (42%) 
n.r.: not reported 
In native coronary arteries the restenosis process takes place in the majority of the 
patients within 6 months after angioplasty. Whether this is similar in restenosis in 
venous bypass grafts is unlawwn. But data reported by Douglas et a!. [52] suggest 
that this time window is longer. They followed 599 patients with successful 
angioplasty and found that restenosis occurred in 32% of lesions dilated within 6 
months of surgery, 43% from 6 months to 1 year, 61% from 1 to 5 years, and 64% 
over 5 years. 
Longterm follow-up after angioplasty of saphenous vein bypass grafts 
The longterm outcome of patients selected for angioplasty of a saphenous venous 
bypass graft is not only influenced by the restenosis rate, and rate of progression of 
disease in the native arteries, but also by the extent of the left ventricular dys-
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function. The frequency of late mortality, myocardial infarction and recurrence of 
angina is listed in Table 4. The wide range of rates reflects the differences in patient 
selection and duration of follow-up. It appears that the clinical event rate is 
significantly higher if the age of the graft is higher. The clinical event rate was 64% 
in grafts over 36 months of age, and 33% in grafts less than 36 months of age [45]. 
Table 4. Longterm results after immediate successful graft lesion angioplasty 
Authors y,.,. No of Mortality Myocardial Recurrence Follow-up 
Patients Infarction Angina Months 
(%) (%) (%) (mean± SD) 
Cote [40] !987 82 2.5 0 29 21 ± 2 
Reed [43] 1989 50 2 2 52 23 ± 11 
P!atko [45] !989 87 ll.5 20 47 17 ± 14 
Webb [46] !990 l!9 7.6 II !9• 33 ± 26 
Reeves {49] !991 50 4 4 54 32 
Meester [47] 1991 69 l!.5 !0 42* 25 
Plokker [ 48] 1991 454 22 n.r. n.r. 60 
* These patients underwent re-operation or re-angioplasty. 
Plokker et al. [48] reported that after a follow-up period of 5 years, 74% of 454 
patients were alive and only 26% of the patients were alive and event-free (no 
myocardial infarction, no repeat bypass surgery or repeat angioplasty) (Figure 5). The 
time interval between angioplasty and surgery was a significant predictor for 5-year-
event-free survivaL The event-free survival rates for patients who had bypass surgery 
l year before, between 1 a1-:td 5 years, and 5 years after bypass surgery were 45%, 
25% and 19% respectively. 
R • H ~ U ~ q W 00 
Months 
Fig. 5. Four hundred fifty-four patients were 
followed for 5 years. The cumulative probabilities 
of survival (1), of survival without AMI (II), 
without AMI and no re-CABG (III) and without 
any cardiac event (IV) (death, AMI, CABG and 
re-PTCA) are shown. ANfi = acute myocardial 
infarction; re-CABG - repeat coronary artery 
bypass grafting; re-PTCA = repeat percutaneous 
transluminal coronary angioplasty. Reproduced 
with permission from Plokker et al. A.m J Cardiol 
1991; 67:361-366, Figure 2. 
The late mortality and late myocardial infarction rate is expected to be high, 
because often these patients present as end-stage coronary artery disease patients. In 
these patients angioplasty should be considered a palliative treatment, and one should 
not expect a beneficial effect on late mor.ality. 
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Balloon Angioplasty of early (within 1 year) occlusion of saphenous venous 
bypass grafts 
Graft occlusion occurring within 1 month after surgery is almost always associated 
with graft thrombosis [18-20,24,27]. Technical factors such as stenosis at surgical 
anastomotic-sites, or intra-operative vein trawna, or poor distal nm-off due to 
severely diseased native arteries play a role and limit the possibilities of immediate 
and sustained beneficial effect of angioplasty. 
Graft occlusion occurring between 1 month and 1 year after surgery is character-
ized by lesions consisting of fibre-intimal hypetplasia with superimposed occlusive 
thrombosis [18-21,24,27,28,30]. These occlusions are predominantly focal, not 
associated with diffuse vein graft disease, and usually the thrombotic component of 
the occlusion is not extensive. These occlusions appear to be amenable to successful 
perforation and dilatation. 
Balloon Angioplasty of chronic totally saphenous venous bypass grafts more 
than 1 year after surgery 
The underlying patho-anatomy plays an important role in the expected success rate 
of angioplasty of a chronic totally occluded graft. Late occlusions (1-3 years after 
surgery) are usually associated with focal atherosclerosis with occlusive thrombosis 
[18-21,24,27,28,30]. These lesions may be amenable to successful perforation and 
dilatation without increased risk of thrombotic embolization. Older occlusive 
obstructions are often composed of large, ulcerated plaques containing friable 
thrombotic material. The chronic total occlusions are often extended over a long 
segment of the graft and are often associated with diffuse graft disease. Obviously, 
perforation and dilatation of these chronic occlusions may be unsuccessful or even 
hannful due to dislodgement of material into the native coronary circulation with 
ensuing myocardial infarction. 
The safety and results of angioplasty in occluded grafts is controversial. De Feyter 
et al [53] reported in 13 patients with chronically totally occluded old degenerated 
grafts that attempts to recanalization of the graft expose the patient to a high risk of 
embolization and even if it is possible to re-open the graft it re-occludes frequently. 
ln their study ouly 1 out of 13 patients had a longterm success and the procedure 
was complicated by a myocardial infarction in 5 patients (Table 5). Apparently the 
presence of large amounts of thrombotic material and the dislodgement of it are the 
main causes of low success and high complications with balloon angioplasty. These 
results contrast highly with a recent report of Kalm et al. [54]. They reported a 83% 
success rate, (64 out of 82 patients) with 1.5% in-hospital death, 3% myocardial 
infarction rate and no urgent bypass surgery. However, at 3 years follow-up only 
33% of the patients were free of repeat PTCA or surgery. The difference in 
immediately results between the 2 reports may be explained by differences in patient 
selection. Results in short occlusions in angiographically reasonably normal 
appearing grafts are probably better than long occlusions in degenerated vein grafts. 
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Table 5. Coronary angioplasty of chronic totally occluded vein grafts 
Author Duration Age Nwnbcr Initial Procedur:il Longterm Late Late 
Occlusion gxafts ofPts Clinical Death Ml Succes Deaths Ml 
Success 
months mean (fls) Pts Pts Pts Pts Pts Pts 
ANG!OPLASTY 
de Feyter [53] 3- 6 6±4 13 7 0 5 0 0 
UROKINASE + ANG!OPLASTY 
Sievert [55] 05-4 0.2- 3.6 7 6 0 0 4 0 0 
Hartmann [56] 05-6 7 (1-13) 46* 36** 0 2 22 4 0 
Levme [57] "-'· nx. 10 6 2 2 0 0 
n.r.: not reported 
* 8 patients with acute non-q-wave infarction. 
** 20 patients had repeat angiogram: 7 had an occluded graft. 
Pre-treaJ:ment of chronic total occlusion with urokinase followed by angioplasty 
Dissolving thrombus in a chronically occluded grafts with short infusion of urokinase 
dramatically improved the short and longterm results (Table 4). Sievert et al. [55] 
showed that after pretreatment with urokinase 6 out of 7 patients were successfully 
recanalized, with a longterm success in 4 patients. Hartmann et al. [56] also showed 
good results with longterm urokinase infusion (7 .5 to 77h; mean 3!h) followed by 
angioplasty. Recanalization could be achieved more easily in patients with a short 
estimated duration of occlusion. The price one must pay for this treatment is the 
occurrence of a significant haematoma in 22% of the patients and the long stay in 
a coronary care unit. Unfortunately, the reocclusionfrestenosis rate is rather high and 
success was sustained in 48% (22 out of 46 patients) of the patients during 1 to 24 
(mean 11) months follow-up period. Levine et a!. [57] demonstrated that in 8 out of 
10 patients patency was achieved (however, 2 patients died and 2 had embolic 
myocardial infarction) but during follow-up at an average of 13 ± 6 months no patient 
was free of reocclusion, myocardial infarction or death. 
Identification of risk factors for unfavourable outcome 
Variables predictive of unfavourable initial result include: 
a) diffuseness of saphenous vein graft disease [40], b) attempts of angioplasty of 
stenoses in grafts older > 4-6 years [45,46], c) chronic totally occluded grafts [13] 
and d) the presence of intra vein graft thrombus [49]. The presence of one or more 
of these variables is associated with a high frequency of major complications (death, 
myocardial infarction and need for urgent bypass surgery) often due to embolization 
of friable material into the coronary circulation or the occurrence of abrupt occlusion 
with thrombosis formation. 
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Variables predictive of late restenosis include: 
a) lesions in old (> 36 months) grafts (restenosis rate 83% vs 42%) [45], b) multiple 
lesions, diffuse graft disease and total occlusion (100% vs 38%) [49], c) small 
diameter(< 2.2 mm) grafted coronary artery (78% vs 27%) [58], d) length(> 10 mm) 
stenosis (62% vs 12%) [58] and e) dilatation of lesion at the proximal site and body 
of the graft (Table 3). 
Limitations of surgical back-up 
In many centers the availability of inunediate surgical back-up is considered a pre-
requisite for performing angioplasties. Although emergency operation for acute 
ischemia may not totally eliminate the developmem of a myocardial infarction, there 
is evidence that prompt revascularization does limit the damage [59]. Time between 
onset of ischemia and revascularization determines the outcome [60]. The ischemic 
period during reoperation is considerably prolonged because immediate access to the 
heart is hampered by the fibrosis of the previous operation, which may require 
considerable time to dissect free the heart. This inevitable delay limits the potential 
of revascularization to reduce myocardial damage. If possible, bail-out techniques for 
instance autoperfusion catheters, should always be used in these situations. Stent 
implantation for threatened closure has produced satisfactory results [61]. 
This expected time delay should be considered when counselling a patient. It 
would be prudent to refer a patient for reoperation, if for instance acute closure of 
a lesion would lead to acute heart failure due to the large area of myocardium at risk 
New interventional techniques for treatment of saphenous venous bypass grafts 
Stent implantation 
The inttacoronary stent was the trrst of the new interventional techniques to be 
applied in bypass graft angioplasty. Shortly after the introduction into the native 
coronary artery system, stents were also implanted in bypass grafts (Figure 6) 
[62-64]. The inunediate angiographic and implantation success rate is extremely 
high, 95% or higher (Table 6) [61-62,64-66]. However, early experience was 
associated with an unacceptable high incidence of subacute thrombosis and serious 
bleeding complications. Increased operator experience and meticulous anticoagulation 
resulted in a substantial decrease in complications [64-66]. Unfortunately, the 
incidence of restenosis does not seem to be reduced (Table 6). One detailed study on 
restenosis following Wall-stent implantation in venous bypass grafts reports an 
incidence of restenosis of 39% according to the 50% diameter stenosis criterion [67]. 
The restenosis rate after implantation of a flexible coil is 35% [61] and the restenosis 
rate after implantation of a Palmaz-Schatz stent was less: 28% [68]. It has been 
shown that restenosis after Wall-stent implantation in bypass grafts occurs more 
frequently than in stented native coronary arteries [69]. The rates were similar in 
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Fig. 6A. Diffuse disease in 7 years of bypass graft implanted on the left anterior descending artery. 
Fig. 6B. Immediate result after implantation of 2 overlapping stents (Wall-stent). 
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grafts and native coronaries after Palmaz-Schatz stent implantation [68]. Whether the 
better results obtained with the Palmaz-Schatz are due to the more favorable features 
of this stent or improved peri-procedural pharmacological management or different 
patient selection is u:nlmovm.. 
Table 6. Stent implantation in venous bypass grafts 
Author Total Implantation Qinica.l Inhospital complications 
No. of success rate Success Death Ml Em/CABG Serious 
patients bleeding 
(%) (%) (%) (%) (%) (%) 
Wallstent 
u,ban [621 l3 95 95 0 0 0 15 
de Scheeroe.- [64] 69 100 87 4* 7 6 33 
Palmaz Schatz 
Pomerantz {65] 54 100 100 0 0 0 n.r. 
Leon [66] 192 98 97 1.6 1.0 1.6 nr. 
Flexible coil 
Bilodeau [61] 37 100 86.5 0 13.5**0 21.6 
Not mutual exclusive 
** 
ni. 
All acute events were seen in patients stented for dissection or threatened closure. 
Not reported 
Restenosis 
(%) 
36 
47 
21 
26 
35 
The longterm clinical follow-up results of Wall-stent implantation in bypass grafts 
collected from 145 patients of 6 European centers is shown in Figure 7 [67]. The 
actuarial event-free survival (freedom from death, myocardial infarction, bypass 
surgery or angioplasty) for bypass graft patients was 37% at 20 months; with an 
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Fig. 7. Clinical follow-up in 145 patients with stent implantation in a bypass graft up to 20 months 
according to actuarial event-free survival. The curves (from upper to lower) represent freedom from death 
(DTH) alone, death plus myocardial infarction (MI); death, MI, plus bypass surgery (BYP); and death, 
MI, BYP plus angioplasty or atherectomy (An. Reproduced with pennission from Strauss et al. Am J 
Cardiel 1992; 69:475-481, Figure 4. 
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overall mortality rate of 9%. lt is noteworthy that about 30% of the adverse events 
were unrelated to the stented lesion, but were due to worsening of a different lesions 
or development of new lesions [64,67]. 
Atherectomy: directional and extractional 
The use of directional atherectomy in saphenous venous bypass grafts is feasible and 
successful in well above 90% of the patients (Table 7) [65,70,71]. The complication 
rate is acceptable, but one can imagine that the use of such a bulky device in case 
of friable, thrombotic lesions easily embolizes material. Preliminary data suggest that 
the restenosis rate is also high. 
Table 7. Initial results of new devices for treatment of lesions of saphenous vein bypass grafts 
Author Year Total No Oinical Complications 
Patients Success Death MI Em/CABG Embolization Restenosis 
(%) (%) (%) (%) (%) (%) 
Directional atherectomy 
Kaufmann [70] 1990 14 93 7* 0 7 63 
Pomerantz [65] 1991 29 93 0 0 0 7 31 
Selm<>n[71] 1991 76 91 0 9.2 1.3 11.5 60 
Extractional atherectomy 
Meany [72] 1992 278 89 0.3 0.3 0.7 35 53 
Excimer laser 
Untereker [73] 1991 225 97 0.4 4.4 0.8 4.4 61 
"' Cross-over to PTCA: abrupt occlusion, Em/CABG: death; n.r. - not reported 
Extractional atherectomy of venous graft lesions is successful in 89% of the 
patients (Table 7) [72]. The complication rate is low and the restenosis rate is 53%. 
lt is conceivable that the use of this device in vein grafts, containing much material, 
is safe and is associated with a higber success rate and decreased risk of emboli-
zation due to the suction, extraction and removal of material with this device, 
althougb embolization occurred in 3.5% of the patients. 
Excimer laser angioplasty 
Jn an initial experience including 225 patients (Table 7) it has been shown that 
excirner laser angioplasty can be performed safely and effectively [73]. A success 
rate of 97% was achieved in lesions in older saphenous venous grafts; however, the 
preliminary reported restenosis rate of 61% is rather high. 
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CONCLUSION 
Currently, sufficient data are lacking to establish the merits of reoperation and 
balloon angioplasty to treat obstructions in venous bypass gtafts. The published 
results on reoperation and balloon angioplasty should not be compared because of 
differences in patient selection and finn conclusions about the superiority of one 
treatment above the other should not be drawn. After reviewing the litterature it 
appears that in selected patients balloon angioplasty may be the preferred strategy or 
in case of inoperability it is the only strategy. 
Angioplasty of non-occlusive obstructions in venous bypass gtafts is safe and the 
success rate is high. The high restenosis rate adversely affects the longterm results. 
The immediate and longterm results of angioplasty for chronic total occlusion in old 
gtafts are poor. 
Patients considered for saphenous vein graft angioplasty may be classified into 3 
groups according to expected early and late outcome: A) those with an initial high 
success, low procedural risk and low restenosis; B) those with an initial high success, 
but high procedural risk and moderate too high restenosis rate; C) those with low 
success, high risk, and high restenosis rate (Table 8). 
Table 8. Oassification of patients with attempted saphenous vein graft angioplasty according to expected 
early and late outcome 
A success> 90%; complication< 2%; restencsis: 30% 
- focal, short lesion 
- graft <: 4-6 years 
- single g;aft 
- distal part sequential graft 
B success > 90%; complication <: 5%; restenosis 45-50% 
- long lesion 
- graft > 4-6 years 
- diffuse vein graft disease 
- intragraft thrombus 
- proximal part sequential graft 
C success<: 50%; complication > 10%; restenosis > 60% 
- chronic totally occluded old vein graft 
- lesion at distal site 
- lesion at proximal site 
- lesion at body 
New techniques have shown to be promising and in particular stent placement may 
be useful to "'tack" friable material. However, defmite conclusions concerning the 
merits of new techniques must await fmalization of ongoing randomized trials. 
Balloon angioplasty is a palliative procedure. not a longterm solution, in previously 
operated patients who often present with far stage coronary artery disease. The high 
restenosis rate is a serious limitation of balloon angioplasty. 
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CHAPTER 9 
MATCHING BASED ON QUANTITATIVE 
CORONARY ANGIOGRAPHY, 
A SURROGATE FOR RANDOMIZED STUDIES? 
COMPARISON BETWEEN STENT IMPLANTATION 
AND BALLOON ANGIOPLASTY OF A NATIVE 
CORONARY ARTERY LESION 
P.P.T. de Jaegere, W.R. Hermans, B.J. Rensing, B.H. Strauss, P.J. de Feyter, 
P.W. Serruys. 
Am Heart J 1993; 125:310-319. 
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Matching based on quantitative coronary 
angiography as a surrogate for randomized 
studies: Comparison between stent 
implantation and balloon angioplasty of native 
coronary artery lesions 
Although intracoronary stenting has been advocated as an adjunct to balloon angioplasty to 
circumvent late restenosis, its effectiveness has not yet been verified. Therefore the aim of this 
study was to determine the differences in the immediate and long-term changes In stenosis 
geometJy between Wallstent implantation and balloon angloplasty In native coronary artery 
lesions. To obtain two study populations with Identical baseline stenosis characteristics, patients 
were matched for lesion site, vessel size. and minimal luminal diameter. Only patients 
undergoing elective and successful coronary intervention of a native coronary artery, In whom a 
control angiographic study had been performed, were included. A total of 186 patients (93 in 
each group) were selected. The coronary angiograms were analyzed with the computer-assisted 
cardiovascular angiographic analysis system. Matching was considered adequate, since there 
was an equal number of lesion sites in each study population and there were no differences in 
baseline reference diameter and minimal luminal diameter. Wallstent implantation resulted in a 
significantly greater Increase in minimal luminal diameter (from 1.22 :!: 0.34 mm to 2.49 :!: 0.40 
mm, p < 0.00001) compared with balloon angioplasty (from 1.21 :t 0.29 mm to 1.92 ~ 0.35 mm, 
p < 0.00001). Despite a greater decrease in minimal luminal diameter after Wallstent implantation 
(OAS :!: 0.74 mm) than after balloon ang'1op1asty (0.20 :!: 0.46 mm), the minimal luminal diameter 
at follow·up was significantly greater after stent implantation (2.01 ± 0.75 mm vs 1.72 :!: 0.54, 
p < 0.0001). It was concluded that Wallstent implantation results ln a superior immediate and 
long·term increase in minimal luminal diameter compared with balloon angioplasty. The larger 
initial gain after stent implantation compensates for the late loss, and thus an improved initial 
resuft and not lessened neointimal hyperplasia is responsible for a reduced incidence of 
restenosis. Studies based on matching of angiographic variables are a surrogate for randomized 
studies, forecasting their results and offering insight into the effects of different interventional 
techniques. Moreover, these studies yield statistical information that may be helpful for the 
proper design of a randomized study (sample size, type II error). (AM HEAR'!' J 1993;125:310.) 
Peter P. de ,Jaegere. :MD. Walter R. Hermans. MD. Benno ,J_ Rensing. MD. 
Bradley H. Strauss, :MD, Pim ,J. de Feyter. :MD. and Patrick W. Serruys. MD 
Rotterdam, The Netherlands 
Percutaneous transluminal coronary angioplasty by 
means of balloon catheters. which was introduced by 
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Gruentzig et al.1• 2 in the late 1970s, has been a major 
breakthrough in the treatment of obstructive corO· 
nary artery disease. Gained operator experience and 
improved catheter technology have resulted in a high 
immediate success rate and a low incidence of com. 
plications, which in turn has resulted in an increas· 
ing number of patients \Vl.th more advanced coronary 
artery disease now being considered candidates for 
balloon angioplasty.3· 4 Unfortunately these favor· 
able results continue to be compromised by the UD· 
predictable problem of late restenosis. which occurs 
in 20% to 40% of patients after successful balloon 
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angioplasty.&.S Despite substantial basic and clinical 
research. thepathophysiologicmecbanism(s) respon-
sible for restenosis remain largely unknown and 
poorly understood. Pharmacologic efforts to reduce 
or eliminate restenosis have so far been unsuccess-
fu1.9·14 Therefore it is not surprising that along with 
pharmacologic interventions, new technologies and 
devices are currently being developed and clinically 
tested to address the problem of restenosis. Direc-
tional rotational atherectomy devices and laser angi-
oplasty do not seem to affect the restenosis rate.15-lS 
The intracoronary stent may be an exception. There 
is some evidence to imply that suboptimal initial 
stenosis geometry after balloon angioplasty contrib-
utes to restenosis. The stent optimizes the dilatation 
process by effective scaffolding of the instrumented 
vessel, thereby preventing recoil, and by tacking back 
intimal flaps, thus covering underlying thrombogenic 
tissue.lS-2l Furthermore, it has been shown that stent 
implantation results in a larger and more homo-
geneous cross-sectional area resulting in normaliza-
tion of the hemodynamic disturbances and flow 
across the dilated segment. 20, 22. 23 Consequently the 
vessel's response to balloon-induced intimal trauma 
is mitigated and the healing response modified. The 
aim ofthis study was to compare the immediate and 
long-term changes in stenosis geometry after stent 
implantation and balloon angioplasty in patients 
with identical baseline stenosis characteristics. 
METHODS 
Patients. At present the data base of the Thora.xcenter 
contains angiog:rnphic data from 411 patients in whom a 
Wallstent device (Schneider & Co. AG. K. ZUrich, Switzer-
land) was implanted in a bypass graft or a native coronary 
artery and 3569 patients who underwent balloon angio-
plasty of u native coronary artery lesion. From this popu-
lation a total of 186 patients (93 in euch group) with iden-
tical bo.seline stenosis characteristics were selected accord-
ing to the matching principle. Putients were eligible if they 
hud undergone elective and successful coronary interven-
tion of a native coronary artery und if a control anglo-
graphic study bud been performed. Since we recently dem-
onstrated thut there is no difference in the restenosis rate 
niter Wullstent implantation for restenosis or for a de novo 
lesion, patients with both types of indications were in-
cluded in the stent population. 24 All patients who under-
went balloon angioplasty wore treated for a primary lesion. 
Description of stent. The stent used in this study was 
the coronary Wallstent device (Fig. 1). It is constructed of 
a surgical grade stainless-steel alloy. braided in a tubular 
wire mesh design. The stent consists of 16 wire filaments, 
each 0.08 m.m in diameter. The stent is collapsed down on 
u delivery catheter equipped with a restraining sheath and 
is deployed by pulling back the sheath. The outer diame-
ter of the stent-catheter system is 1.57 mm. The device is 
radially self-expanding and long:itud.inully flexible. The s~­
leetion of the stent size wns based on visual assessment of 
the vessel size. The size of the Wallstent device wo.s selected 
to obtain un unconstrained dim:neter thut wns 0.5 rnm 
larger than the vessel. The size (mean ± SD) of the uncon-
strained W allstent device proved to be 3.60 ± 0.48 m.m. In 
co.se of incomplete expansion of either stent, repeat balloon 
dilutation within the stent wns performed. 
Quantitative coronary angiography. To ussess the im-
mediate und long-term changes in stenosis geometry, ull 
coronary cineang:iogr= were analyzed by means of the 
computer-assisted cardiovascular angiography annlysis 
system described in detail elsewhere.2'" Thi~:< system allows 
an objective und reproducible quantification of coronary 
artery stenosis. Briefly. a region of interest (::Uze 6.9 X 6.9 
m.m) in a selected cineframe (overall dimension 18 X 24 
m.m) encompassing the desired arterinl segment is digitized 
by a high-resolution charge coupled device (CCD) camera 
with resolution of 512 x 512 pixels and eight bits of bright-
ness resolution. The coronary segment to be analyzed is 
determined by selecting a number of center-line points. 
which are connected by linear interpolation. An automated 
edge-detection progrom determines the arterial contours 
by assessing the brightness profile along scan lines perpen-
dicular to the center line. After correction for pincushion 
distortion und calibration with the use of the guiding cath-
eter as a sealing device, a diameter function can be deter-
mined from the contour analysis by computing the dis-
tances between the left und right contours. From this 
diameter function several parameters can be computed, 
such 1lS the minimal luminal diameter, reference diameter, 
and diumeter stenosi~. The vflriubility. prerision. nnrl 
accuracy of the system have been reported previously.~6 All 
angiograms for subsequent analysis were obtained after 
intracoronary injection of 2 mg isosorbide dinitrate. 
Matchlng. Lesions were matched for lesion site. minimal 
luminal diameter, and reference diameter. The coronary 
artery tree wo.s subdivided into 15 segments according to 
the American Heart Association guidelines. 27 The variabil-
ityofrepeuted measurement of the m.inimul.luminal diam-
eter und interpolated reference diameter from the same 
cineangiogram. by use of the computer-assisted coronary 
angiographic analysis system, has been shown to be 0.10 
mm for both angiographic parameters.2U Therefore patient 
pairs were selected in which the difference between those 
angiographic variables did not exceed 0.20 mm (tv.':ice the 
variubility or 95% confidence interval). 
End points. For euch dilated or stented segment. the 
postangioplasty or poststent and follow-up minimal lumi-
nal diameters were taken o.s the mean vulues from multi-
ple matched projections. The primary angiographic end 
point of the present study was the minimul. luminal diam-
eter ut follow-up 1lS determined by quantitative angiogra-
phy. Furthermore, since data from experimental animals 
indicate that there is a correlation between the severity of 
vC!>sel wall injury and subsequent neointimal thickening, 
the relntionship between relative gain (o.s an index for ves-
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Fig. 1. Self-expanding stent (WallBtent). A, With membrane partially pulled back and expanding stent. 
B, Stent in position illustrating longitudinal flexibility. 
Table I. Immediate and long-te-rm changes in minimnlluminal diameter after stent implantation and balloon 
angioplasty 
Minimu.lluminul diumerer (=l 
Diameter stenooia (SO) 
All paramete"' lll'l.' ..xpre......-d."" mean :!: SD. 
Walls tent 
Post 
1.22 :t 0.34 2.49 = 0.40 
59:tl0 19:7 
p <0.00001 
FU 
2.01 ± 0.75 
35 :t 20 
p < 0.00001 
&tloon angioplcsty 
1.21 :!: 0.29 1.92 :!: 0.35· 
59:t8 36:tlO• 
p < 0.00001 
FU 
1.72 ± 0.54t 
42 ± 15:j: 
p < 0.00001 
Th'-"'~'Mlfi no .tnti.Rtica! dill=ne~ i.n bW~ellne ""'!iO!:Jnphicvariable" betwron the two ~rudy populations. Unpairod t toot. betwron two study populatio!ll!.. 
'p < 0.00001; tP < 0.003; ~p < O.Ql. 
sel wall injury) and relative los$. (us an index forneointimal 
thickening) wns studied by means of regression anulysis. 
Relutive gain and relative loss are defined as follows: Rel-
ative guin = MLD post- MLD pre/RD. and Relative 
loss = MLD pof!t- MLD fuJRD. where MLD is the mini-
mal luminal diameter. RD is the reference diameter. pre 
and post refer to before and after the procedure. respec-
tively. and fu is follow-up. The finol outcome of the proce-
dure was evaluated by calculating the net gain index. This 
index represents the ratio of the net gain in lumen 
improvement at follow-up and the reference diameter and 
is described by the following equation: MLD fu - MLD 
pre/RD. 
Statistics. Values obtained by quantitative coronary 
angiogruphy are expreMed as means ± SD. The changes in 
each angiogrophic variable before and immediately after 
the intervention ond at follow-up were compared by anul-
ysis of variance. If significant differences were found, two-
108 
tailed paired t tests were applied to compm-isons within 
each treatment group and two-tailed unpaired t tests for 
comparisons between treatment groups. A statistical prob-
ability of less than 0.05 wns considered significant. 
RESULTS 
Matching. Matching was considered adequate since 
the baseline interpolated reference diameter and 
minimal luminal diameter did not differ between 
groups (Wallstent: 2.99 ± 0.54 mm and 1.22 ± 0.34 
mm. balloon angioplasty: 3.01 ± 0.53 mm and 
1.21 ± 0.29 mm. respectively: unpaired t test 
p > 0.05: Table I). Furthermore. there was an equal 
number of patients with a lesion in the left anterior 
descending artery (47 patients), right coronary artery 
(36 patients), and left circumflex artery (10 patients) 
in both groups. 
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Fig. 2. Cumulative distribution of minimnlluminol diameter (MLD) at baseline and immediately after 
stent implantation or balloon angioplasty. 
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Fig. 3. Cumulative distribution of minimal luminal diameter (MLD) at baseline and nt follow-up after 
stent implantation or balloon angiopla.sty. 
Angiographic results. Table I and Figs. 2 and 3 
summarize the results of quantitative coronary an-
giography. Both coronazy interventions resulted in a 
significant immediate increase in minimal luminal 
diameter, although to a significantly greater extent 
after Wallstent implantation (from 1.22 ± 0.34 mm 
to 2.49 ± 0.40 mm) compared with balloon angio-
plasty (from 1.21 ± 0.29 mm to 1.92 ± 0.35 mm). 
This was associated with a significant reduction in 
diameter stenosis from 59 :!:: 10% to 19 ± 7% and 
36 ± 10%, respectively. The reference diameter re-
mained unchanged throughout the study period 
{2.99 ± 0.54 mm, 3.10 ± 0.49 mm, and 3.09 ± 0.62 
mm at baseline, after stent implantation, and at fol-
low-up, respectively, and 3.01 ± 0.53 mm. 
3.03 ± 0.54 mm, and 2.97 ± 0.58 mm before and af-
ter balloon angioplasty and at follow-up, respective-
ly). 
Repeat angiography was performed in all patients 
at a mean interval of 6.3 ± 3.7 months (Wallstent 
population) and 5.1 ± 1.4 months (balloon angio-
plasty population). The minimal luminal diameter 
109 
314 de Jacgcrc et aL 
r 
FO!>tuary 1993 
American H""rt Joumal 
1.5 2 2.5 3 3.5 4 
MLD (mm) 
Fig. 4. Loss in minima! luminal diameter (MLD). Cumulative distribution of minimal luminal diameter 
immediD.tely after stent implnntation und balloon angioplasty nnd at follow-up. 
was found to have decreased from 2.49 ± 0.40 mm to 
2.01 ± 0.75 mm (p < 0.00001) after Wal.lstent im-
plantation and from 1.92 ± 0.35 m.m to 1. 72 ± 0.54 
mm after balloon angioplasty (Table I, Fig. 3). The 
percentage of stenosis had increased from 19 ± 7% 
to 35 ± 20% and from 36 ± 10% to 42 ± 15%. 
respectively (Table I). To allow comparison with 
other interventional techniques potentially applied 
in vessels of different sizes, the final angiographic re-
sult was normalized for vessel size and expressed as 
the net gain index, as defined previously. Despite a 
greater loss in minimal luminal diameter after Wall-
stent implantation (0.48 ± 0.74 mm vs 0.20 ± 0.46 
mm), the final outcome was superior in this group 
(2.01 ± 0.75 m.m vs 1.72 ± 0.54 mm. p < 0.003; Fig. 
4). As a result the net gain index after Wallstent im-
plantation was superior to that after balloon angio· 
plasty (0.27 vs 0.18, respectively; p < 0.003). Fig. 5 
depicts the relationship between relative gain and 
relative loss. A weak but positive correlation was 
found after balloon angioplasty. No such relationship 
was observed in the W allstent population. 
DISCUSSION 
Matching. The only method to compare short- and 
long-term clinical and angiographic results of differ-
ent coronary interventions is a randomized study. It 
is beyond the scope of this report to outline the time. 
energy, and financial burden of such a study. Not-
withstanding its utmost importance, other methods 
such as matching may be used as a surrogate for a 
randomized study. Subjects can be matched not only 
as they enter a study but also retrospectively, so that 
110 
for each patient in one group there are one or more 
patients with the same chmacteristics in the com-
parison group. Therefore matching may not only 
forecast the results of a randomized study but may 
also offer insight into the effects of novel therapeutic 
coronary interventions.28• 29 Although it would be 
desirable to match subjects for both clinical and an-
giographic variables, this would require a substantial 
number of patients in the data base to obtain two 
study populations of sufficient size. The major dis-
advantage of such a study method is its retrospective 
design and the inevitable presence of selection bias. 
It controls for bias only for those variables taken into 
account. Matching for all variables is usually not 
possible because of practical difficulties in finding 
patients who meet all of the matching criteria. More-
over. if categories for matching are relatively crude, 
there may be room for substantial differences be-
tween matched groups. In this study matching was 
based on angiographic variables and was limited to 
lesion site. minimal luminal diameter, and reference 
diameter. The baseline stenosis characteristics of the 
patients reported herein are similar to those reported 
in other studies, and therefore the population of this 
study may be considered representative of the angi-
oplasty population encountered in clinical prac-
tice.S. 14, 30,31 
Angiographic parameters defining restenosis andre-
sults. Restenosis is the reparative response of the 
vessel wall after injury. The most accurate method to 
define and quantify restenosis is direct measurement 
of neointimal thickening after coronary interven-
tion.SZ. 33 Obviously this is not possible in humans. 
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Fig. 5. Relationship between relative gain (RG) nnd relative loss (RL) after Wtillstent impluntntion and 
balloon angioplru,'iy, 
Although quantitative coronary angiography indi-
rectly measures the restenosis process without defin-
ing its nature (recoil, organized mural thrombus, or 
neoir1timal hyperplasia), it is the most objective and 
reproducible method to date to describe the changes 
in stenosis geometry after intervention and therefore 
has been accepted as the '"gold standard" to define 
restenosis. r;, S. 34-38 Whereas the clinician is best served 
by a '"present/not present" assessment of restenosis, 
the process of restenosis itself is best analyzed by 
measuring an absolute angiographic dimension on a 
continuous scale.14• 39-4l In this study the minimal 
luminal diameter was selected, because results of 
previous studies based on quantitative coronary an-
giography have demonstrated that this parameter 
provides more reliable and meaningful information 
than percentage diameter stenosis, with regard to the 
hemodynamic significance of a coronary artery le-
sion.42-46 Furthermore, it has been sho'(:VQ that the 
minimal luminal diameter at follow-up correlates 
with recurrence of angina or exercise-induced myo-
cardial ischemia.47-48 Although the process of rest-
enosis can best be addressed by measuring the 
changes in the obstruction diameter, the final out-
come can best be evaluated by measuring the mini-
mal luminal diameter at follow-up, which describes 
the severity of the lesion at that pnrticular moment. 
This is especially true when different interventional 
techniques with a different initial gain are compared. 
Figs. 2 and 3 elegantly illustrate how the use of this 
angiographic variable in a continuous approach may 
be applied to a comparative study of immediate and 
long-term outcome after balloon angioplasty and 
stent implantation. The advantage of ranking the 
minimal luminal diameter for the entire study pop-
ulation is that it depicts the process of restenosis in-
dependent of any definition without the application 
of an artificial threshold dichotomizing restenosis. 
Furthermore, it allows comparison of the immediate 
and long-term effects of different interventional 
techniques. 
Inasmuch as lesions are matched not only for min-
imalluminal diameter but also for reference diame-
ter, the initial gain and the late loss within and 
between each treatment group can easily be gleaned 
from the figure. It is easily appreciated that although 
stent implantation is associated with a significantly 
greater initial increase in minimal luminal diameter 
compared with balloon angioplasty (1.27 ± 0.39 mm 
vs 0.71 ± 0.35 mm), late loss is significantly greater 
(0.48 ± 0.74 mm vs 0.20 ± 0.46 mm). However, de-
spite this greater loss, the minimal luminal diameter 
at follow-up after stent implantation is larger than 
that in patients who underwent balloon angioplasty 
(Table I. Fig. 4). This is in accordance with the an-
giographic observations of recent uncontrolled stud-
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Table II. Changes in minimal luminal diameter after balloon angioplo.sty and stent impl.an.tation 
Follow·r.tP 
No. of Patients with patent 
Procedure Rcfercru:c patients Pre-PTCA Post·PTCA Post-stent AU patients stcnt at dischcrgc 
Balloon ang:ioplnsty 
88 1.13:!:. 0.41 2.10 ± 0.40 1.69:!:. 0.55 
H 
"' 
0.99 :!:. 0.35 1.77 ± 0.34 1.46 :!:. 0.59 
" 
300 0.98 :!:. 0.35 1.77 ± 0.34 1.48 :!:. 0.54 
57 60 1.02:!:. 0.20 1.80 ± 0.30 
Stent impimltation 
Wnllstent 50 1.17 :!:. 0.52 2.53:!:. 0.52 1.59 :!:. 1.08 1.99 :!:. 0.84 
Wiktor 30 50 1.09 :!:. 0.26 2.45 :!:. 0.35 1.59 ± 0.79 1.78 ± 0.60 
Pnl.J:o.=.Schatz• 
" 
50 1.00 :!:. 0.57 3.26:!:. 0.31 2.39 ± 1.15 
BcnllBWnt 57 60 1.02 :!:. 0.20 2.40 :!:. 0.50 
PTCA. Pcrcutwloous trnnslumiruol COJ:'Onmy angiopl.as.ty. 
• All eoronazy angiol:l'ruru; were analyzed with the eomputer-rniRistcd CJlrdiova.'ICUklr angiogrnphie analysis "Y"tem except for the Pnlmm:-&:hatzsWnt. in whicll 
the method of Brown et nl.!"' was used.. 
ies. s. 14• 30. 49·52 Overall a twofold increase in minimal 
luminal diameter is observed after stent implanta-
tion, whereas the increase in mio.imall\l.ID.iD.al diam-
eter after balloon angioplasty is <1.0 mm. However, 
a decrease in the minimal luminal diameter at 
follow-up of 1.0 mm may be expected after stent im-
plantation, when all patients are analyzed including 
those with subacute stent occlusion, and 0.50 mm 
when only those patients with a patent stent at hos-
pital discharge are considered. In contrast, balloon 
angioplasty is associated with a loss of 0.29 ± 0.49 
mm to 0.31 ± 0.54 mm (Table IT). This is nicely re-
flected when the process of restenosis is presented in 
a categorical approach. The incidence ofrestenosis is 
25% after Wallstent implantation and 15% after 
balloon angioplasty according to the 0.72 mm crite-
rion and 15% and31%, respectively, according to the 
50% diameter stenosis criterion. This underscores 
the observation that the greater initial gain after 
stent :implantation compensates for the late loss, and 
thus the improved initial result and not the lessened 
neointimal hyperplasia is responsible for a reduced 
incidence of restenosis. The clinical importance of 
this matter has been outlined previously; that is, the 
degree of obstruction at follow-up is strongly related 
to the recurrence of angina and myocardial ische-
mia.47,48 
The pathophysiologic mechanism(s) responsible 
for restenosis are largely unknown. Schwartz et 
al.3Z. 33 studied the relationship between the degree of 
vessel wall injury after coil implantation in porcine 
coronary arteries and the extent of subsequentneoint-
imal thickening. They found that the severity of ves-
sel injury correlated strongly with neointimal thick-
ness. Consistent with this hypothesis, the relation-
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ship between relative gain (as an index of vessel wall 
injury) and relative loss (as an index of neointimal 
thickening) has recently been analyzed after balloon 
angioplasty, Wiktor stent (Medtronic Inc., Minne-
apolis, Minn.) implantation, and directional atherec-
tomy. In all instances a linear relationship was found 
with a correlation coefficient of 0.26, 0.39 and 0.65. 
respectively. 53· 54 In contrast to these observations, 
such a correlation was not found after Wallstent im-
plantation in this study. This observation was unex-
pected, and because it is at variance with all other 
reports we believe the fact that there was no prede-
termined time to control angiographic study, which 
is reflected by the large standard deviation of time to 
"follow-up(6.3 ± 3.7monthscomparedwith5.1 ± 1.4 
months). explain this discrepancy. 
Use of the angiographic data emerging from this 
study may be justified to improve statistical power 
calculations in a randomized study. Indeed the proper 
design of a randomized study comparing different 
interventional techniques not only requires selection 
of the appropriate angiographic variable reflecting 
the restenosis process in a well-validated system of 
quantitative coronary angiography with known ac-
curacy, precision, and variability but also requires a 
sufficient number of patients undergoing repeat an-
giography at a predetermined time for restudy to ad-
equately compare the effects of the two types of 
treatment. This number depends on (1) the vari-
ablity in outcome among patients, (2) the magnitude 
of the difference in outcome, and (3) the alpha and 
beta errors.'55 Given the herein reported variability in 
outcome of 0.75 mm (stent population) and 0.54 mm 
(balloon population) and the difference in outcome of 
0.29 mm. 208 patients (104 per treatment group) are 
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Fig. 6. Power calculations for rondomized study using continuous and cutegoricul approach based on ret-
rospective comparison of short- and long-term angiographic results of stcnt implnntntion nnd balloon nn-
gioplosty. 
PTS 
935 POWER: 90% 
900 6 MLD: 0.30mm 95% Cl: 0.11-0.49 
700 
500 15 
300 34 
150 104 76 58 46 100 37 
0 
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0,MLD(mm) 
Fig. 7. Number of patients needed for randomized study using continuous nppronch defining restenosis. 
with power of90% nnd based on difference in minimnllurninal diameter (MLD) at follow-up between stent 
implnntntion and balloon nngioplasty ronging from 0.11 to 0.49 mm. 
needed for a randomized study, accepting an alpha 
error of 0.05 and a beta error ofO.lO (power of90%. 
Fig. 6). Changing the power of the study in one way 
or another will affect the number of patients needed. 
Accepting a greater chance of missing an effective 
treatment (large beta error and thus reduced power), 
substantially fewer patients are needed. The ob-
served difference of 0.30 mm is only a point estimate 
of the true value that lies within the range of 0.11 to 
0.49 mm (95% confidence interval). A true difference 
at these extremes would imply 935 or 37 patients per 
treatment group, respectively (Fig. 7), 
In conclusion. Wallstent implantation results in 
greater immediate and long-term increases in mini-
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mal luminal diameter than balloon angioplasty. The 
higher initial gain after stent implantation compen-
sates for the late loss. and thus an improved initial 
result and not a decrease in neointimal hyperplasia is 
responsible for the reduced incidence of restenosis. 
Although this study based on matching is a retro-
spective comparison of two selected populations. it 
offers insight into the effects of different interven-
tional techniques, forecasting the results of a ran-
domized study and yielding statistical information 
that might be helpful for the proper design of such a 
study (sample size, type II error). 
We thnnk Mnrie-AngClc Morel for performing the quantitative 
u.no.lysis and for her assistance in the dutabn.~~ 1lWJlllgement nnd 
statiatienl nno.lysiB. 
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CHAPTER 10 
CLINICAL AND ANGIOGRAPHIC RESULTS OF 
THE PILOT PHASE OF THE BENESTENT STUDY 
The Benestent Study Group. 
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INTRODUCTION 
Despite increased operator experience and improvements in catheter design, the risk 
of abrupt vessel closure and late restenosis continue to limit the safety and efficacy 
of balloon angioplasty (PTCA) [1,2]. To address these two major shortcomings, a 
number of new treatment modalities have been advocated, either as an adjunct to 
PTCA or as a stand alone therapy. One of these is the intracoronary stent [3]. The 
intracoronary stent is at present the only catheter technology which scaffolds the 
vessel from its endoluminal site. It has proved not only to be successful in treating 
coronary dissections and thus in preventing acute or threatened closure but also may 
reduce the incidence of restenosis by optimizing the immediate angiographic resnlts 
[4,5]. The latter appeared to be especially true in case of single stent implantation for 
a de novo lesion in a native coronary artery [6]. Unfortunately, all coronary stents 
currently available are metallic and thus highly thrombogenic. In the early days of 
stenting, subacute stent thrombosis was noted in an unacceptable high number of 
patients [7]. However, with gained experience and insights, and the implementation 
of a stringent anticoagnlation regimen the thrombosis rate gradually decreased to a 
level which is currently below the incidence of PTCA related abrupt vessel closure 
[8]. To prevent stent thrombosis, a meticuluous and intensive anticoagulation is 
mandatory. This exposes the patient to an increased risk of major bleeding and 
puncture site related complications [9]. Despite these limitations and despite the fact 
that it is still uncertain whether stent implantation reduces the restenosis rate, they 
are increasingly being used in an exponential and, sometimes, uncontrolled fashion. 
Therefore, a number of European interventional cardiologists took the initiative to set 
up a working group on intracoronary stenting and to design and conduct a 
mnlticenter randomized study with the objective of analyzing and comparing the 
safety and efficacy between stent implantation and PTCA in patients with stable 
angina pectoris and a single de novo lesion in a native coronary artery. This study 
origiually started in Belgium and the Netherlands and is therefore called the 
Benestent Study. The purpose of this chapter is to report the data of the pilot study. 
METHODS 
Patients 
All consecutive patients who were schednled to undergo PTCA of a single de- novo 
lesion in a native coronary artery because of symptoms of stable angina pectoris were 
entered into the trial, provided that none of the following clinical- and angioplasty-
related exclusion criteria applied: 
- Clinical exclusion criteria: 1) age under 30 or above 75 years, 2) potentially child 
bearing women, 3) contraindication to anticoagnlation and[ or antiplatelet therapy with 
acetyl salicylic acid, 4) intended surgical interventions, 5) no candidate for bypass 
surgery, 6) life expectancy less than 1 year or factors making follow-up difficnlt or 
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unlikely, 7) unstable angina or evolving myocardial infarction, and 8) previous 
participation in this study or participation in another study with any investigational 
drug or device within the past 30 days. 
- Angiop/asty-related exclusion criteria: 1) intended angiopl.asty of a lesion in a 
vessel smaller than 3.0 mm and/or longer than 15 mm and/or supplying a large 
myocardial infarction area, 2) presence of other lesion(s) in the same vessel segment, 
3) ostial lesions, 4) lesions giving origin to a large side branch or with a large side 
branch proximal or distal from the target lesion but having an ostial stenosis which 
would be covered after stenting the target lesion, 5) lesion in a bend of > 45 degrees, 
6) presence of intracoronary thrombus and 7) intended angioplasty of a lesion in a 
vessel supplied by a venous or arterial graft. 
The study was carried out according to the declaration of Helsinki and informed 
consent had to be obtained in every patient. 
Randomization. 
After informed consent was obtained, the randomization center at the Core 
Laboratory Cardialysis, Rotterdam, The Netherlands was contacted via a telephone 
service. Following a screening interview to document the operator eligibility and 
patient demographic data, a random assignment was given to either PTCA or stent 
implantation. To guarantee an equal distribution of both treattnents per center, the 
randomization sequence was developed on a site basis in blocks of 6 treattnent 
assignments. 
Fig. 1. The Palmaz.Schatz stent is an articulated device consisting of two shorter segments (7nun each) 
of slotted tubes connected by a small bridging strut (lnun). Initially, each tube consisted of eight rows 
of staggered rectangles (slots) and was later modified into twelve rows. Upon expansion, each rectangular 
slot adopts a diamond-like configuration while preserving the length of the stent. The stent is mounted on 
a commercial available balloon catheter and can expand 4 to 6 times the collapsed diameter. 
!!9 
Stent used 
In this study, the articulated Pahnaz-Schatz stent was used (Figure 1). The operator 
was free to use either the Sheath Delivery System (stent mounted on a balloon 
catheter by the manufacturer and covered by a protective sheath) or the "bare or 
naked" Palmaz-Schatz stent which had to be mounted on a conventional angioplasty 
balloon catheter by the operator himself. 
Anticoagulation protocol 
The anticoagulation and antiplatelet drug therapy in patients who received a stent and 
in those who were treated with PTCA are shown in Figure 2. In case of PTCA, the 
anticoagnlant drug therapy consisted of a bolus of 10.000 U of heparin for the first 
honr of the procedure followed by an additional bolus if necessary. No special 
monitoring of the activated Partial Thromboplastin Time (aPTT) or Activated Clotting 
Time (ACT) was requested during the procedure. It was left at the discretion of the 
operator to continue heparin after the procedure for 24 hrs or longer if he or she felt 
this was necessary. In case of stent implantation, detailed monitoring of the anticoag-
ulation was performed by measuring the aPTT or ACT for the heparin therapy and 
the Thrombo-Test (TT) or International Normalized Ratio (INR) for the oral anti-
coagulant drug therapy (Warfarin). Heparin therapy consisted of a bolus of 10.000 U 
after insertion of the arterial sheath, and repeated once just before stent implantation. 
After stent implantation, no further heparin was administered to allow sheath removal 
on the day of stenting when the aPTT or ACT reached twice the normal value. One 
to 6 hours after sheath removal, heparin therapy was reinstituted by administering a 
bolus of 5000 U in association with a continuous intravenous infusion, titrated accord-
ing the aPTT or ACT. In the mean time, a total of 1000 cc of dextran was infused 
R/ D 3 mths 6 mths 
ASA 
(250-500 mg) 
COUMADIN 
(according to TT or INR) 
DEXTRAN ~ 
(max 1000 cc, atarting 2hrs before procedure) 
HEPARIN = 
(accordfng to APTT or ACT) 
R/: Treatment (PTCA or STENT implantation). 0: discharge 
ASA: acetylsalicylicacid. For further details see text 
STENli 
BALLOOII! 
Fig. 2. Anticoagulant and anti platelet drug therpay in patients undergoing PTCA and stent implantation. 
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intravenously. The dose of heparin was progressively decreased when TI (warfarin) 
was in the therapeutic range for at least 36 hours (3 consecutive measurements). The 
patient was discharged when TI had been stabilized at the therapeutic level. 
Additional drug therapy and medication at dischrage 
In addition to these anticoagulants and antiplatelet drugs, calcium antagonists were 
administered in both treatment groups. When calcium antagonists were already being 
taken before randomization they could be continued. If not, diltiazem CR 120 mg 
b.i.d. was administered until discharge. The medication at discharge consisted of 
warfarin for 3 months, acetylsalicylic acid 250 - 500 mg/day and dipytidamole 75 
mg t.i.d. for 6 months in patients who received a stent while ouly the latter 2 drugs 
were adminsitered in the patients who were treated with PTCA. Other cardiac drugs 
were continued if the patient were taking these drugs for other reasons than angina 
pectoris (e.g. hypertension). Antiplatelet drugs including non-steroidal anti-
inflammatory drugs other than acetylsalicylic acid were not allowed. 
PTCA and stent implantation procedure and follow-up angiography 
- PTCA was performed with a steerable, movable guide wire system via the femoral 
or brachial approach. Choice of balloon and brand as well as inflation pressure and 
duration were left at the operator's discretion. Stent implantation was performed after 
predilatation of the target lesion with an undersized balloon catheter to facilitate stent 
delivery. A balloonfstent assembly, equal or 0.50 mm larger than the vessel to be 
stented was then positioned at the lesion site followed by a single dilatation up to 6 
atmospheres during 30 sec. to deploy the stent. The balloon was then deflated and 
removed. In case of incomplete expansion or in case of suboptimal luntinal result, 
additioual balloon inflation within the stent was performed. 
- For the purpose of the study, three coronary angiograms were obtained in each 
patient - one just before the intervention, one immediately after, and one at follow-
up. To achieve maximal vasodilatation, each angiogram was preceded by either 
nitroglycerin or isosorbide dinitrate given intracoronarily. Angiograms were recorded 
in such a way that they were suitable for quantitative analysis by the computer-
assisted Coronary Angiography Aualysis System (CAAS), described in detail 
elsewhere [10]. All necessary details of the procedure were recorded in the case 
record form and drawings of the segments to be analyzed were made by the 
investigator. Before the post~intervention angiogram, radiopaque guide wires were 
removed to avoid interference with automated edge detection. For calibration 
purposes, the catheter tip not filled with contrast had to be clearly visible in each 
flimed view preferably near the center of the screen and were cutt off and sent with 
the cinefilm to the angiographic core laboratory (Cardialysis, Rotterdam, The 
Netherlands). To standardize the method of data acqnisition and to ensure exact 
reproducibility of post-intervention and follow-up angiograms, measures were 
undertaken as has been described earlier [2,11]. 
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Follow-up Evaluation 
After successful PTCA (less than 50% diameter stenosis post-PTCA without 
occurrence of any of the clinical events during hospital stay described below) or stent 
implantation (it was recommended to obtain a diameter stenosis less than 20% post 
stenting), patients returned to the outpatient clinic at !, 3 and 6 months for an 
interview, physical examination and electrocardiography. At 6-month follow-up, an 
excercise test was performed according to the Bruce protocol. The follow-up 
coronary angiognun was performed at the 6-month visit. If symptoms recurred within 
6 months, coronary angiography was carried out earlier. If the time to follow·up was 
less than 3 months and if no definite restenosis was present and no repeat inter-
vention was performed, the patient was asked to undergo another coronary 
angiography at the predetermined 6 months. 
End points 
Distinction was made between primary clinical and primary angiographic end points. 
In addition, a number of secondary clinical and angiographic end points were 
evaluated. 
- The primary clinical end points of the study were the occurrence of any of the 
following: cardiac death, intracranial hemorrhage or stroke, myocardial infarction, the 
need for repeat intervention (PTCA, stent, atherectomy or other) or bypass surgery 
of the previously treated lesion between the initial procedure (PTCA or stent 
implantation) and repeat angiography at 6 ± 1 months (or 6 months calendar time if 
6 months repeat angiography is not performed). This combined end point included 
periprocedural infarction, emergency bypass surgery or bailout stent implantation. In 
addition, the functional class according to the Canadian Cardiovascular Society at 6 
month follow-up was assessed. An indication to perform repeat intervention or 
bypass surgery based on the fmdings at 6 month repeat angiography constituted an 
end point provided that the treating physician could substantiate the decision on the 
basis of fmdings at angiography in combination with chest paiD and/or electro· 
cardiogic or scintigraphic evidence of myocardial ischemia either at rest or exercise. 
All events which were potential end points were centrally reviewed by the critical 
event committee. 
End point defmitions were as follows: cardiac death: all deaths were considered 
cardiac unless an unequivocal non-cardiac cause can be established. Intracranial 
hemorrhage: all cerebrovascular accidents occurring in patients receiving anti-
coagulant drug therapy were considered as intracranial hemorrhage unless computer 
tomography of the brain unequivocally demonstrated an ischaemic stroke. Myocardial 
infarction: the presence of at least two of the following : (!) occlusion of a 
previously patent coronary artery; (2) prolonged chest pain; (3) a serial enzyme 
pattern typical for myocardial infarction with at least one cardiac enzyme raised to 
more than twice the local upper limit for normal; (4) the development of a new 
Q-wave. Repeat intervention: repeat intervention of the previously dilated or stented 
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lesion (e.g., PTCA, atherectomy or other) after the initial procedure which was 
considered completed at the time when the guiding catheter was removed out of the 
arterial sheath. Angiographic assessment without subsequent intervention was not 
considered as an end point. Bypass surgery: emergency or elective bypass surgery 
involving the previously dilated or stented segment. Emergency bypass surgery was 
defined as immediate transfer from the angioplasty suite to the operative room during 
the initial treatment phase. Bailout stent implantation in patients who underwent 
PTCA was considered equivalent to emergency bypass surgery. However, stent 
implantation was considered as a bailout stent implantation only in case of TIMI 
flow grade 0 or I after PTCA or in case of worsening of the TIMI flow by one grade. 
In all instances an attempt to improve the suboptimal result with a perfusion balloon 
catheter had to carried out before bailout stenting could be considered. Coronary 
bypass surgery or revascularization by means of percutaneous intervention involving 
other coronary arteries did not constitute an end point. 
- Secondary clinical end points were: I) the occurrence of symptoms and signs of 
(recurrent) myocardial ischemia (i.e., chest pain with ST -segment or T -wave changes 
on the electrocardiogram) without myocardial necrosis over the period from the 
initial procedure until hospital discharge, 2) cross-over of the assigned treatment to 
another and 3) the incidence, severity and location of bleeding events other than 
intracranial hemorrhage. 
- The primary angiographic end point of this study was the minimal luntinal 
diameter at follow-up as determined by quantitative angiography. If a revascnlar-
ization procedure involving the dilated or stented segment had been performed before 
6 months repeat angiography, the last angiogram obtained before the intervention, if 
available, was used as an end point, irrespective of the timing of repeat intervention 
(hours, days, weeks). In the absence of a 6 months repeat angiogram, the last 
angiogram obtained within the previous 3 months, if available, was used, provided 
that no end point had taken place. For each dilated or stented segment, the minimal 
luntinal diameter was taken as the mean values from multiple matched projections. 
Secondary angiographic end points included 1) the changes in the minimal luntinal 
diameter and percentage diameter stenosis (100% x [reference diameter - minimal 
luntinal diameter/ reference diameter) following intervention and at follow-up 
angiography, 2) evidence of restenosis at 6 months repeat angiography indicated by 
a change from < 50% stenosis post PTCA or stent implantation to > 50% at follow-
up and by a decrease in minimal luntinal diameter ~ 0.72 =, 3) cross-over of the 
assigned treatment to another and the incidence, severity and location of bleeding 
complications other than intracrauial hemorrhage. 
Analytical plan 
The main clinical analysis consisted of a single comparison between the 2 study 
groups of the primary clinical end point, irrespective of the time of occurrence, 
involving all randomized patients with the exception of those in whom no PTCA or 
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stent implantation had taken place (intention to treat analysis). In addition to a total 
account of all clinical events (non-mutually exclusive analysis), the clinical events 
were ranked according to the highest category on a scale ranging from: 1, death, 2, 
intracranial hemorrhage or stroke, 3, myocardial infarction, 4, bailout stent 
implantation/emergency bypass surgery, 5, elective bypass surgery, 6,repeat PTCA. 
The main angiographic analysis consisted of a single comparison between the 2 
study groups with analyzable angiograms. For both the clinical and angiographic end 
points, randomized patients in whom an intervention has taken place were analyzed 
in their assigned treatment group irrespective of the angioplasty technique used 
according to the intention-to-treat principle. Additionally, an efficacy analysis was 
performed according to the technique actually used at the time of the intervention, 
irrespective of the randomization, implying the inclusion of the patients who crossed 
over from the assigned treatment to the other. A per protocol analysis will be 
performed for the total study population of the Benestent Study (n = 520 patients). 
The latter is defmed by the analysis of those patients who have received the assigned 
treatment as dictated by the randomization and which thus excludes the patients who 
crossed over from one treatment to the other. 
RESULTS 
Between June and December 1990, a total of 60 consecutive patients were 
randomized at 8 participating centers. Of these, 27 patients were randomized to stent 
implantation and 33 patients to PTCA. Their baseline clinical and angiographic 
characteristics are depicted in Table 1 and 2. No baseline differences were observed 
between the two groups. Figure 3 shows the flow diagram of the patients randomized 
and their actual treatment. 
Clinical results 
Implantation success rate: Five out of the 27 patients randomized to stent did not 
receive a stent. In 1:\Vo patients, neither a stent implantation nor a PTCA was 
performed because of unability to cross an unexpected totally occluded coronary 
artery in one and because neither a stent nor a balloon catheter could be advanced 
to the target lesion despite the presence of a guide wire in situ in the other. The first 
patient received medical treatment, the second was referred for elective bypass 
surgery. Three other patients did not receive a stent but were successfully treated 
with PTCA. In two patients the operator decided not to implant a stent because the 
size of the target vessel proved to be much to stuall (1.83 mm) during on-line 
quantitative coronary analysis in one patient and because of inappropriate fitting of 
the guiding catheter in the ostium of the left main stem in the other. In the remaining 
patient, stent implantation was attempted but a tortuous segment proximal to the 
target lesion prevented stent delivery. In this patient, the stent which was mounted 
on a conventional balloon catheter by the operator, dislodged from the balloon when 
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Table 1. Baseline clinical characteristics. 
Stent PTCA 
n 27 33 
age (mean ± SD) 58± 11 58± 11 
male 18 (67%) 23 (70%) 
CCS Class! I ( 4%) 0 
n 7 (26%) 9 (27%) 
ill 13 (48%) 18 (55%) 
IV 4 (15%) 5 (15%) 
Non-exertional 2 ( 7%) I ( 3%) 
Prior:MI 5 (19%) 7 (21%) 
Prior CABG 0 0 
Prior PTCA 0 0 
Hypertension 7 (26%) 10 (30%) 
Hypercholesterolemia 6 (22%) 9 (27%) 
Smoking 5 (19%) 10 (30%) 
Diabetes 2 ( 7%) 2 ( 6%) 
MI: myocardial infarction, CABG: coronary artery bypass grafting 
No statistically significant differences were observed between the two treatment groups. 
Table 2. Baseline angiographic characteristics. 
RD(nun) 
MLD(nun) 
DS(%) 
RA (nnn2) 
MLCA(mm2) 
AS(%) 
Length (nnn) 
Plaque(mrn2) 
Synunetry 
Target vessel LAD 
LCX 
RCA 
Stent 
(N- 27) 
2.82 ± 0.50 
0.99 ± 0.30 
64 ± 12 
6.44 ± 2.24 
0.88 ± 053 
88 ± 10 
6.3 ± 2.3 
7.7 ± 4.2 
05 ± 0.3 
18 (67%) 
5 (18%) 
4 (15%) 
PTCA 
(N- 33) 
2.82 ± 0.45 
0.99 ± 0.22 
64 ± 8 
6.43 ± 2.15 
0.82 ± 0.62 
88 ± 12 
6.6 ± 1.9 
8.1 ± 3.4 
05 ± 0.2 
27 (82%) 
2 (6%) 
4 (12%) 
No statistically significant differences were observed between the two treatment groups. 
pulling back the balloonfstent assembly and embolized into the femoral artery. The 
postoperative course was uneventful. In one patient randomized to PTCA, a bailout 
stent was implanted because of coronary dissection. 
Clinical events: A total account, and ranking of clinical events, following stent 
implantation and PTCA is depicted in Table 3 and 4. Since the postoperative course 
and long-term clinical follow-up was uneventful in the three patients who crossed 
over from stent implantation to PTCA, there was no difference between the intention 
to treat and efficacy analysis. 
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Fig. 3. Diagram illustrating the patient flow after randomization. See text for further explanations. 
All clinical events during hospital stay were related to either subacute stent 
thrombosis or abrupt vessel closure after PTCA. Stent thrombosis was documented 
in two patients at day 2 and 3 after implantation while abrupt vessel closure after 
PTCA occurred at 30 min. and 1 day after the procedure. Both patients with subacute 
stent thrombosis underwent repeat PTCA and emergency bypass surgery. The 
postoperative course was uneventful in one. The other patient sustained an anterior 
myocardial infarction (CPK 3035 Uf!). The two patients with (sub)acute vessel 
closure after PTCA were treated with repeat PTCA with uneventful course, except 
for a small non-Q wave myocardial infarction (CPK 280 Ufl) in one. 
One patient randomized to stent implantation received two stents. Implantation of 
the frrst stent in the trrst segment of the right coronary artery resulted in dissection 
type C in association with a signillcant residual stenosis. A second stent was 
successfully implanted with restoration of the antegrade flow. The immediate and 
long-term clinical and angiographlc outcome was uneventful. As already mentioned 
above, one patient randomized to PTCA received a stent because of dissection after 
PTCA. 
One patient died three weeks following successful stent implantation due to 
hypovolemic shock and infection in association with repeated surgical repair of an 
arterio-venous tJStula. Two patients (one in each group) sustained an acute 
myocardial infarction. This event was related to repeat coronary intervention in the 
patient in the PTCA group. This patient underwent directional atherectomy 4 months 
after PTCA, which was complicated by a small infarct (CPK 202 Uf!) and a transient 
ischemic cerebrovascular accident. The other patient sustained a Q-wave myocardial 
infarction 4 months after stent implantation. The cause of this event remains unclear. 
There was no evidence of angina whatsoever at the time of the infarct and control 
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Table 3. Total account of clinical events following stent implantation and PTCA. 
Stent (N - 27) PTCA (N- 33) RR (95% Cl) 
Death 
pre-discharge 0 0 
post ~discharge 0 
All 0 NA 
ICH/stroke 
pre-discharge 0 0 
post-discharge 0 
All 0 NA 
AMI 
pre~discharge 
post-discharge 1 
All 2 2 1.22 (0.18 ; 8.11) 
EmCABG{bail~out stent 
pre-discharge 3 1 
post~discharge 0 0 
All 3 3.67 (0.40 ; 33.3) 
Elective CABG 
pre-discharge 
post-discharge 2 2 
All 2 2 1.22 (0.18; 8.11) 
re-PTCA 
pre-discharge 2 2 
post ~discharge 1 10 
All 3 12 0.31 (0.10; 0.97) 
Total account of events 11 18 0.75 (0.43 ; 1.30) 
ICH : Intracranial hemorrhage, (Em)CABG : (Emergency) bypass surgery, RR : relative risk, 95 % CI 
: 95 % Confidence interval, NA : not applicable. 
angiography 2 months later revealed apart from some radiolucency at the origin of 
the fJISt septal perforator which was covered by the stent, no other abnormalities. In 
contrast to the PTCA patients, the two patients in the stent group sustained a 
transmural myocardial infarction (CPK 3035 and 1620 Uji). 
The major difference between the two study groups, was the need for elective 
revascularization during follow-up. Bypass surgery or repeat PTCA was performed 
in three patients randomized to stent implantation compared to twelve patients 
randomized to PTCA (Table 3). The 6-month event and symptom free survival 
(freedom from death, intracranial hemorrhage or stroke, myocardial infarction, bypass 
surgery or repeat intervention and angina pectoris) was 67% after stent implantation 
and 55% after PTCA. 
No patient in the PTCA group sustained a major bleeding or puncture site related 
complication compared to seven patients in the stent group (surgical repair and 
transfusion because of pseudoaneurysm: 2, surgical repair: 1, surgical repair and 
transfusion because of an arterio-venous flstula: 1, transfusion because of groin 
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Table 4. Clinical events following stent implantation and PTCA according to a ranking scale ranging 
from death to re-PTCA. 
Stent (N = 27) PTCA (N- 33) RR (95 % Cl) 
Death 
pre-discharge 0 0 
post -discharge 0 
All 0 NA 
ICH/stroke 
pre-discharge 0 0 
post-discharge 0 
All 0 NA 
AMI 
pre-discharge 
post -discharge 0 
All 2 2.44 (0.23 ; 25.5) 
EmCABGjbail-out stent 
pre-discharge 2 I 
post-discharge 0 0 
All 2 2.44 (0.23 ; 25.5) 
Elective CABG 
pre-discharge 0 0 
post-discharge 2 2 
All 2 2 1.22 (0.18; 8.!1) 
re-PTCA 
pre-discharge 0 0 
post-discharg~ 9 
All 9 0.14 (0.02 ; !.01) 
Total 8 14 0.70 (0.35 ; 1.41) 
Abbreviations: see Table 3. 
hematoma; 3 patients). The hospital stay was (mean± sd) 2.2 ± 1.3 days for the 
patients who underwent PTCA compared to 11.5 ± 5.7 in the patients who received 
a stent. 
Angiographic results 
Table 5 and Figures 4-7 summarize the quantitative angiographic fmdings. A total 
of 54 out of the 58 patients (93%) eligible for follow-up completed their angie-
graphic follow-up study at (mean± sd) 5.3 ± 1.9 months. According to both the 
intention to treat and the efficacy analysis, the increase in minimal luminal diameter 
innnediately after stent implantation was significantly greater than after PTCA. 
Despite a higher loss, the minimal luminal diameter at follow-up proved to be greater 
after stent implantation than after PTCA. This did not reach statistical significance, 
due to the small number of patients treated. However, the 95% confidence interval 
of the difference in minirnalluntinal diameter at follow-up between the two treatment 
groups was -0.13 to 0.57 mm according to the intention to treat analysis and 
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Fig. 4. Cumulative distribution curves of the 
minimal luminal diameter and its changes post 
PTCA or post stent implantation and at follow-up 
according to the intention to treat analysis. X-axis: 
minimal luminal diameter, Y -axis: relative number 
of patients. 
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Fig. 6. Cumulative distribution curves of the 
percent diameter stenosis and its changes post 
PTCA or post stent implantation and at follow-up 
according to the intention to treat analysis. X-axis: 
diameter stenosis, Y -axis: relative number of 
patients. 
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Fig. 5. Cumulative distribution curves of the 
minimal luminal diameter and its changes post 
PTCA or post stent implantation and at follow-up 
according to the efficacy analysis. X-axis: minimal 
luminal diameter, Y -axis: relative number of 
patients. 
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Fig. 7. Cumulative distribution curves of the 
percent diameter stenosis and its changes post 
PTCA or post stent implantation and at follow-up 
according to the efficacy analysis. X-axis: diameter 
stenosis, Y ~axis: relative number of patients. 
-0~03 - 0~69 mm according to the efficacy analysis. The incidence of restenosis is 
shown in Table 6. 
DISCUSSION 
This is the rrrst report describing the results of a randomized study in which stent 
implantation was compared with balloon angioplasty. It needs to be stressed that it 
concerned the pilot phase in which ouly a limited number of patients have been 
randomized and treated. 
- Taking into account this small sample size, the rrrst striking feature is the low stent 
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Table 5. Changes in minimal luminal diameter (MLD) and diameter stenosis (DS) following stent 
implantation and PTCA 
MLD (mrn) 
pre 
post 
FU 
DS (%) 
pre 
post 
FU 
MLD (mm) 
pre 
post 
FU 
DS (%) 
pre 
post 
FU 
Intention to treat analysis 
Stent (N - 27) PICA (N- 33) 
0.99 ± 0.30 0.99 ± 0.22 
2.19 ± 0.70 1.85 ± 0.31 
1.67 ± 0.77 1.45 ± 0.59 
64 ± 12 64 ± 8 
27 ± 18 34 ± 9 
41 ±23 50± 19 
Efficacy analysis 
Stent (N - 23) PTCA (N- 35) 
1.00 ± 0.24 1.00 ± 0.21 
2.41 ± 0.46 1.81 ± 0.31 
1.75 ± 0.77 1.42 ± 0.58 
65 ± 8 63 ± 8 
22 ± 10 35 ± 8 
43 ± 22 50± 19 
p 
NS 
O.Dl 
NS 
NS 
0.04 
NS 
p 
NS 
<.0001 
NS 
NS 
<.0001 
NS 
All changes within each treatment group (paired t-test) were highly significant. The reference diameter 
(2.82 ± 0.50 and 2.82 ± 0.45 mm) remained unchanged. 
Table 6. Incidence of restenosis following stent implantation and PTCA 
0.72 mm 
50% DS 
0.72 mm 
50% DS 
Intention to treat analysis 
Stent (N - 27) 
29% 
30% 
Efficacy analysis 
Stent (N - 23) 
27% 
24% 
PICA (N- 33) 
27% 
47% 
PTCA (N- 35) 
28% 
50% 
implantation success rate. It contrasts with the general experience in which a success 
rate exceeding 90% has been reported [9]. Patient selection cannot fully explain this 
high implantation success rate reported in the literature since this also holds for a 
randomized study with its specific in- and exclusion criteria. Most likely, the 
difference is explained by the fact that in nonrandomized studies, failed attempts may 
not always have been registered andfor reported. The protocol of the Benestent Study 
requests that only patients with a vessel larger than 3.0 mm be included. Despite this, 
the median value of the reference diameter proved to be 2.91 mm (range 1.83-4.10 
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mm) and 2.83 mm (range 2.14-4.12 mm) for the stent and PTCA group, 
respectively. Detailed analysis of this angiographic variable of the 60 patients herein 
reported discloses that a total of 42 patients or 70% of the total study population had 
a vessel smaller than 3.0 mm. The erroneous inclusion of the patient with a vessel 
as small as 1.83 mm was due to the fact that neither the field size of the image 
intensifier nor the size of the diagnostic catheter used in the refering institution were 
known which resulted in a wrong visual estimation of the vessel size. When the true 
vessel size became apparent during on-line quantitative coronary angiography just 
prior to the actual treatment, it was wisely decided not to implant a stent. Apart from 
the risk of subacute stent thrombosis in such a patient, successful stent delivery was 
not very likely considering the profile of the Sheath Delivery System of the Pahnaz-
Schatz stent (5 F). True failure of stent delivery occurred in 4 patients. In addition 
to the patient with a vessel of 1.83 mm, the target vessel proved to vary between 
2.03 and 2.90 nnn in three other patients. In one of these patients, stent delivery 
failed due to a tortuous segment proximal to the target lesion. This underscores that 
in addition to vessel size and catheter profile and appropriate fitting of the guiding 
catheter, longitudinal flexibility of the device are prerequisites for successful 
implantation. Improvements in stent design are currently under way to improve the 
stent profile and longitudinal characteristics [12]. It is of note that with progress of 
the Benestent study, the implantation success rate increased to 94% in the firS! 129 
consecutive patients [13]. 
- One patient died three weeks after stent implantation. Although the stent was patent 
at pathologic examination, death has to be considered procedure- and thus stent-
related. In retrospect, one may argue whether this patient should have been referred 
for surgical repair of an arterio-venous fistula. This is usually well tolerated and is 
genetally not considered as an indication for surgery. 
- The incidence of vessel closure was identical between the two treatment groups. 
Stent thrombosis occurred in 2 out of the 23 patients (9%). Although the number of 
patients in the pilot phase is too small to draw any fmu conclusions, it is in 
accordance with the general experience reporting an incidence, expressed as the 
weighted average of all studies, of 8.2% [14]. Such an incidence of stent thrombosis 
is too high to be accepted but is influenced by the high incidence of stent thrombosis 
in the early days of stent implantation during which an incidence of 20% within the 
firSt two weeks has been repcrted [7]. Recent studies report a much lower stent 
thrombosis rate. The overall incidence of stent thrombosis following Palmaz-Schatz 
stent implantation is 3.3% and just recently an incidence of 0.4% was reported 
[8,14]. Noteworthy is that the stent thrombosis rate in the first 129 consecutive 
patients of the Benestent study was 2.3% [13]. In contrast to abrupt vessel closure 
after PTCA which generally occurs within 24 hrs after the procedure, stent 
thrombosis appears to occur after a lapse of a few days [15]. In the current study, 
stent thrombosis occurred at day I and 3 after implantation. Although clinical, 
haemostatic and angiographic variables may be found to predict stent thrombosis, it 
remains largerly an unpredictable event. Notwithstanding the utmost impcrtance of 
proper institution of the anticoagulant drug therapy, the cause of stent thrombosis is 
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most likely multifactoriaL Bail out stem implantation, small stent size or final stent 
Wam.eter and left ventricular function have been identified as independent predictors 
of subacute stent thrombosis [15,16]. It remains controversial whether the use of 
multiple stents is associated with an increased risk of stent occlusion. Shaknovich et 
a!. did not observe a difference in the subacute stent thrombosis rate between single 
and multiple stent impiantation (3.9% and 3.7%, respectively) while in the single 
center experience reported by Doucet et a!., the use of multiple stents was identified 
as an independent predictor [15,17]. Perhaps, one of the major determinants is flow. 
One of the patients with stent thrombosis herein reported had a lesion distal to the 
stented segment. This may have contributed to this event or even be the actual cause. 
- Not unexpected, the incidence of major bleeding complications was significantly 
higher and the hospital stay was longer in patients treated with a stent. The overall 
incidence expressed as weighted average of groin hematomas and of pseudoaneurysm 
reported in the literature is 7.5% (range 2.7%- 26%) and 4.2% (range 0.0% -
10.8%), respectively [14]. These numbers represent the overall experience including 
the experience of the II!St period of intracoronary stenting during which the 
anticoagulation protocol evolved and during which thrombolytics were quite often 
used [7]. Despite improvements in postoperative management and unification and 
improved monitoring of the anticoagulation, these numbers have not decreased 
[14,18]. This may be related to a more aggressive application of the anticoagulation 
regimen to avoid stent thrombosis. Indeed, while there is a clear trend towards a 
reduced stent thrombosis rate, the incidence of vascular access site related 
complications did not drop [14]. The use of new hemostatic devices may have a 
beneficial influence. Controlled compression with a belt-held pneumatic compression 
device proved to be higly successful and reduced the incidence of pseudoaneurysm 
in our hands and those of others [19]. 
- Despite the risk of stent thrombosis and the need for an intensive anticoagulation, 
the symptom and event free survival (freedom from death, cerebrovascular accident, 
myocardial infarction, bypass surgery or repeat intervention) was higher following 
stent implantation than following PTCA (67% versus 55%). These long-term clinical 
results of the patients treated with PTCA in the pilot phase of the Benestent Study 
is strikingly similar to the long-term clinical results reported in the PARK Study. In 
this study, which is a multicenter randomized, double-blind, placebo controlled trial 
evaluating the effects of ketauserin in the prevention of restenosis, the symptom and 
event free survival was 54% in the ketanserin group and 51% in the placebo group 
[20]. The difference in the long-term clinical results of the current study, is largely 
explained by the difference in the need for repeat intervention or elective bypass 
surgery between the two study groups. A total of three patients in whom a stent was 
implanted needed bypass surgery (two patients) or repeat PTCA (one patient) 
compared to twelve patients (bypass surgery: 2 patients, repeat PTCA or directional 
atherectomy: 10 patients) in whom a PTCA was performed. The reduced need for 
repeat intervention or surgical revascularization is most likely explained by the 
significantly superior improvement in stenosis geometry after stent impiantation 
(Table 5). According to both the intention to treat and efficacy analysis the increase 
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in minimal luninal diameter was 1.20 ± 0.75 mm and 1.40 ± 0.43 mm after stent 
implantation compared to 0.85 ± 0.30 mm and 0.81 ± 0.28 mm after PTCA. Despite 
a greater loss at follow-up, the minimal luminal diameter still proved to be greater 
in patients who received a stent compared to patients in whom a PTCA was 
performed. This did not reach statistical significance due to the small number of 
patients treated. Noteworthy is the value of the minimal luminal diameter at follow-
up in the PTCA group. It was equal or less than 1.45 mm. This value was found to 
correlate with recurrence of angina at follow-up in a population with single vessel 
disease who underwent a single site balloon dilatation [21]. Furthermore, the 
angiographic data shown in table V and VI underscore the concept that the higher 
initial gain following stent implantation compensates for the late loss and thus that 
improved initial results and not lessened neointimal hyperplasia is responsible for a 
reduced incidence of angiographic restenosis [5,6]. 
CONCLUSIONS 
In this limited number of patients randomized to either stent implantation or balloon 
angioplasty, the long-term clinical and angiographic outcome proved to be superior 
in patients who received a stent. However, this was achieved at the cost of a 
significant risk of vascular access site complications and a longer hospital stay. These 
results have encouraged the investigators to start with the defmite study in which a 
total of 520 patients will be randomized. 
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Benestent Study Group 
Participating Clinics and invesgigators. 
The following institutions and investigators participated in the Benstent study. The 
number of patients enrolled at each center are given in parenthesis, with specification 
of the patients enrolled in the pilot study: 
1) University Hospital San Carlos, Madrid, Spain [76]: C. Macaya, MD, principal 
investigator, F. Alfonso, MD, J. Goicolea, MD, A. Iniguez. 
2) University Hospital Rotterdam - Dijkzigt, Thoraxcenter, Rotterdam, The 
Netherlands (57 of whom 23 in the pilot study): P.P.T. de Jaegere, MD, 
principal investigator, P.W. Serruys, MD, P.J. de Feyter, MD, M.A. Morel, RN. 
3) Onze Lieve Vrouwe Gasthnis, Amsterdam, The Netherlands (50 of whom 18 in 
the pilot phase): F. Kiemeneij, MD, principal investigator, GJ. Laarman, MD, 
R. vander Wieken, MD. 
4) Freie Universitat Berlin, Universiliitsklinikum Rudolf VirchowfCharlottenburg, 
Berlin, Germany [39]: W. Rutsch, MD, principal investigator. 
5) Onze Lieve Vrouw Ziekenhnis, Aalst, Belgium (38 of whom 5 in the pilot 
phase): G. Heyndrickx, MD, principal investigator, B. de Bruyne, MD. 
6) Med. Clin. I. Sahlgrenska Hospital, Goteborg, Sweden [36]: H. Emanuelsson, 
MD, principal investigator, P. Albertsson, MD. 
7) Clinique Pasteur, Toulouse, France (32 of whom 1 in the pilot phase): J. Marco, 
MD, principal investigator, J Fajadet, MD, S. Doucet, MD. 
8) Sart-Tilman, Centre Hospitalier Universitaire, Liege, Belgium (32 of whom 6 
in the pilot phase): V. Legrand, MD, principal investigator. 
9) Hopital Citadelle, Liege, Belgium (19 of whom 2 in the pilot phase): P Mateme, 
MD, principal investigator, J Boland, MD. 
10) Instimto Cardiovascular de Buenos Aires, Buenos Aires, Argentina [19]: J. 
Belardi, MD, prinicipal investigator, J. Berrocal, MD. 
11) Royal Brompton, National Heart, London, United Kingdom [12]: U. Sigwart, 
MD, prinicipal investigator, N. Buller, MD. 
12) Centro Cuore, Milano, Italy (11): A. Colombo, MD, prinicipal investigator, L. 
Maiello, MD. 
13) CHUV, Lausanne, Switzerland (11): J.J. Goy, principal investigator, E. 
Eeckhout, MD. 
14) Middelheim Ziekenhnis, Antwerpen, Belgium (10 of whom 3 in the pilot phase): 
P. van den Heuvel, MD, principal investigator, F. van den Brande, MD. 
15) Gregorio Maranon, Madrid, Spain (10): J. Delcan, MD, principal investigator, 
E. Garcia, MD. 
16) Ziekenhnis de Weezeulanden, Zwolle, The Netherlands (8): H. Suryapranata, 
MD, principal investigator, J. Hoomtje, :MD. 
17) St. Antonius Ziekenhnis, Nieuwegein, The Netherlands (8): Th. Plokker, MD, 
principal investigator, G. Mast, MD. 
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18) Hospital Maggiore, Trieste, Italy (8): S. Klugmann, MD, principal investigator, 
E. di Garzia, MD, A. Salvi, MD. 
19) Hopital Cantonal Universitaire, Geneve, Switzerland (7): P. Urban, prinicipal 
investigator, E. Camenzind. 
20) Academisch Ziekenhuis Groningen, The Netherlands (6): P. den Heijer, MD, 
principal investigator, R. van Dijk, MD. 
21) Academisch Medisch Centrum, Amsterdam, The Netherlands (6): J. Piek, MD, 
principal investigator, K. Koch, MD. 
22) Christian Albrechts University, Kiel, Germany (6): R. Simon, MD, principal 
investigator, Fr. Herrmann, MD. 
23) Centre Cardiologique de Nord, Paris, France (5): M.C. Morice, MD, principal 
investigator, T. Royer, MD. 
24) James Hospital, Dublin, Ireland (5): P. Crean, MD, prinicipal investigator. 
25) Catharina Ziekenhuis, Eindhoven, The Netherlands (3 of whom 2 in the pilot 
phase): H. Bonnier, MD, principal investigator, J. Koolen, MD, F. Bracke, MD. 
26) Clinique Universitaire St. Luc, Universite Catholique Louvain, Bruxelles, 
Belgium (2): W. Wijns, MD, principal investigator, J. Renkin, MD. 
27) CHUR, Nancy, France (2): N. Danchin, MD, prinicipal investigator, Y. Juilliere, 
MD. 
28) Policlinique Volney, Rennes, France (2): C. Bourdonnec, MD, principal 
investigator. 
REFERENCES 
1. de Feyter PJ, de Jaegere PPT, Murphy ES, Serruys PW. Abrupt coronary artery occlusion during 
percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1633-1642. 
2. Serruys PW, Luijten HE, Beat KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JHC, ten 
Katen HJ, vanEs GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: 
a time~related phenomenon. Circulation 1988;77:361-371. 
3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L Intravascular stent to prevent occlusion 
and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706. 
4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley W A, Breland J. Intracoronary 
stenting for acute and threatened closure complicating Percutaneous Transluminal Coronary 
Angioplasty. Circulation 1992;85:916-927. 
5. de Jaegere PPT, Hermans WR, Rensing BJ, Strauss BH, de Feyter PJ, Serruys PW. Matching based 
on quantitative coronary angiography. A surrogate for randomized studies? Comparison between 
stent implantation and balloon angioplasty of a native coronary artery lesion. Am Heart J, February 
1993;125:310-319. 
6. Fischman DL, Savage MP, Ellis SG, Schatz RA, Leon MB, Bairn D, Goldberg S. Restenosis after 
Palmaz-Schatz Stent implantation, in P.W. Serruys, B.H. Strauss and S.B. King ill (eds): Restenosis 
after intervention with new mechanical devices, pp. 191-205. Kluwer Academic PublisheiS 1992. 
7. Serruys PW, Strauss BH, Beatt KJ, Bertrand :ME, Puel J, Rickards AF, Meier B, Kappenberger L, 
Goy J, Sigwart U. Angiographic follow-up after placement of a self-expanding coronary-artery stent. 
N Eng! J Med 1991;324:13-17. 
135 
8. Carrozza J, Kuntz R. Levine M. Pomerantz R. FlShman R. Mansour M, Gibson M, Senerchla C, 
Diver D, Safian R. Bairn D. Angiographic and clinical outcome of intra coronary stenting: immediate 
and long-term results from a large single-center experience. JAm Coil Cardiol 1992,20:328-337. 
9. de Jaegere PPT, de Feyter PJ, van der Giessen W, Serruys PW. Endovascular stents:. preliminary 
clinical results and future developments. Qinical Cardiology 1993, in press. 
10. Reiber JHC. An overview of coronary quantitation techniques as of 1989, in Reiber JHC, Serruys 
PW (eds): Quantitative coronary angiography, pp 55-132, K.Iuwer Academic Publishers, 1991. 
1 I. Reiber JHC, Serruys PW, Kooyman CJ, Slager CJ, Schuurbiers JHC, Boer A den. Approaches 
toward standardization in acquisition and quantitation of arterial dimensions from cineangiograms, 
in Reiber JHC, SerruysPW (eds): State oftheartin quantitative Quantitative coronary angiography, 
pp 145-155, Dordrecht, Martinus Nijhof Publishers, 1986. 
12. Stanton J. Row, Director Coronary Systems, Johnson & Johnson, personal communication. 
13. Serruys PW, de Jaegere PP, K.iemeneij F, Macaya C, Emanuelsson H, Heyndrickx G, de Bruyne B, 
Rutsch W, Legrand V, Materne P, Boland J, Marco J, Fajadet J, vanden Heuvel P, vande Brande 
F, Bonnier H, Braclre F, Colombo A, Morel MA. Clinical events and angiographic results of the first 
120 patients randomized in the Benestent Study. Circulation 1992,86: 1488A. 
14. de Jaegere P, de Feyter P, Serruys PW. Intracoronary Stenting, in E. Topol, PW Serruys (eds): 
Annual of Interventional Cardiology, in press. 
15. Doucet S, Fajadet J, Caillard J, Cassagneau B, Robert G, Marco J. Predictors of thrombotic 
occlusion following coronary Palmaz-Schatz stent implantation. Circulation I992,86:0450A. 
16. Agrawal SK, Hearn JA, Liu MW, Cannon AD, Bilodeau L, Iyer SS, Baxley W A, Dean SD, Roubin 
GS. Stent thrombosis and ischemic complications following coronary artery stenting. Circulation 
!992;8M52A. 
17. Shaknovich A, Rocha-Singh K, Teirstein P, Lieberman S, Moses J. Subacute stent thrombosis in 
Palmaz-Schatz stents in native coronary arteries: Time course, acute management and outcome. U.S. 
Multicenter experience. Circulation 1992;86:449A. 
18. Hafner G, Swars H, Erbel R. Ehrentahl W, Rupprecht HJ, Lotz J, Meyer J, Prellwitz W: Monitoring 
prothrombin fragment Fl + 2 during initiation of oral anticoagulant therapy after intracoronary 
stenting. Ann Hematol 1992; 65:83-87. 
19. Nordrehaug J, Chronos N, Foran J, Wainwright R, Rickards A, Buller N, Sigwart U. Randomized 
evaluation of a new inflatable femoral artery compression device after coronary angiography. 
Circulation 1992,86:1523A. 
20. Serruys PW, Klein W, Tijssen JPG, Rutsch W, Heyndrickx GR. Emanuelsson H, Ball SG, Wijns 
WR, Schroeder E, Liebermann H, Eichorn E, Willerson IT, Anderson HV, Khaja F, Alexander RW, 
Bairn D, Melkert R. van Oene JC, van Gool R Evaluation of ketanserin in the prevention of 
restenosis after percutaneous transluminal coronary angioplasty; a multicenter randomized double-
blind placebo-controlled trial. Submitted for publication. 
21. Rensing BJ, Hennans WR, Deckers JW, de Feyter PJ, Serruys PW. Which angiographic parameter 
best describes functional status 6 months after successful single vessel coronary balloon angioplasty? 
JAm Coli Cardiol 1993, in press. 
136 
CHAPTER 11 
INTRACORONARY STENTING 
P.P.T. de Jaegere, P.J. de Feyter, P.W. Serruys. 
In: Armual of lnterventioual Cardiology (Eds: E. Topol and P.W. Serruys). 
Current Medicine, 1993, in press. 
137 
INTRODUCTION 
Percutaneous Transluminal Coronary Angioplasty by means of balloon catheters 
(PTCA) is now widely accepted as an effective treatment for selected patients with 
obstructive coronary artery disease. Gained operator experience and improved 
catheter technology have increased the inunediate success rate to more than 90% and 
reduced the incidence of procedure related complications[l,2]. However, abrupt 
vessel closure during or inunediately following PTCA and late restenosis continue 
to limit the safety and effectiveness of this procedure [3,4]. 
Abrupt closure has been reported to occur in 2 to 10% of patients treated and is 
the major determinant of in-hospital morbidity and mortality [3]. When refractory to 
prolonged balloon inflation, dilatation with an oversized balloon and/or adjunct 
thrombolytic therapy, emergency bypass surgery may be necessary to limit 
myocardial damage. Even then, abrupt closure is associated with a 3 to 6% mortality 
and up to a 50% frequency of periprocedural myocardial infarction [5-9]. 
The incidence of restenosis varies between 20 and 57%, depending on the 
defmition used, patient population studied and time to and completeness of follow-up 
angiography. It necessitates repeat intervention or eventually bypass surgery in up to 
20% of the patients [1,4,10]. 
To address these two major shortcomings, a number of new devices have been 
developed. One of these, is the intracoronary stent. The first clinical experience with 
stent implantation dates back to the late sixties when Charles Dotter implanted tube 
grafts in peripheral arteries [ 11]. His intention was to reduce the high rate of 
restenosis in patients who had undergone peripheral balloon angioplasty of occluded 
femoro-popliteal arteries. While in his initial experiments using plastic tube grafts all 
stents thrombosed within 24 hours of implantation, the results improved when using 
stainless steel coils. Since then, the development of intravascular stents has 
progressed steadily. At present, a number of different stents for coronary use are 
available, each with its own specific design, physico-chemical characteristics and 
mode of implantation (Table 1). Distinction can be made between self -expanding and 
balloon-expandable stents. The frrst is a spring-like design that can be constrained 
Table I. Design and characteristics of stents in clinical evaluation. 
Stent Configuration Filament Filament Stent Stent Surface Radio-
Composition Thickness Diameter Length Area paque 
(mm) (mm) (mm) (%) 
Self-expanding 
Wallstent Wire-mesh Stainless steel 0.07-0.10 3.5-6.0 21-45 18.5-20 No 
Balloon-expandable 
Palmaz-Schatz Slotted tube Stainless steel 0.08 3.0-4.0 IS 10 No 
Gianturco-Roubin Coil Stainless steel 0.15 2.0-4.0 20 10 No 
Wik.tor Coil Tantalum 0.125 3.0-4.5 15-17 5-10 Yes 
Strecker Woven-wire Stainless steel om 2.0-3.5 15-25 No 
Tantalum Yes 
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to a small diameter and then expands to a predetennined dimension when the 
constraint is removed. The balloon-expandable stent relies on plastic deformation of 
metal beyond its elastic limits. 
While the long-term impact of stent implantation in tenns of safety and efficacy 
still remains to be detennined, its demonstrated ability to improve the innnediate 
angioplasty results and therefore its potential for reducing the incidence of late 
restenosis and its application as a bail-out device have stimulated an explosive use 
of these devices. The pnrpose of this paper is to sununarize the clinical experience 
with stent implantation in human coronary arteries. 
STENT TO TREAT ABRUPT VESSEL CLOSURE 
Acute symptomatic occlusion refractory to repeat dilatation with or without 
adjunctive phannacologic treatment is one of the most troublesome situations one 
may encounter during coronary angioplasty and is associated with a significant 
morbidity and mortality [3,5-9]. Therefore, any technique or device capable of 
restoring and maintaining ante grade flow, stabilizing the clinical condition and 
obviating the need for emergency bypass surgery would be most welcome. 
The rationale for using intracoronary stents in this situation is based on their 
unique physical properties. At present, it is the only catheter based technology which 
provides a scaffold for the instrumented vessel. It prevents vessel collapse and tacks 
back intimal and medial tears, sealing the thrombogenic subintimal space. This was 
frrst demonstrated in pathologic studies in which a balloon-expandable stent was 
implanted in diseased human cadaver coronary arteries (Figure 1) [12]. Clinical 
experience with bail-out stent implantation was frrst reported by Sigwart eta!. [13]. 
In a very limited number of patients, the self -expanding W allstent was implanted 
which resnlted in an innnediate restoration of adequate coronary flow with 
normalization of the ECG and relief of symptoms with no evidence of acute 
myocardial infarction. Since then, each of the clinically available ste.11ts have been 
used for this purpose with encouraging resnlts (Figure 2A+B, Table 2). All authors 
report a high implantation success rate which is remarkable taking into account the 
technical difficnlties one may encounter in a bail-out situation. Disappearance of 
angiographic landmarks and spasm of the vessel segment may render stent delivery 
and correct positioning very laborious. Therefore, extra operator experience and skill 
is required. The selection of the device may influence the delivery success rate. In 
case of dissection in a vessel with an acute takeoff or tortuosity, stents with a higher 
longitudinal flexibility such as the self -expanding W allstent and the balloon-
expandable coil stents (Wiktor, Gianturco-Roubin and Strecker stent) may preferably 
be used instead of the stents with a more rigid mesh structure. Although the radiop-
acity of the WLlctor stent may be helpful in correct positioning, comparable delivery 
rates have been reported with non-radiopaque stainless-steel devices (Table 2). 
Obviously, the nltimate goal of bail-out stent implantation is the reduction and 
possibly the elimination of the acute ischemic complications due to acute vessel 
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Fig. I. Transversal section of a hwnan cadaver coronary artery. The intimal and medial tear is tacked 
back by the stent. 
Reproduced with permission from Schwartz et al. Circulation 1989; 79:445-457. 
Fig. 2A + B. Dissection of the left anterior descending artery after PTCA (panel A), which was 
effectively treated with stent implantation {panel B). 
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Table 2. In-hospital events following stent implantation for threatened or acute occlusion after PTCA. 
Author Ref. Year Study n pt:->. n. stcnt:-> Successful Complications SubscquCJI\ occlusim1 
Period stent delivery 
Death AMI Em CABO Incidence Time interval 
Wallstent 
Sigwart et al. (13) '87 n.r. 4 4 100% 0 0 0 0 0 
Sigwart et al. (14) '88 '86- '88 II 13 100% I (9%) 0 0 I (9%) n.r. 
de Feyter et al. (15) '90 '89-'90 15 19 100% I (6.6%) 2 (13.3%) 9 (60%)* 3 (20%) day0-7 
Goy et al. (16) '92 n.r. 17 n.r. 100% 0 I (5.8%) 0 I (5.8%) day 0 
Palmaz-Schatz stent 
Haude et al. (17) '91 n.r. 15 22 100% 0 0 I (6.7%) I (6.7%) day 0 
Hemnann et a!.** (18) '92 '88-'91 56 n.r. 98% 2 (3.6%) II (20%) 7 (13%) 9 (16%) day 1-10 
Reifart et al. (19) '92 '90-'91 64 71 95% 4 (6%) 2 (3%) 7 (II%) 20 (31 %) day 0-19 
Gianturco-Roubin stent 
Roubin et al. (20) '92 '89-'91 II5 137 96% 2 (1.7%) 8 (6.7%)*** 5 (4.2%) 9 (7.6%) day I - 5 
Strecker stent 
Reifart et al. (19) '92 '90-'91 48 56 97% 5 (10%) I (2%) 3 (6%) 10 (21 %) day 0-19 
Wiktor slent 
Vrolicx eta\. (2 I) '92 '91 119 n.r. 95% 4 (3%) n.r. 7 (6%) 14 (12%) n.r. 
Total 464 19 (4.1 %) 25 (10.6%) 39 (8.4%) 68 (14.7%) 
95% CI 2.3-5.9% 7.4-13.8% 5.8-10.9% 11.5-17.9% 
pts =patients; AMI "'acute myocardial infarction; Em. CABG =emergency bypass surgery.* :Including the 8 patients in whom the stent was used as bridge to 
surgery, **:Events within 30 days after stent implantation are reported. ***:if patients in whom stent was implanted because of evolving AMI are excluded: 4%; 
CI = confidence interval. 
~ 
.,.. 
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closure. It is the general appreciation of many interventional cardiologists that stents 
indeed do reduce the need for emergency bypass surgery and incidence of acute 
myocardial infarction [20]. Unfornmately, data from randomized studies proving the 
superiority of stents to other techniques or devices are lacking. Nevertheless, the 
incidence of major cardiac events following bail-out stent implantation compare very 
favourably with those after abrupt closure following PTCA (Table 3). 
Some have advocated that intracoronary stents should be available in all centers 
for bail-out procedures [33]. This could lead to an exponential ( over)use of these 
devices not taking into account potential technical and clinical pitfalls in bail-out 
stent implantation, Firstly, the coronary angiogrant may be misleading in the 
distinction between dissection and intracoronary thrombus as the cause of acute 
occlusion. In latter case, the stent may exacerbate the pathological process rather than 
have a beneficial effect. Secondly, apart from correct positioning of the stent, the 
choice of the stent size may be difficult because acute coronary occlusion is often 
associated with spasm of the reference vessel segment. With respect to the clinical 
pitfalls, one should note that patients with acute occlusion are often clinically 
unstable, with long-lasting periods of ischemia, hemodynamic deterioration and 
extensive dissection which may have induced activation of platelets and the clotting 
system. all of which may lead to an increased risk of thrombosis which is higher 
following bail-out stent implantation. 
The incidence of subacute stent thrombosis has been reported to vary between 
9-18% following bail-out stent implantation, compared with 2 to 3% after elective 
stent implantation [34,35]. To avoid stent thrombosis, an intensive and meticulous 
anticoagulation is necessary. This, in turn, exposes the patient to an increased risk 
of serious bleeding complications (Table 4). 
Since antegrade flow should be restored as soon as possible and since bail-out stent 
implantation is not without risk, one should avoid Ullllecessary stenting by frrst using 
classical manoeuvres such as prolonged inflation with or without an oversized balloon, 
but, avoid extensive vessel wall damage by frequent and repetitive balloon inflations. 
In this respect, the use of a temporary stent may offer an alternative to permanent 
intravascular stenting provided it may be retrieved in a time period short enough to 
avoid anticoagulation but sufficient long enough to effectively control the dissection 
[43]. If this proves to be superior to the general manoeuvres of using prolonged 
balloon inflations, oversized balloons or autoperfusion balloon catheters, it may avoid 
the morbidity associated with permanent stenting or emergency bypass surgery. 
There are no clear guidelines with respect to the decision to refer the patient for 
semi-elective bypass surgery after successful bail-out stent implantation. This 
decision should be based on a number of factors such as the clinical status of the 
patient after stenting (relief of angina, normalization of ECG and[ or haemodynamic 
parameters), angiographic factors (TIMI flow, presence or absence of intracoronary 
thrombus, complete or incomplete covering of the dissection, residual stenosis, 
territory at risk, presence or absence of collaterals), procedural factors (number and 
size of stents used) and indication for bail-out stent implantation (suboptimal result 
versus threatened or frank vessel closure). 
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Table 3. In-hospital events following (sub)acute occlusion during or immediately after PTCA. 
Author Ref Year Study n pts. Incidence (sub) Complications 
Period acute occlusion 
Death AMI Em.CABG 
Dorros et al. (22) '83 '77-'81 1500 69 (4.6%) 3 (4.3%) 25 (36%) 50 (72%) 
Hollman et al. (23) '83 '80-'82 935* 20 (2.1 %) 0 5 (25%) 5 (25%) 
Shiu et al. (24) '85 209 20 (9.5%) 2 (10%) 5 (25%) 14 (70%) 
Simpendorfer et al. (25) '87 '83-'85 1500 32 (2.0%) 14 (44%) 4 (13%)** 
Sinclair et a!. (26) '88 '81-'86 1160 54 (4.7%) 1 (1.9%) 19 (35%) 18 (33%) 
Ellis ct al. (27) '88 '82-'86 4772 210 (4.4%) 4 (2.9%)*** 56 (40%)*** 78 (55%)*** 
Meyerovitz et al. (28) '88 '84-'86 514 44 (8.5%) [ (2.3%) 1 (2.3%) 13 (30%) 
Gaul et al. (29) '89 '80-'86 714 22 (3.1 %) 0 6 (27%) 6 (27%) 
Delre eta!. (30) '90 '85-'86 1801 122 (6.8%) 6 (4.9%) 49 (40%) 49 (40%) 
de Feyter et at. (31) '91 '86-'88 1423 104 (7.3%) 6 (6.0%) 37 (36%) 30(31%) 
Lincoff et a!. (32) '92 '88-'90 1319* 109 (8.3%) 9 (8.3%) ~10 (9.2%) 33 (30%) 
Total 15847 806 (5.1 %) 32 (4.1 %) 227 (28%) 300 (37%) 
95% CI 4.8-5.4% 3.8-4.4% 27-29% 36-38% 
pt.s =patients;* =procedures; **=an additional9 pi!:> (28%) underwent semi-elective bypass surgery; ***"'subgroup analysis of 140 pts; CI =confidence interval. 
~ 
~ 
-j;: 
Table 4. Incidence of hemorrhagic complications and pseudoaneurysm following stent implantation. 
Author Ref Year Study n. pis Hemorrhagic complications 
Period 
ICH Groin Gastrointestinal Other Pseudoaneurysm 
Sigwart et al. (I4) '88 '86- '88 11 0 I (9.I %) 0 0 n.r. 
Urban et al. (36) '89 '86-'88 13 0 1 (7.8%) 0 0 1 (7.8%) 
Levine eta!. (37) '90 '88-'89 37 0 1 (2.7%) 0 1 (2.7%) 4 (10.8%) 
Schatz et aL (38) '91 '87-'89 226 1 (0.4%) 8 (3.S%) 2 (0.9%) 3 (1.3%) 3 (1.3%) 
Haude ct a!. (17) '91 n.r. IS 0 I (6.7%) 0 0 0 
Haude eta!. (39) '91 n.r. so 0 3 (6.0%) 2 (4.0%) 0 0 
de Scheerder et al. (40) '92 '88-'90 69 2 (2.9%) 18 (26%) 2 (2.9%) 1 (1.4%) 7 (10%) 
Roubin eta!. (20) '92 '89-'91 115 0 7 (6.1 %) 4 (3.5%) 3 (2.6%) 4 (3.S%) 
de Jaegere et a!. (41) '92 '90 50 0 6 (12%) 3 (6.0%) 0 n.r. 
Herrmann et al. (18) '92 '88-'91 56 0 2 (3.6%) 5 (8.9%) 3 (5.4%) 5 (8.9%) 
Carrozza et al. (42) '92 '88-'91 220 12 (5.5%) 
Total 862 3 (0.5%) 48 (7.5%) I8 (2.8%) 11 (1.7%) 36 (4.2%) 
95% CI 0.04-1.0% 5.5-9.5% 1.5-4.1% 0.7-2.7% 2.9-5.5% 
pts = patients; ICH = intracranial hemorrhage; n.r. = not reported; CI = confidence interval. 
Although the recurrence of stenosis at follow-up is not an issue at the moment in 
bail-out stent implantation, some authors have reported a restenosis rate as low as 
23% [44]. It is interesting to note that in a recent study the indication for stent 
implantation (elective or bail-out stent implantation) was not identified as a risk 
factor of restenosis [ 45]. 
STENTS TO PREVENT RESTENOSIS 
To solve the problem of restenosis, one has to understand its biology and the 
pathophysiologic mechanisms involved. It is evident from histologic studies that any 
kind of injury applied to the vessel wall, whatever its nature, will invariably be 
associated with neointimal hyperplasia as a non-specific tissue reaction leading to 
restenosis when excessive [46,47]. Immediately after stent implantation., neoimimal 
hyperplasia is corrfmed to the area in direct contact with the stent wires and consists 
of organized thrombus covered by a monolayer of endothelial cells. In a short period 
of time, thrombus is replaced by myofibroblastic cells and at 4 weeks the neointimal 
hyperplasia covers the entire stented segment (Fignre 3A + B) [46]. Both animal 
studies and postmortem pathologic observations in humans have shown that the 
degree of this vessel wall reaction is related to the severity of vessel wall injury 
(Fignre 4) [47,48]. Recent studies using quantitative coronary angiography lend 
support to this concept by showing that excessive oversizing of the stent relative to 
the vessel reference diameter is predictive for late angiographic narrowing [45,49]. 
Fnrthermore, it has recently been demonstrated that there is a positive linear 
correlation between the relative gain - as index of vessel wall injury - and relative 
loss - as index of neointimal thickening - following stent implantation (Fignre 5) 
[50,51]. 
From the above, it is clear that intracoronary stent implantation can not be expected 
to eliminate restenosis. However, it may reduce the incidence of angiographic 
restenosis by optimizing and improving the immediate angiographic results. It is now 
well recognized that in addition to the long-term changes in stenosis geometry after 
PTCA, more inunediate changes occur which contribute to restenosis. It has been 
shown for example that nearly 50% of the immediate gain of PTCA is lost due to 
elastic recoil of the vessel wall [52]. This compares with recoil of only 8% following 
Wiktor stent implantation in diseased huntan coronary arteries and of 9% in non-
atherosclerotic coronary arteries of the pig [46,53]. 
In addition, the stent may reduce the angiographic restenosis rate by creating a 
more patent vessel lumen which may accommodate subsequent neo-intimal 
hyperplasia. A number of studies using quantitative angiography have shown that 
stent implantation indeed results in a significant fnrther improvement in stenosis 
geometry than PTCA (Table 5). Although these data are stemming from indirect 
comparisons between nonrando:mized studies, there is a more than a 1.0 mm increase 
in minimal luminal diameter after stent implantation compared to less than 1.0 nun 
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Fig. 3A + B. Transversal section of the left anterior descending artery 1 week after Wiktor stent 
implantation (panel A) and of the left circumflex artery 4 weeks after stent implantation. During the first 
week, neointirnal hyperplasia is confined to the area in direct contact with the stent wires while at 4 weeks 
the stented segment is completely covered by neointimal hyperplasia. 
Reproduced with permission from van der Giessen et al. Circulation 1991; 83:1788-1798. 
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Fig. 4. Exessive stent oversizing with deep penetration of the stent wire into the media results in a more 
pronounced neointimal hyperplasia (left panel). Deep arterial injury during balloon angioplasty (right 
panel) is associated with more extensive intimal proliferation. 
Reproduced with permission from Schwartz et al. Circulation 1990; 82:2190-2200 and from Nobuyoshi 
et al. JAm Coli Cardiol 1991; 17:433-439. 
Relative loss 
1.4,---~~~--------------------------~ 
1.2 
1 
0.8 
0.6 
0.4 
0.2 
0 
-0.2 
-0.4 
0 
0 
0.2 
0 
0 
0.4 0.6 
Relative gain 
RL• .61 RG -.06 
R• .38 (p•.001) 
0.8 1.2 
Fig. 5. The relation between relative gain (increase in minimal luminal diameter normalized for vessel 
size) and relative loss (decrease in minimallwninal diameter normalized for vessel size) was studied using 
quantitative coronary angiography. There is a weak but positive linear correlation between the two 
variables suggesting that a larger vessel trauma will result in a greater loss. 
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Table 5. Immediate and long-term change,s in minimal luminal diameter (MLD) following balloon angioplasty and stent implantation 
Author Ref. n pts. MLD-pre MLD MLD MLD at follow-up Incidence of Restenosis 
post-PTCA post-stent 
all pts pts without (%,per pat) 
subacute occl. SO% 0.72 mm crit. 
Balloon angioplasty 
Serruys ct al. (1) 261* 0.99 ± 0.35 1.77 ± 0.34 1.46 ± 0.59 19 
Mercator Study (54) 309* 0.98 ± 0.35 1.77 ± 0.34 1.48 ± 0.54 28 16 
Rensing et a!. (55) 1353 1.03 ± 0.36 1.78 ± 0.36 1.50 ± 0.57 31** 17** 
Benestent (59) 60 0.99 ± 0.22***** 1.85 ± 0.31 1.45 ± 0.59 47 27 
1.00 ± 0.21****** 1.81 ± 0.31 1.42 ± 0.58 50 28 
Stent inlplantation 
Wallslent 
Serruys et al. (56) 105 1.21 ± 0.56 1.88 ± 0.43 2.48 ± 0.51 1.68 ± 1.20 2.26 ± 0.78 14 33 
Strnuss et al. (57) 166*** 1.17 ± 0.52 2.53 ± 0.53 L59 ± 1.08 1.99 ± 0.81 18 34 
101**** 1.39 ± 0.64 2.81 ± 0.69 2.03 ± 1.27 2.21 ± 1.16 39 54 
Palmaz-Schatz stent 
Haude eta\. (39) 50 1.00 ± 0.57 2.02 ± 0.47 3.26 ± 0.31 2.39 ± 1.15 24 37 
Fischman et al. (58) 205 1.92 ± 0.57 34 50** 
Benestent (59) 60 0.99 ± 0.30***** 2.19 ± 0.70 1.67 ± 0.77 30 27 
1.00 ± 0.24****** 2.41 ± 0.46 1.75 ± 0.77 24 29 
Wiktor stent 
De Jaegere et a!. (41) 50 1.09 ± 0.26 1.80 ± 0.32 2.45 ± 0.35 1.59 ± 0.79 1.78 ± 0.60 29 45 
pts "' patients; * "" Control group (there was no difference in the changes in MLD between control group and active treatment group); ** = incidence of rcstenosis 
per lesion;*** = stent implantation in native vessels;****= stent implantation in venous bypass grafts;*****=intention to treat analysis; ******=efficacy analysis. 
after balloon angioplasty. Moreover, stent implantation results in a residual diameter 
stenosis of less than 20% with nonnalization of the calculated resistances to flow and 
pressure drop across the stenosis [60,61]. 
Despite a larger loss in minimal luminal diameter at follow-up, the minimal 
luminal diameter is still greater after stent implantation than in patients who 
nnderwent balloon angioplasty. Therefore, it is not surprising that in comparison with 
PTCA, the incidence of restenosis is higher when using the 0.72 mm criterion, but, 
is lower when using the 50% diameter stenosis criterion (Table 5). It underscores the 
concept that improved initial results compensate for late neointimal hypetplasia 
which in tum explains the lower restenosis rate according to the 50% diameter 
criterion. 
To readily answer the question of whether stent implantation reduces the incidence 
of restenosis, randomized compa..-isons are needed. The Benestent study is a 
multicenter randomized study comparing stent implantation with PTCA in patients 
with stable angina pectoris and a de novo lesion in a native coronary artery [62]. The 
data from the pilot phase, which started in June 1991, confnm the angiographic 
fmdings of the above mentioned nonrandornized studies [63]. At follow-up 
angiography, the obstruction diameter of the patients in whom a stent was implanted 
proved to be higher than in patients who underwent PTCA. Furthermore, the 
incidence of restenosis was lower (Table 5). 
To fully appreciate the role and value of intracoron.ary stenting, it is not sufficient 
to only detennine the restenosis rate. All aspects of stent implantation have to be 
considered, especially the in-hospital complications and the long-term clinical 
outcome. The intrinsic thrombogenicity of all metalic stents clllTently available is a 
matter of concern. It exposes the patient to the risk of stent thrombosis which may 
result in a fatal or non-fatal acute myocardial infarction andfor emergency bypass 
surgery. An intensive anticoagulation is therefore imperative to avoid stent 
thrombosis but exposes the patient to the risk of major bleeding and puncture site 
related complications (Table 4 and 6). The anticoagulation protocol which is now 
widely used consists of acetyl salicylic acid, dipyridamole, dextran, heparin and oral 
anticoagulants during the acute phase followed by a combination of antiplatelet 
therapy and oral anticoagulants during the next three to six months. This is based on 
animal studies indicating less thrombus fonnation on stents pretreated with acetyl 
salicylic acid, dipyridamole, heparin and dextran and on clinical experience, showing 
a (sub)acute closure rate of 18% in absence of oral anticoagulation [38,66]. Tiris 
polypha.-macologic approach has recently been questioned by Simonet al who failed 
to demonstrate any beneficial effect of dextran and dipyridamole in the prevention 
of acute closure [67] 
Oral anticoagulation in combination with antiplatelet therapy has to be maintained 
until complete endothelialization of the stent. Although the time period in which this 
process occurs in humans is unknown, experimental animal studies have shown that 
stents become embedded in the vessel wall and are covered by endothelium in 1 to 
4 weeks [46,68,69]. 
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Table 6. In-hospital events and incidence of (sub)acute occlusion following stent implantation 
Author Ref Year Study n. pts n. stcnts In-hospital events (Sub)acutc occlusion 
Period 
Death AMI Em. CABG Incidence Time interval 
Wallstent 
Urban eta!. (36) '89 '86-'88 13 20 0 0 0 0 
Serruys et al. (56) '91 '86- '89 105 ll7 5 (4.7%) n.r. n.r. 21 (20%) day0-14 
Goy et al. (64) '91 '86-'87 56 68 2 (3.6%) 5 (8.9%) 1 (1.8%) 4 (7.1 %) day 1 - 7 
Strauss et al. (57) '92 '86-'90 265 373 ll (4.2%) n.r. n.r. 40 (15%) n.r. 
de Scheerder et a!. (40) '92 '88-'90 69 !36 3 (4.3%) 5 (7.2%) 4 (5.8%) 7 (10%) day 1 - 12 
Palmaz-Schatz stent 
Levine et al. (37) '90 '88-'89 37 45 n.r. n.r. n.r. 1 (2.7%) day 8 
Schatz et a!. (38) '91 '87-'89 226 321 0 6 (2.8%) 2 (0.9%) 8 (3.7%) day 2 - 11 
Haude et al. (39) '91 n.r. 50 61 1 (2.0%) 3 (6.0%) 2 (4.0%) 8 (16%) day 0, 5-9 
Carrozza et al. (42) '92 '88-'91 220 250 0 0 1 (0.4%) 1 (0.4%) day 8 
Colombo et al. (65) '92 '89-'91 100 126 2' (2.0%) 2 (2.0%) 4 {4.0%)** 3 (3.1%) day 4-6 
\Yiktor stent 
de Jaegere et a!. (41) '92 '90 50 50 0 5 (10%) I (2%) 5 (10%) day 0 - 5 
Total ll91 24 (2.0%) 26 (3.3%) 15 (1.9%) 98 (8.2%) 
95% CI 1.2-2.8% 2.3-4.3% 1.1-2.7% 6.6-9.8% 
pts =patients; AMI = acute myocardial infarction; Em.CABG = emergency b)'Pass surgery, n.r. = not reported 
* reported as not stent related; ** including 2 patients in whom a stcnt was implanted as a bridge to surgery; CI = confidence interval. 
Improvements of the stent design are currently being investigated to reduce its 
thrombogenic properties. A potential solution is the change of the surface characteris-
tics of the stents by either seeding the stent with endothelial cells or by coating the 
stent with either a thin layer of a synthetic polymer - with or without the addition 
of a drug such as low molecular weight heparin - or with polymerized fibrinogen 
(biopolymer coating) [70,71,72]. Another option is the development of biostable 
polymer stents which are entirely composed of a synthetic polymer [73]. It has been 
shown that polymer surfaces are smoother and thereby limit the adhesion of air 
bubbles and cellular elements, associated with thrombosis and tissue proliferation, 
respectively. Furthermore, by varying polymerization processing teclmiques, the 
mechanical properties can be manipulated in such a way that polymer stents can be 
constructed which settle themselves in a much smoother fashion against tfie arterial 
wall, which may reduce the acute and chronic vessel wall damage. 
As long as a "'non-thrombogenic·· stent is not available, the risk of thrombosis may 
be reduced by a more fme nming of the anticoagulation therapy. Titis can be done 
by measuring prothrombin fragment 1 + 2 [74]. An increase in these fragments 
reflects an activation of the coagulation system which may be predictive of stent 
thrombosis. It offers the clinician sufficient time to adjust the anticoagulation therapy. 
Titis in combination with local vascular hemostatic devices may also reduce bleeding 
and vascular complications which unnecessarily prolongs the hospital stay [74,75]. 
Despite these limitations of all stents in clinical use, it is noteworthy that the 
results of the pilot phase of the Benestent study disclosed a 6-month event and 
symptom free survival (freedom from death, myocardial infarction, bypass surgery, 
repeat PTCA) of 67% after stent implantation compared to 55% after PTCA [63]. It 
may be inferred that the lessons of the past have been learned resulting in better 
patient selection, improved implantation teclmique and postoperative management. 
STENTS FOR VENOUS BYPASS GRAFTS 
The management of patients with recurrence of angina pectoris after coronary artery 
bypass operation poses a problem. Repeat coronary artery bypass grafting is 
technically more difficult and is associated with a higher morbidity and mortality. 
Furthermore, symptomatic improvement and long-term clinical results are less 
satisfactory compared with a ftrst bypass operation [76]. Angioplasty of vein grafts 
may offer an alternative to re-operation. The immediate results of PTCA have been 
sho'Wll to be favorable in patients with discrete lesions in venous bypass grafts, but 
are considerably less in diffusely diseased grafts [77-79]. Furthermore, the incidence 
of restenosis varies between 40 to 70% depending on lesion site and extent of graft 
diseases [80-83]. 
Therefore, it is not surprising that a number of new interventional teclmiques are 
currently being used to improve the inunediate and long-term results of PTCA in 
bypass grafts. 
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As for native coronary arteries, the Wallstent was the f:rrst stent implanted in 
saphenous vein grafts with an almost 100% successful implantation success rate and 
a subacute stent thrombosis rate which proved to be lower (8-10%) than in native 
coronary arteries (19%) [36,40,56,57]. This was achieved, however, at the cost of an 
unacceptably high incidence of major bleeding complications, including fatal 
intracranial hemorrhage, and vascular access site bleedings [40]. 
More favourable initial results have recently been reported with the Palmaz-Schatz 
stent [84]. Subacute stent thrombosis rate amounted to only l.l% compared with 
6.0% in native coronary arteries. However, there was a significant higher frequency 
of major cardiac events such as death and myocardial infarction (6%) in patients with 
stent implantation in saphenous vein grafts compared with patients in whom a stent 
was implanted in native coronary arteries (2%) [84]. 
Restenosis following stent implantation in vein grafts has been reported to be 35 
and 54% according to the 50% diameter stenosis and 0.72 mm criteria, respectively, 
which is significantly higher than following stent implantation in native coronary 
arteries (18 and 34%, respectively) [57]. Despite this difference in restenosis rate, the 
one-year event free survival (freedom from death, myocardial infarction, bypass 
surgery or angioplasty) was similar for bypass grafts (50%) and for native vessels 
(55%). It is noteworthy that 25 to 30% of the adverse events were unrelated to the 
stented lesion, but due to progression of disease [40,57]. 
A low overall restenosis rate of 22% to 28% has recently been reported following 
Palmaz-schatz stent implantation which, moreover, did not differ from the restenosis 
rate in native coronary arteries (30%) [42,84]. Considering the incidence of restenosis 
of 13% in case of single stent implantation for a de novo lesion in a bypass graft, the 
overall low restenosis rate may be explained by a preponderance of de novo lesions 
and by the larger vessel size of vein grafts. 
Despite these promising results, the wide variety of patients treated in a non-
randomized fashion precludes any fmn conclusions with respect to the role and 
merits of stent implantation in venous bypass grafts. Current indications for stent 
implantation may be 1) patients with an increased risk for embolization of friable 
graft material such as in case of diffusely diseased grafts with long lesions since the 
stent can contain this material, 2) patients with ostial or very proximal graft stenosis 
since they are at higher risk of restenosis after balloon angioplasty, and 3) in case of 
the need of emergency bypass surgery since the ischemic period is substantially 
longer because more time is needed to dissect free the heart [85]. 
One shonld realize, however, that especially in the fJTSt category of patients, stent 
implantation may only provide a temporary solution but not long lasting clinical 
improvement due to further progression of disease [40,57,85]. 
HOW CAN WE IMPROVE THE RESULTS? 
The intrinsic thrombogenicity of all stents currently available and consequently the 
need for an intensive anticoagulation are the major limitations of the use of 
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intracoronary stents. However, one may reduce the risk of subacute stent thrombosis 
and bleeding complications by taking into account some obvious clinical and 
angiogtaphic parameters. One should stay away from the noncompliant patient or the 
patient with concomitant non-cardiac disease which interferes with the anti-
coagulation, Since frequent blood sampling is mandatory for proper institution of the 
anticoagulation, one should check the availability and quality of arm veins. In the 
very obese patient, it may difficult to fmd or pnncture one. These patients are, 
furthermore, at higher risk of vascular access site bleedings. 
Stents should not be implanted in vessels smaller than 3.0 mm since this is 
associated with an increased risk of stem thrombosis [86]. There are conflicting data 
on the risk of stent thrombosis following the use of multiple stents. In one study, it 
was found to be an independent predictor of stent thrombosis while in another there 
was no difference in thrombosis rate between single and multiple stent implantation 
[86,87]. It is unclear whether the presence of intracoronary thrombus is an absolute 
contra-indication for stem implantation. In the series reported by Fischman et al, a 
thrombus was observed in 8% of the patients. Despite this, only 3.8% of the total 
study population sustained a stem thrombosis which was predominantly explained by 
an 18% incidence of stent thrombosis in the first 39 patients who did not receive 
warfarin [38,58]. 
As already outlined above, a more detailed monitoring of the anticoagulation 
therapy may be helpful in the prevention of stent thrombosis. It may, furthermore, 
be speculated that with the advent of new and more potent anticoagulant drugs such 
as hitudin, the risk of stent thrombosis will be reduced [88]. 
Access site bleedings may be reduced by more appropriate patient selection, 
quality of puncture and timing of sheath removal. Obese patients and patients with 
chronic cough or who suffer from obstipation are more prone to access site related 
bleedings because of frequent Valsalva manoeuvres. The puncture should be low to 
optimize postoperative hemostasis. Sheath removal on the day of stenting is, 
furthermore, associated with less bleeding complications [42]. Although the use of 
collagen plugs may be attractive for time efficiency, they do not reduce bleeding 
complications [89]. Other techniques are currently available such as a controlled 
compression with a belt-held pnewnatic compression device. It proved to be higly 
successful and reduced the incidence of pseudoaneurysm in our hands and those of 
others [75]. 
The ultimate solution, of course, is the non-thrombogenic stent. The intensive 
research to achieve this goal is currently restricted to the experimental laboratory. 
However, it will invariably result in a next generation of less or eventually non-
thrombogenic devices. 
In addition to these immediate results of stent implantation, the battle against 
restenosis is promising. The lowest restenosis rate so far reported amounts to 13% 
in case of single stent implantation for a de novo lesion in a native coronary artery 
[58]. In addition to patient selection, this may be achieved by a more complete stem 
dilatation resulting in an ahnost negligible residual diameter stenosis post stent 
implantation [90]. 
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SUMMARY 
To address the two major shortcomings of balloon angioplasty (abrupt vessel closure 
and late restenosis), a number of new catheter technologies have been developed and 
entered clinical testing. The data presented and discussed in this thesis focus on the 
clinical and angiographic aspects of intracoronary stent implantation in human 
coronary arteries. 
It has been hypothesized that intracoronary stenting may reduce the incidence of 
restenosis by improving the inunediate angiographic results. Therefore, in the frrst 
part, special attention was paid to the changes in stenosis geometry inunediately after 
stent implantation using quantitative coronary angiography. Tbe data of non-
randomized comparisons in chapter 2, 3 and 5 indicate that stent implantation indeed 
results in a superior improvement in stenosis geometry compared with balloon 
angioplasty. No difference was observed between balloon-expendable and self-
expanding devices (chapter 3). Fnrthermore, the data of chapter 5 confttm that stent 
implantation effectively prevents recoil. In populations with identical baseline 
stenosis characteristics, directional atherectomy and stent implantation result in a 
similar inunediate improvement (chapter 4). 
However, to fully appreciate the role and merits of intracoronary stent implantation, 
it is not sufficient to consider only these technical aspects which potentially may 
explain a reduction in the incidence of restenosis. All aspects must considered and 
in particnlar the inunediate and long-term clinical outcome. It is of utmost 
importance for as well the patient as the society, which faces exploding health care 
costs, to select the most appropriate treatment. This means the treatment which 
produces more health than harm and which yields more health benefits and/or less 
risks than alternative treatments or the natural course of the disease. This matter is 
in detail eloborated in part two. 
There is no doubt that stents can be implanted with a high technical success rate. 
However, this is done at the cost of a high incidence of in-hospital events related to, 
on one hand, the intrinsic thrombogenicity of the device with the risk of (sub )acute 
thrombotic occlusion and, on the other hand, the need for an intensive anti-
coagulation associated with an increased bleeding risk and vascnlar complications. 
The necessity of anticoagulation prolongs the hospital stay and is one of the factors 
which renders the procedure more expensive. These aspects are discussed in chapter 
6, 10 and 11. 
One of the methods to assess the proper role and merits of intracoronary stenting 
is the conduction of a randomized trial The results of the pilot phase of the 
Benestent Study is discussed in chapter 10. Despite the above mentioned limitations 
of intracoronary stents, the most striking feature is the superior 6-month symptom 
and event-free survival in patients who received a stent. Of course, the small number 
of patients included precludes any fttm conclusions at present. Fnrthermore, one 
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should bear in mind that even if randomization guarantees homogeneity between the 
two treatment groups and thus allows comparison of two treatment modalities, it will 
not tell the whole story since a substantial number of patients do not enter the trial 
due to the in- and exclusion criteria outlined in the protocoL The lower restenosis 
rate after stent implantation is explained by the observation that the higher initial 
gain after stent implantation compensates for the late loss and thus improved initial 
results and not lessened neointimal hypetplasia is responstble for a reduced incidence 
of restenosis (chapter 9). The role and merits of stent implantation in venous bypass 
grafts remains unclear. Based on current data on reoperation and experience with 
balloon angioplasty and stent implantation in venous bypass grafts, stent implantation 
may be envisaged in 1) patients with an increased risk for embolization of friable 
graft material, 2) patients with ostial or very proximal graft stenosis, and 3) in those 
needing emergency bypass surgery (chapter 8). 
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